

# Study on characterization of antimicrobial resistant *Listeria monocytogenes* and their biocontrol by using specific bacteriophages and natural antimicrobial substances

エイ ティーダ マウン

<https://hdl.handle.net/2324/7329545>

---

出版情報 : Kyushu University, 2024, 博士 (農学), 課程博士  
バージョン :  
権利関係 :



**Study on characterization of  
antimicrobial resistant *Listeria*  
*monocytogenes* and their biocontrol  
by using specific bacteriophages and  
natural antimicrobial substances**

**AYE THIDA MAUNG**

**2024**

**Study on characterization of antimicrobial  
resistant *Listeria monocytogenes* and their  
biocontrol by using specific bacteriophages and  
natural antimicrobial substances**

**A thesis submitted by  
AYE THIDA MAUNG  
in the Partial Fulfillment of the Requirements for the Degree  
of Doctor of Philosophy  
at the Department of Bioscience and Biotechnology,  
Graduate School of Bioscience and Bioenvironmental  
Sciences  
Kyushu University, Japan**

**2024**

# Table of Contents

|                                                                                                                            |           |
|----------------------------------------------------------------------------------------------------------------------------|-----------|
| <b>Chapter 1. Introduction.....</b>                                                                                        | <b>1</b>  |
| <b>1.1. An overview of <i>Listeria monocytogenes</i>.....</b>                                                              | <b>1</b>  |
| 1.1.1. <i>Listeria monocytogenes</i> as a pathogen.....                                                                    | 1         |
| 1.1.2. Antimicrobial resistance of <i>L. monocytogenes</i> .....                                                           | 2         |
| 1.1.3. Biofilm formation of <i>L. monocytogenes</i> .....                                                                  | 3         |
| <b>1.2. An overview of bacteriophages .....</b>                                                                            | <b>5</b>  |
| 1.2.1. Bacteriophage .....                                                                                                 | 5         |
| 1.2.2. Life cycle of bacteriophages .....                                                                                  | 7         |
| 1.2.3. Application of bacteriophage as therapeutic agents.....                                                             | 8         |
| 1.2.4. Application of bacteriophage as biocontrol agents in the food industry .....                                        | 9         |
| <b>1.3. An overview of essential oils.....</b>                                                                             | <b>10</b> |
| 1.3.1. Essential oils (EOs).....                                                                                           | 10        |
| 1.3.2. Antimicrobial activity of EOs.....                                                                                  | 11        |
| 1.3.3. Application of essential oils in the food industry .....                                                            | 13        |
| <b>1.4. Research objectives .....</b>                                                                                      | <b>14</b> |
| <b>Chapter 2. Occurrence and characterization of <i>Listeria monocytogenes</i> in recent 5-year in Fukuoka, Japan.....</b> | <b>15</b> |
| <b>2.1. Introduction.....</b>                                                                                              | <b>15</b> |
| <b>2.2. Materials and methods .....</b>                                                                                    | <b>16</b> |
| 2.2.1. Sample collection.....                                                                                              | 16        |
| 2.2.2. Isolation and identification of <i>L. monocytogenes</i> .....                                                       | 16        |
| 2.2.3. MALDI-TOF MS analysis .....                                                                                         | 17        |
| 2.2.4. Serotyping .....                                                                                                    | 17        |
| 2.2.5. Antimicrobial susceptibility testing (AST).....                                                                     | 18        |
| 2.2.6. Detection of virulence genes.....                                                                                   | 18        |
| 2.2.7. Determination of biofilm-forming ability .....                                                                      | 19        |
| 2.2.8. Statistical analysis .....                                                                                          | 19        |
| <b>2.3. Results .....</b>                                                                                                  | <b>20</b> |
| 2.3.1. Occurrence of <i>L. monocytogenes</i> in food .....                                                                 | 20        |
| 2.3.2. Identification of the isolates by MALDI-TOF MS analysis .....                                                       | 20        |

|                                                                                                                                                                                                         |           |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 2.3.3. Serotyping of the isolates .....                                                                                                                                                                 | 21        |
| 2.3.4. Antimicrobial susceptibility of the isolates.....                                                                                                                                                | 21        |
| 2.3.5 Comparison of occurrence, serotyping, and AMR of <i>L. monocytogenes</i> isolates in 2012, 2017, and 2022.....                                                                                    | 21        |
| 2.3.6. Comparison of virulence genes possession and biofilm-forming ability of <i>L. monocytogenes</i> isolates in 2012, 2017, and 2022 .....                                                           | 22        |
| <b>2.4. Discussion.....</b>                                                                                                                                                                             | <b>23</b> |
| <b>2.5. Summary.....</b>                                                                                                                                                                                | <b>27</b> |
| <b>Chapter 3. Isolation and characterization of bacteriophages specific to <i>Listeria monocytogenes</i> .....</b>                                                                                      | <b>40</b> |
| <b>3.1. Introduction.....</b>                                                                                                                                                                           | <b>40</b> |
| <b>3.2. Materials and methods .....</b>                                                                                                                                                                 | <b>41</b> |
| 3.2.1. Bacterial strains and culture conditions .....                                                                                                                                                   | 41        |
| 3.2.2. Isolation, purification, and propagation of bacteriophages.....                                                                                                                                  | 41        |
| 3.2.3. Host range determination of isolated phages .....                                                                                                                                                | 43        |
| 3.2.4. Morphological observation of plaques.....                                                                                                                                                        | 43        |
| 3.2.5. Transmission electron microscopy (TEM) observation.....                                                                                                                                          | 43        |
| 3.2.6. Temperature and pH stability tests .....                                                                                                                                                         | 43        |
| 3.2.7. Genomic DNA sequencing and bioinformatic analysis .....                                                                                                                                          | 44        |
| 3.2.8. Determination of latent period and burst size .....                                                                                                                                              | 44        |
| <b>3.3. Results .....</b>                                                                                                                                                                               | <b>45</b> |
| 3.3.1. Isolation of <i>L. monocytogenes</i> specific phages.....                                                                                                                                        | 45        |
| 3.3.2. Host range of isolated phages .....                                                                                                                                                              | 45        |
| 3.3.3. Morphology of plaques .....                                                                                                                                                                      | 45        |
| 3.3.4. Morphology of isolated phage .....                                                                                                                                                               | 45        |
| 3.3.5. Temperature and pH stability of phages .....                                                                                                                                                     | 46        |
| 3.3.6. Genetic characterization of phages .....                                                                                                                                                         | 46        |
| 3.3.7. Latent period and burst size of a lytic phage vB_LmoS-PLM9 .....                                                                                                                                 | 47        |
| <b>3.4. Discussion.....</b>                                                                                                                                                                             | <b>48</b> |
| <b>3.5. Summary.....</b>                                                                                                                                                                                | <b>50</b> |
| <b>Chapter 4. Evaluation of plant-based essential oils and their application in single or combined with phage vB_LmoS-PLM9 against pathogenic <i>Listeria monocytogenes</i> in broth and milk .....</b> | <b>68</b> |

|                                                                                                                                                                                                    |           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| <b>4.1. Introduction.....</b>                                                                                                                                                                      | <b>68</b> |
| <b>4.2. Materials and methods .....</b>                                                                                                                                                            | <b>69</b> |
| 4.2.1. Preparation of bacterial culture .....                                                                                                                                                      | 69        |
| 4.2.2. Preparation of bacteriophage vB_LmoS-PLM9 .....                                                                                                                                             | 69        |
| 4.2.3. Preparation of EOs .....                                                                                                                                                                    | 70        |
| 4.2.4. Antibacterial activity of EOs .....                                                                                                                                                         | 70        |
| 4.2.5. Determination of phage activity in the presence of EOs .....                                                                                                                                | 71        |
| 4.2.6. Determination of viability of <i>L. monocytogenes</i> treated with phage<br>and/or EOs in broth .....                                                                                       | 71        |
| 4.2.7. Determination of viability of <i>L. monocytogenes</i> treated with phage<br>and/or EOs in milk .....                                                                                        | 71        |
| 4.2.8. Statistical analysis .....                                                                                                                                                                  | 72        |
| <b>4.3. Results .....</b>                                                                                                                                                                          | <b>72</b> |
| 4.3.1. Antibacterial activity of EOs against <i>L. monocytogenes</i> .....                                                                                                                         | 72        |
| 4.3.2. MIC and MBC values of EOs against <i>L. monocytogenes</i> .....                                                                                                                             | 72        |
| 4.3.3. Effects of EOs on phage survivability .....                                                                                                                                                 | 72        |
| 4.3.4. Effects of phage and/or EOs against <i>L. monocytogenes</i> in broth .....                                                                                                                  | 73        |
| 4.3.5. Effects of phage and/or EOs against <i>L. monocytogenes</i> in milk.....                                                                                                                    | 73        |
| <b>4.4. Discussion.....</b>                                                                                                                                                                        | <b>74</b> |
| <b>4.5. Summary.....</b>                                                                                                                                                                           | <b>78</b> |
| <b>Chapter 5. Control of pathogenic <i>Listeria monocytogenes</i> on various<br/>solid foods and its biofilm by using bacteriophage vB_LmoS-PLM9<br/>and/or cinnamon bark and clove oils .....</b> | <b>86</b> |
| <b>5.1. Introduction.....</b>                                                                                                                                                                      | <b>86</b> |
| <b>5.2. Materials and methods .....</b>                                                                                                                                                            | <b>88</b> |
| 5.2.1. Preparation of <i>L. monocytogenes</i> culture .....                                                                                                                                        | 88        |
| 5.2.2. Preparation of bacteriophage vB_LmoS-PLM9 .....                                                                                                                                             | 88        |
| 5.2.3. Preparation of EOs .....                                                                                                                                                                    | 88        |
| 5.2.4. Determination of viability of <i>L. monocytogenes</i> treated with phage<br>and/or cinnamon oil on ham, boneless skinless chicken meat, smoked salmon,<br>and natural cheese .....          | 89        |
| 5.2.5. Determination of viability of <i>L. monocytogenes</i> treated with phage<br>and/or cinnamon oil on ham and salmon fillet.....                                                               | 89        |

|                                                                                                                                                                                    |            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| 5.2.6. Determination of viability of <i>L. monocytogenes</i> treated with phage and/or cinnamon oil in mixed salad and coleslaw .....                                              | 90         |
| 5.2.7. Determination of biofilm of <i>L. monocytogenes</i> after the treatment with phage and/or cinnamon and clove oils.....                                                      | 90         |
| 5.2.8. Statistical analysis .....                                                                                                                                                  | 91         |
| <b>5.3. Results .....</b>                                                                                                                                                          | <b>91</b>  |
| 5.3.1. Effects of phage and/or cinnamon oil on the viability of pathogenic <i>L. monocytogenes</i> on ham, boneless skinless chicken meat, smoked salmon, and natural cheese ..... | 91         |
| 5.3.2. Effects of phage and/or clove oil on the viability of pathogenic <i>L. monocytogenes</i> on ham and salmon fillet .....                                                     | 93         |
| 5.3.3. Effects of phage and/or cinnamon and clove oils on the viability of pathogenic <i>L. monocytogenes</i> in mixed salad and coleslaw .....                                    | 93         |
| 5.3.4. Effects of phage and/or cinnamon oil on removal of <i>L. monocytogenes</i> biofilm.....                                                                                     | 94         |
| 5.3.5. Effects of phage and/or clove oil on removal of <i>L. monocytogenes</i> biofilm.....                                                                                        | 94         |
| <b>5.4. Discussion.....</b>                                                                                                                                                        | <b>95</b>  |
| <b>5.5. Summary.....</b>                                                                                                                                                           | <b>100</b> |
| <b>Chapter 6. Conclusions .....</b>                                                                                                                                                | <b>109</b> |
| <b>Acknowledgment .....</b>                                                                                                                                                        | <b>113</b> |
| <b>References .....</b>                                                                                                                                                            | <b>114</b> |

## Chapter 1. Introduction

### 1.1. An overview of *Listeria monocytogenes*

#### 1.1.1. *Listeria monocytogenes* as a pathogen

*Listeria monocytogenes* was originally described as *Bacterium monocytogenes* by Everitt George Dunne Murray in 1926 and proposed by Pirie in 1940. A few outbreaks were reported in developed countries in 1970 and 1980, and it was verified as the causative agent of foodborne listeriosis in 1983. In the following years, *Listeria* has been the subject of important discoveries among the most researched bacterial infections (Liu, 2008).

The genus *Listeria* spp. is a Gram-positive, rod-shaped, non-spore-forming, facultative intracellular and aero-anaerobic bacteria. It includes twenty currently recognized species, which can be subdivided into two major groups: (i) *Listeria sensu stricto*, constituted by *L. monocytogenes*, *L. innocua*, *L. welshimeri*, *L. seeligeri*, *L. ivanovii*, and *L. marthii*; and (ii) *Listeria sensu lato*, constituted by *L. grayi*, *L. rocourtiae*, *L. fleischmannii*, *L. weihenstephanensis*, *L. floridensis*, *L. aquatica*, *L. cornellensis*, *L. riparia*, *L. grandensis*, *L. booriae*, *L. newyorkensis*, *L. costaricensis*, *L. goaensis* and *L. thailandensis*. Among them, *L. monocytogenes* and *L. ivanovii* are pathogenic species for humans and animals (Allerberger and Wagner, 2010; Quereda et al., 2020; Quereda et al., 2021).

*Listeria monocytogenes* is a serious foodborne pathogen, widely distributed in the environment and responsible for listeriosis outbreaks. Meloni et al. (2015) reported the outbreaks occurred by consumption of contaminated ready-to-eat meats, seafood, meat and meat products, milk and dairy products, and vegetables. This bacterium can thrive in various conditions including temperatures (0–45 °C), pH ranges (4.3–9.4), high salt concentration (up to 14 %), and water activity (above 0.92). These physiochemical

factors promote the survival and growth of *L. monocytogenes* in varieties of foods (Bouymajane et al., 2021).

The pathogenicity of *L. monocytogenes* is determined by their virulence factors and dangerous serotype distributions. The virulence factors are distributed across the genome or grouped in pathogenicity islands LIPI-1, LIPI-3, and LIPI-4 (Maury et al., 2016). The *hlyA* gene encodes listeriolysin O; *inlA*, *inlB* genes encode internalin; *clpC* gene encodes ClpC ATPase; *plcA* gene encodes phosphatidylinositol-phospholipase C; *iap* gene encodes Iap invasion associated protein; and *prfA* gene for virulence regulator, all these genes responsible for virulence of *L. monocytogenes* (Cao et al., 2018; Soni et al., 2014; Wu et al., 2016). Based on somatic O and flagellar H antigens, *L. monocytogenes* have been classified into 13 serotypes (Maćkiw et al., 2016). Among them, serotypes 1/2a, 1/2b, 1/2c, and 4b can cause 95 % of human listeriosis by contaminated food, animal and human samples. Serotype 4b is the most common in clinical cases, whereas serotypes 1/2a and 1/2b are mainly found in food (Bouymajane et al., 2021; Skowron et al., 2020).

*Listeria* infections can cause septicemia, encephalitis, meningitis, and abortion in elderly people, fetuses, and pregnant women with a fatality of 20-40 % (Karadal and Yildirim, 2014). Rodríguez-Campos et al. (2019) reported that human listeriosis causes 23,000 cases of invasive infections yearly in global. Listeriosis outbreaks were recorded with mortality rates of 42 % in South Africa in 2017-2018 (Desai et al., 2019) and 17.6 % in the European Union in 2019 (Panera-Martínez et al., 2022). However, only 0.65 listeriosis cases per million inhabitants were reported in Japan in 2010 (Ochiai et al., 2010). Nevertheless, the contamination rates of *L. monocytogenes* in foods in Japan are almost comparable with other countries, including the United States and Europe.

### **1.1.2. Antimicrobial resistance of *L. monocytogenes***

Antimicrobial resistance (AMR) has been recognized as a serious public health issue worldwide. The AMR pathogens can be distributed between humans, animals,


foods, and environments (water, soil, and air) due to uncleaned facilities, unsecured food processing, and inappropriate infection control (Doyle et al., 2013). Several antibiotics are used in humans and animals for different purposes such as preventing infections, treating diseases, and promoting growth in many countries including Japan (Phillips et al., 2004; Tamura, 2016). The misuse and overuse of antibiotics increased antimicrobial resistance of bacterial pathogens and the proliferation of resistant pathogens through the food chain, leading to increased public health consequences in terms of morbidity, mortality, and treatment costs (Gyles, 2008).

*Listeria monocytogenes* are susceptible to most antibiotics, however, they are naturally resistant to cephalosporins and fosfomycin (Iwu and Okoh, 2020). Since multidrug-resistant *L. monocytogenes* strains were found in France in 1988 (Poyart-Salmeron et al., 1990), one or multiple antibiotic-resistant strains were continuously isolated from various foods and environmental sources (Aiyedun et al., 2020). Many studies reported that *L. monocytogenes* strains were resistant to gentamycin, streptomycin, kanamycin, erythromycin, rifampin, and sulfonamide, therefore, different antibiotic classes have been alternatively applied (Poros-Gluchowska and Markiewicz, 2003; Prieto et al., 2016; Walsh et al., 2001). The  $\beta$ -lactams group such as ampicillin/ penicillin alone or combined with the aminoglycoside group, especially gentamycin becomes the preferred medication for treating listeriosis (Al-Mashhadany, 2019; Wang et al., 2013). Trimethoprim with sulfamethoxazole, erythromycin, and vancomycin are used as second-choice treatments, especially in pregnant women (Charpentier and Courvalin, 1999; Kemnic and Coleman, 2019).

### **1.1.3. Biofilm formation of *L. monocytogenes***

Biofilm is a complex microbial community that adheres to surfaces and produces a slimy, protective matrix of extracellular polymeric substances (EPS) (Monds and O'Toole, 2009). They are ubiquitous and can form on both living and non-living surfaces. Depending on the type of isolates and environmental variables, the biofilm

formation structure varied from interwoven chains and dense, three-dimensional formations resembling mushrooms or honeycombs to cellular monolayers with little or no extracellular matrix, as illustrated in Fig. 1.1 (Borucki et al., 2003; Finn et al., 2023; Milanov et al., 2009).



**Fig. 1.1.** Demonstration of *L. monocytogenes* mature biofilm with a three-dimensional mushroom shape (Finn et al., 2023).

*Listeria* biofilm production can be influenced by a variety of environmental conditions. Temperature seems to be one of the primary contributors (Colagiorgi et al., 2017). Research typically reports that *L. monocytogenes* adherence and biofilm formation increase as temperature rises to 30-37 °C (Chavant et al., 2002). Topography also influences the growth of listerial biofilm (Møretrø and Langsrud, 2004). Rougher surfaces like corroded or worn offer greater space for biofilm formation because surface flaws can trap water and nutrients to encourage bacterial growth (Chmielewski et al., 2003). In comparison to hydrophobic materials like polystyrene, several investigations have found that biofilm formation occurs more quickly and at higher rates on hydrophilic surfaces like stainless steel (Finn et al., 2023). However, other reports have indicated contradictory results. These may be due to variations in the test strains and/or experimental setups (Djordjevic et al., 2002; Møretrø and Langsrud, 2004; Takahashi

et al., 2010).

The growth of listerial biofilm can also be significantly influenced by NaCl content, pH, and nutrient availability (Valderrama et al., 2013). *L. monocytogenes* cultivated in general-purpose media added with 0 % or 6 % NaCl (w/w) did not affect significantly, while those with 1 % showed a significant reduction in inhibiting listerial biofilm formation (Caly et al., 2001). Additionally, several studies have demonstrated that increasing the acidity of the growing medium by introducing citric or lactic acid, can facilitate the adherence of *L. monocytogenes* onto stainless steel (Briandet et al., 1999a and b). Another study reported that stainless steel was most effectively colonized by *L. monocytogenes* Scott A at pH 7.0 (Smoot and Pierson, 1998a and b).

Other studies demonstrated that nutrient limitation is also important in reducing the production of biofilms (Combrouse et al., 2013; Zhou et al., 2012), but biofilm formation ability of *L. monocytogenes* under various nutritional circumstances may rely on the surface material and strain (Folsom et al., 2006). Moreover, interactions with other bacteria may play an important role in forming listerial biofilms. For instance, *Pseudomonas* spp., which are frequently found in food-related surfaces, have been demonstrated to either encourage or prevent the production of *L. monocytogenes* biofilms, depending on the strain or the circumstances (Carpentier et al., 2004; Finn et al., 2023).

## **1.2. An overview of bacteriophages**

### **1.2.1. Bacteriophage**

Bacteriophages (phages) are viruses that infect bacterial cells and are widely distributed in the biosphere. The term bacteriophage comes from “bacteria” and the Greek word *phagein*, which means “to devour” (Clokier et al., 2011). FW Twort and Félix d'Herelle discovered independently BTwort-d'Herelle phenomena or Bacteriophage phenomena in 1915 and 1917 (Sulakvelidze et al., 2001). The


International Committee on the Taxonomy of Viruses (ICTV) determined the virus taxonomy in 1971 and updated it in March 2021-2022. There were 862 species, 321 genera, 30 subfamilies, 22 families, and one order newly created. The class *Caudoviricetes* was replaced with the order *Caudovirales*, which included all-tailed bacterial and archaeal viruses with icosahedral capsids and a double-stranded DNA (dsDNA) genome (Lefkowitz et al., 2018; Turner et al., 2023).

The genomes of bacteriophages have distinct characteristics such as diversity, mosaicism, and differential gene movement. Phage genomes are extremely diverse, accounting for 15 % of all viruses with known unique sequences. Approximately 750 distinct bacteriophage genomes have been sequenced containing a variety of nucleic acid compositions and virion morphologies. Approximately 90 % of all genetically characterized phages are members of dsDNA phage families. The remaining families of phages are members of single-stranded DNA phage (ssDNA), single-stranded RNA (ssRNA), and double-stranded RNA (dsRNA) (Singh et al., 2024).

Bacteriophages are classified into 13 categories according to the type of encapsulated nucleic acid and the morphology of their virion. There are nine families of dsDNA, including *Myoviridae*, *Siphoviridae*, *Podoviridae*, *Corticoviridae*, *Fuselloviridae*, *Lipothrixviridae*, *Plasmaviridae*, *Rudiviridae*, and *Tectiviridae*; two families of ssDNA, including *Microviridae* and *Inoviridae*; ssRNA, *Leviviridae*; and dsRNA, *Cystoviridae* respectively. Sixty percent of the recognized phages belong to the three major families such as *Siphoviridae*, *Myoviridae*, and *Podoviridae* under the order of *Caudovirales* (Lopes et al., 2018). However, only 3–4 % of the analyzed phages are associated with the ten families under investigation, some of which are incredibly tiny (Ackermann, 2007).

### 1.2.2. Life cycle of bacteriophages

Bacteriophages have two different life cycles: lytic and lysogenic as shown in Fig. 1.2. Another name for lytic phage is virulent phage. The four stages that distinguish bacteriophage replication cycles are adsorption (attachment), infection, multiplication, and discharge (release) (Guttman et al., 2005). In the attachment phase, phage particles attach to the surface of the bacterial host cell by specific receptors. Then, the phage genetic material enters the host cell through a process akin to injection, which causes the infection phase. After the phage multiplies within the host, the host bacteria lyse and rupture, releasing new phage particles. During the replication process, the chromosome of the host bacterial cell may be crammed into the capsid, resulting in transduction-mediated horizontal gene transfer. The threat posed by pathogenic bacteria resistant to antibiotics can be neutralized with virulent phages (Gamachu and Deballo et al., 2022). In the lysogenic life cycle, temperate phages integrate viral genetic material with the bacterial genome to form prophages, which ensures that the viral genetic material replicates indefinitely without endangering the infected host (Inal, 2003).



**Fig. 1.2.** Life cycles of the lytic and lysogenic phages (Costa et al., 2023).

### 1.2.3. Application of bacteriophage as therapeutic agents

Bacteriophages can infect and kill bacteria without impacting humans or animals, which explores clinical therapy against bacterial pathogens. Previous studies have demonstrated that phage can successfully treat illnesses in humans, animals, and plants (Sulakvelidze et al., 2005a and b). Before the discovery of antibiotics, phages were used to treat many bacterial illnesses such as septicemia, typhoid fever, cholera, dysentery, skin infections, peritonitis, and external otitis (Wittebole et al., 2014).

The rebirth of interest in bacteriophages as antimicrobial agents was largely due to two significant advancements. First, we now have fewer therapeutic alternatives due to AMR bacterial pathogens' emergence and extensive distribution. Furthermore, most newly approved novel antibiotics are modified versions of existing drugs, increasing the likelihood that they may lose their effectiveness quickly (Talbot et al., 2019). Second, antibiotic-mediated disruption of the microbiome is indeed thought to be a factor in several chronic and non-communicable diseases (Dietert and Dietert, 2015).

According to Hyman (2019), bacteriophages have the potential to be exploited therapeutically because (i) the bacteriophage must be lytic and capable of widely damaging the target bacterium by cytotoxicity, (ii) it must remain entirely lytic and refrain from turning into a lysogenic phage, (iii) the host bacterium should be able to be transduced by the bacteriophage, (iv) the intended host range ought to be present, (v) toxin genes that may have an impact on the patient should be examined. Phage can be applied alone or combined with other antibacterial agents to treat infections caused by antibiotic-resistant bacteria (Domingo-Calap and Delgado-Martínez, 2018). Approximately 800 phages are available to combat pathogens such as *Salmonella*, *Escherichia coli*, *Klebsiella*, *Enterococcus*, *Pseudomonas*, *Staphylococcus*, and *Listeria* (Weber-Dabrowska et al., 2016).

#### **1.2.4. Application of bacteriophage as biocontrol agents in the food industry**


Globally, foodborne illnesses originating from microbiological cause a serious threat to food safety. Foodborne bacterial infections have a significant influence on public health as well as economic burden (Scharff, 2012). The “One Health” strategy states that providing a safe food supply and preventing bacterial contamination in food are high-priority areas for controlling foodborne disease outbreaks. Bacteriophages are used for pathogen detection and control in the food-producing process, “farm to fork” as promising candidates because of their natural ability to attack and destroy target bacteria without being harmful to humans and animals. Many bacteriophage-based products have been designated as Generally Recognized as Safe (GRAS) by the US Food and Drug Administration (FDA) (Costa et al., 2023). Commercially available phage products such as ListShield™, Listex™ P100, and Phageguard Listex for *L. monocytogenes*; SalmoFresh and Phageguard S for *Salmonella*; and EcoShield PX and PhageGuard E. for *E. coli*, respectively are used to control foodborne pathogens in the foods (de Melo et al., 2017; Sulakvelidze, 2011).

Since the 1980s, phages have been utilized for the following purposes: (i) phage therapy, which prevents or lessens colonization and diseases in livestock; (ii) phage sanitation and biocontrol, which decontaminates raw foods and disinfects food contact surfaces; and (iii) bio-preservation, which extends the shelf life of perishable manufactured foods (García et al., 2008; Leverentz et al., 2003; Martínez et al., 2008). Owing to their unique characteristics, phages are employed as promising candidates to treat food directly and clean food contact surfaces in farms or food processing plants. This significantly reduces the growth of bacteria colonies on surfaces and biofilm formation, thereby decreasing the risk of pathogen transmission throughout the food supply chain (Endersen et al., 2014; Loc-Carrillo et al., 2011).

### 1.3. An overview of essential oils

#### 1.3.1. Essential oils (EOs)

EOs are mixtures of volatile lipid-soluble organic compounds extracted from different parts of plants (Matera et al., 2023). In the 16<sup>th</sup> century, Quinta essential was the term used by Paracelsus von Hohenheim to define “essential oil” (Pichersky et al., 2006). The most common methods for producing EOs for commercial use are steam distillation and hydro distillation, while they can also be obtained by extraction, effleurage, fermentation, expression, or other procedures (Burt, 2004; Tajkarimi et al., 2010). In addition to their unique aroma which makes them useful in perfumery, EOs have a wide range of biological activity which represents the basis for their long history of use in folk and traditional medicines (Dhifi et al., 2016; Mancianti and Ebani, 2020). The applications of EOs in different industries are illustrated in Fig. 1.3 (Herman et al., 2019).



**Fig. 1.3.** General applications and functions of essential oils in different industries (Herman et al., 2019).

Approximately 3000 EOs have been identified, of which 10 % are employed in or have the potential to be utilized in food products. About 300 EOs were recognized under the US FDA's GRAS lists of food additives (Matera et al., 2023). De Almeida et al. (2010) stated that numerous researchers discovered the biological activities of natural and plentiful herbal plants all over the world, demonstrating that plant-based essential oils and extracts are effective in controlling the growth of a wide range of microorganisms, including bacteria, yeasts, and fungi. Moreover, EOs possess analgesic, anti-inflammatory, antiprotozoal, anticarcinogenic, gastroprotective, and acetylcholinesterase properties. EOs have also shown significant promise in the food industry's efforts to control foodborne microorganisms, therefore, there is currently focusing on using plant extracts as conventional antimicrobials (Herman et al., 2019).

### **1.3.2. Antimicrobial activity of EOs**

**Antibacterial activity:** Essential oils exhibit potent strong bacteriostatic and bactericidal effects against various bacterial species (Callaway et al., 2011). Cinnamon, clove bud, oregano, thyme, bay leaf, ginger, lemongrass, and allspice oils were shown as the most commonly effective in controlling various foodborne pathogens including *L. monocytogenes*, *S. aureus*, *C. jejuni*, *E. coli*, and *Salmonella* (Friedman et al., 2002). Sheng and Zhu (2014) also investigated the antibacterial activity of cinnamon oils against the “top six” Shiga-toxin-producing *E. coli* O26, O45, O103, O111, O121, and O145. The distinct antibacterial qualities of each dynamic component and their combined effects account for the varied efficacies of the different EOs. Moreover, interactions between different major and minor elements of EOs may also play a significant role in the antibacterial activity (Chouhan et al., 2017; Marchese et al., 2017).

The antibacterial mechanisms of EOs involve damaging the cell membranes of microorganisms, interfering with enzymatic processes, ion transport, and ATP synthesis, as well as reducing the pH of the surrounding environment (Burt, 2004). Furthermore, the concentration and duration of an oil's exposure to microorganisms

determine its effectiveness. The bactericidal effect increases with concentration and duration of contact (Żukowska and Durczyńska, 2024). Kim et al. (2011) reported that most EOs had better antimicrobial activities against Gram-positive than Gram-negative bacteria. It could be due to a direct interaction between the cell membrane and the hydrophobic components of the EOs. On the other hand, Gram-negative bacteria are more resistant to EOs due to their hydrophilic cell wall. As a result, EOs hold great potential as antibiotic substitutes, particularly in the treatment of diseases caused by multidrug-resistant strains.

**Antiviral activity:** Several EOs such as clove, lemon, oregano, and thyme oils have been shown to have inhibitory effects on many viruses, including influenza, herpes, polioviruses, and SARS-CoV-2 (Elsebai et al., 2022; Sharifi-Rad et al., 2017). According to Bayala et al. (2014), EOs can reduce viral replication more effectively than some typical antiviral drugs when used in quantities that do not harm human cells.

The antiviral mechanisms of EOs involve direct viral inactivation, inhibition of adsorption and penetration into cells, disruption of nucleic acid replication, and viral protein synthesis (Nazzaro et al., 2013). Although *in vitro* trials are promising, further human clinical research is required to demonstrate the safety and efficacy of EOs in treating viral infections. There is inadequate data to propose oils as conventional therapy (Żukowska and Durczyńska, 2024).

**Antifungal activity:** EOs are also used as promising natural products for fungal inhibition (Hu et al., 2017; Kalemba and Kunicka, 2003). Certain EOs such as cinnamon, lemon, thyme, rosemary eucalyptus, grapefruit, mint, and cedar wood have shown unique properties in addition to preventing the proliferation of mycelia (Hossain et al., 2016). Basil, rosemary, sage, savory, thyme, fennel, lavender, marjoram, oregano, peppermint, and wild mint exhibited potentially significant antifungal activity against *Botrytis cinerea* and *Penicillium expansum* on apple (Fatemi et al., 2013). Additionally, oregano oil has significantly reduced the spores of *Aspergillus terreus* and *Penicillium*

*expansum*, whereas lavender oils have similarly reduced the spores of *Fusarium oxysporum* and *Penicillium expansum* (Abdi-Moghadam et al., 2023).

The antifungal mechanisms of EOs are preferentially absorbed onto the lipophilic surface of mycelia, with the degree of inhibition rising with the mycelial area. It is thought that EOs establish irreversible cross-links with fungal cell membrane components, resulting in intracellular leakage (Kiran et al., 2016). The differences in water solubility and lipophilic properties of EOs show variable action. Cinnamon, which contains linalool, has a stronger antifungal impact than basil and peppermint, which primarily contain methyl chavicol and menthol. Specific functional groups can disrupt membrane-associated enzyme proteins, influencing the inhibitory processes of EOs (Nazzaro et al. 2017).

### **1.3.3. Application of essential oils in the food industry**

The use of EOs as antimicrobial food additives has been categorized as GRAS by the US FDA. The food industry is interested in these compounds because they are abundant sources of biologically active substances with proven antimicrobial and antioxidant properties (Herman et al., 2019). The fundamental strategy for ensuring food safety is to lower the initial microbiological load and/or restrict the proliferation of residual bacteria during post-process applications, such as manufacturing and storage, by employing active packaging (Yildirim et al., 2018). Cinnamon and clove EOs are included in the most popular natural preservatives due to their active major components. The primary element of cinnamon essential oil is cinnamaldehyde, which effectively inhibits a variety of food spoilage microorganisms. The clove oil contained eugenol, which possesses insecticidal and antibacterial properties. These oils meet the current standards for "natural, safe, and healthy" preservatives as they are naturally antibacterial agents (Ju et al., 2018). According to Haddi et al. (2017), cinnamon EOs have been described as the most significant oil used in the food and cosmetic sectors, particularly as an antibacterial agent because of its several uses including as flavoring

and aromatic agents. Cinnamon oil encapsulation in cyclodextrin nano sponges offers a possible application for antibacterial food packaging (Simionato et al., 2019). Moreover, chicken packed with the linear low-density polyethylene (LLDPE) surface chemically modified by chromic acid and coated with clove oil films exhibited strong antimicrobial activity against *Salmonella* Typhimurium and *Listeria monocytogenes* at refrigeration for 21 days (Mulla et al., 2017). Khaleque et al. (2016) described that high concentrations of clove and cinnamon oils have been shown to control the *L. monocytogenes* in ground beef. Therefore, EOs are natural, safe, and GRAS-recognized for application in the food industry with small or large concentrations based on the impacts of bioactive components that have been shown to enhance product quality and safety without compromising nutritional value or sensory experience (Herman et al., 2019).

#### **1.4. Research objectives**

The main purpose of this study is to characterize the antimicrobial-resistant *L. monocytogenes* and their biocontrol by using specific bacteriophages and plant-based essential oils. The specific objectives of this research are:

- 1) To isolate and characterize the *L. monocytogenes* strains in 2022, and compare their prevalence, antimicrobial resistance, and pathogenicity profiles in 2017 and 2012,
- 2) To isolate and characterize bacteriophages specific to *L. monocytogenes*,
- 3) To evaluate the anti-listerial activity of EOs and their application in single and combined with phage vB\_LmoS-PLM9 against pathogenic *L. monocytogenes* in broth and milk, and
- 4) To investigate the effects of phage vB\_LmoS-PLM9 and/or cinnamon bark and clove oils on the viability of *L. monocytogenes* in solid foods and their biofilm.

## Chapter 2. Occurrence and characterization of *Listeria monocytogenes* in recent 5-year in Fukuoka, Japan

### 2.1. Introduction

A dangerous foodborne pathogen, *Listeria monocytogenes* is abundantly found in environments and causes listeriosis infection in the elderly and fetuses. A significant death rate of up to 30 % is linked to contaminated foods including milk, meats, seafood, and vegetables (Ai et al., 2022; Bouymajane et al., 2021). Among the identified 13 serotypes, serotypes 1/2a, 1/2b, and 4b occurred in more than 95 % of human listeriosis cases; of these, 1/2a and 1/2b have primarily been isolated from food, while 4b from clinical samples (Jamali and Thong, 2014). Since the matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) became the modernized technique to classify and identify microorganisms quickly and accurately, many researchers are approaching to characterize the *L. monocytogenes* by this method (Li et al., 2022; Thouvenot et al., 2018).

Antimicrobial-resistant (AMR) *L. monocytogenes* have emerged because of antibiotic misuse in human and veterinary medicine, raising concerns for global public health. Since the first antimicrobial-resistant *L. monocytogenes* was discovered in France in 1988, certain multidrug-resistant strains were commonly isolated from food and environment (Matereke and Okoh, 2020; Maung et al., 2019; Poyart-Salmeron et al., 1990). Antimicrobial resistance determinants can be exchanged between *L. monocytogenes* and other bacterial species through efflux pumps, horizontal gene transfer, and the ability to build biofilms. The biofilm capability of bacterial pathogens can increase their resistance to antibiotics, detergents, and environmental stressors compared to their planktonic counterparts (Henriques and Fraqueza, 2017; Lee et al., 2019). The pathogenicity of *L. monocytogenes* varied depending on biofilm formation intensity and virulence factors of the types of the isolates. The virulence genes, including *hlyA*, *inlA*, *plcA*, and *clpC*, play important roles during the various phases of

*Listeria* infections (Quereda et al., 2021).

The isolation source, and environmental, temporal, seasonal, and regional variations influence the incidence, AMR, virulence, and biofilm formation capability of foodborne pathogens such as *L. monocytogenes* (Matereke and Okon, 2020). The AMR profiles of *L. monocytogenes* isolated from raw chicken meat in 2012 and 2017 were described in our previous investigation (Maung et al., 2019), however, an assessment of the current circumstances is still necessary. Therefore, this study aimed to (i) determine the occurrence, characterization in serotyping and MALDI-TOF analysis, and AMR of *L. monocytogenes* isolates in 2022; (ii) compare their profiles to those of the previous isolates from 2012 and 2017; and (iii) examine the virulence genes and biofilm development of *L. monocytogenes* strains isolated in 2012, 2017 and 2022.

## **2.2. Materials and methods**

### **2.2.1. Sample collection**

Eighty-five raw chicken meat and internal organs samples were randomly purchased from 11 supermarkets (A-J) in Fukuoka City, Japan from February to June 2022. On the same day as sampling, all samples were delivered to the Laboratory of Food Hygienic Chemistry, Kyushu University for analysis.

### **2.2.2. Isolation and identification of *L. monocytogenes***

The bacterial strains of *L. monocytogenes* were isolated using the method reported by Maung et al. (2019). Briefly, each of the samples (10 g) was weighed in a stomacher bag, added 90 mL of Fraser broth (CM0895, Oxoid Ltd., UK) containing Half-Fraser supplement (SR0166E, Oxoid Ltd., UK), homogenized and incubated at 30 °C for 24 h. Later, the secondary enrichment culture (SEC) was prepared by mixing 0.1 mL of primary enrichment culture (PEC) and 10 mL of Fraser broth including Fraser supplement (SR0156E, Oxoid Ltd., United Kingdom), and the mixture was incubated at 37 °C for 48 h. Both enrichment cultures were streaked on CHROMagar™ *Listeria*

(CHROMagar, Paris, France) and kept at 37 °C for 24-48 h. Suspected colonies were shown as blue with white halos and continuously identified using CHROMagar™ Identification *Listeria* (CHROMagar, Paris, France). After 24 h incubation at 37 °C, mauve colonies with halos were detected as *L. monocytogenes*. The laboratory strain no.174 (Liu et al., 2012) and ATCC15313™ standard strain were used as positive controls.

### **2.2.3. MALDI-TOF MS analysis**

The isolates in 2022 (n=17), 2017 (n=12), and 2012 (n=12) were analyzed using the MALDI-TOF MS (Bruker Daltonik GmbH., Bremen, Germany) and the profile spectrum is compared to that of a library of well-characterized bacteria. In brief, the isolates were grown on TSA agar at 37 °C for 24 h. Colonies were suspended in sterilized water (300 µL) and vortexed for 30 s before adding 900 µL of 99.5% high-graded ethanol. The prepared samples were promptly stored at –20 °C until analysis at Fukuoka Sangyo University. The manufacturer's (Bruker) recommendations were followed when applying the identification score criteria. As a result, scores of  $\geq 2.000$  indicate species-level identification, 1.700–1.999 for genus-level identification, and  $< 1.700$  for no adequate identification. Three separate MALDI-TOF MS analyses were performed on the samples of isolates. Strains with scores  $> 2.0$  were used to build dendrograms. Principal component analysis (PCA) dendrograms were constructed to assess the protein similarity of MALDI-TOF MS on the tested isolates using the Biotyper software.

### **2.2.4. Serotyping**

The serotyping of *L. monocytogenes* isolates (n=17) was performed using a *Listeria* antisera kit (Denka Seiken Co., Tokyo, Japan) followed by the manufacturer's instructions and Maung et al. (2019). *L. monocytogenes* possessed serotype 1/2a (strain no.174) was employed as a control.

### 2.2.5. Antimicrobial susceptibility testing (AST)

As previously reported by Maung et al. (2019), AST was determined by broth microdilution method using a 96-well DP 32 dry plate (Eiken Chemical Co., Tokyo, Japan). Briefly, the colonies on BHI agar were suspended in 0.9 % NaCl and adjusted to attain an OD<sub>600</sub> of 0.1. Bacterial inoculum was prepared by diluting with Mueller Hinton broth to yield a cell suspension with  $5 \times 10^4$  CFU/mL and added 100  $\mu$ L to each well of the DP 32 containing different concentrations of 18 antimicrobial agents: oxacillin, ampicillin, cefazolin, cefmetazole, flomoxef, imipenem, gentamycin, arbekacin, minocycline, cefoxitin, erythromycin, clindamycin, vancomycin, teicoplanin, linezolid, fosfomycin, sulfamethoxazole/trimethoprim and levofloxacin. The suspension was added to a well without any antibiotics as a control. After incubation at 37 °C for 18-24 h, culture absorbance was measured with a microplate reader Infinite F50/Robotic (Tecan Trading AG, Switzerland). The minimum inhibitory concentrations (MIC), MIC<sub>50</sub>, and MIC<sub>90</sub> were evaluated. Based on CLSI (2021) and Maung et al. (2019), the interpretation was classified as resistant, intermediate, or susceptible.

### 2.2.6. Detection of virulence genes

A total of 36 isolates were used from selected 12 isolates in each year of 2012, 2017, and 2022 (Tables 2.1 and 2.4). The polymerase chain reaction (PCR) was employed to detect the virulence genes such as *hlyA*, *plcA*, *clpC*, and *inlA* using the primer sequences shown in Table 2.2. The PCR mixture (25  $\mu$ L) was prepared by adding 12.5  $\mu$ L of GoTaq Green Master Mix (Promega, Madison, WI, USA), 8  $\mu$ L of double-distilled water, 1.25  $\mu$ L of each 10  $\mu$ M primer, and 2  $\mu$ L of template DNA. The PCR conditions were set up with initial denaturation at 94 °C for 3 min, followed by 30 cycles of denaturation at 94 °C for 30 s, annealing at 57 °C for 30 sec, extension at 72 °C for 1 min, and final extension at 72 °C for 2 min. The amplified PCR products

were electrophoresed on a 1 % agarose gel stained with Midori Green Advance DNA stain (Nippon Genetics Europe GmbH, Germany), and visualized on WSE-6100H LuminoGraph I (ATTO, Tokyo, Japan). *L. monocytogenes* strain no.1 (serotype 1/2a) harboring *hlyA*, *plcA*, *clpC*, and *inlA* genes (Honjoh et al., 2008) was used as a positive control.

### **2.2.7. Determination of biofilm-forming ability**

The biofilm development of the 36 isolates was assessed using a microtiter plate assay, as previously described by Miyamoto et al. (2011). In brief, overnight cultures of each isolate were adjusted with BHI broth to achieve OD<sub>660</sub> of 0.7. The adjusted culture (200 µL) was applied to each 96-well polystyrene microtiter plate, which was then incubated at 30 °C for 24 h. Following biofilm formation, the suspension was carefully pipetted out and planktonic cells were rinsed twice with phosphate-buffered saline (PBS). After drying at room temperature, 200 µL of 0.1 % crystal violet (CV) was added to each well and allowed for 30 min to stain bacterial biomass. The plates were rinsed 4 times with PBS to remove excess stains. Then, 95 % ethanol (200 µL) was applied to solubilize the residual CV and measured with OD<sub>595</sub> using an Infinite F50/Robotic microplate reader (Tecan Trading AG, Switzerland) to assess biofilm-forming capacity. The cut-off value (OD<sub>c</sub>: the average OD of the negative control) was ascertained by measuring the OD of sterile BHI broth, which was utilized as the negative control. The results were classified as follows: weak (OD<sub>c</sub> < OD<sub>595</sub> ≤ 2 × OD<sub>c</sub>), moderate (2 × OD<sub>c</sub> < OD<sub>595</sub> ≤ 4 × OD<sub>c</sub>), or strong (4 × OD<sub>c</sub> < OD<sub>595</sub>) biofilm production (Stepanović et al., 2000).

### **2.2.8. Statistical analysis**

Statistical analysis was performed using IBM SPSS Statistics version 25.0 (IBM Corp., Armonk, New York). Significant differences ( $P < 0.05$ ) between isolates from

5-year intervals were analyzed by one-way ANOVA and Tukey's multiple comparison test.

## **2.3. Results**

### **2.3.1. Occurrence of *L. monocytogenes* in food**

Nine out of the 85 samples, 10.6 % were positive for *L. monocytogenes*, and 17 strains were isolated from PEC and SEC of various chicken samples. The sample numbers (1–85) and enrichment cultures (PEC and SEC) were used to create the names of the isolated *L. monocytogenes*. The isolates were found in the samples of 3 breast meats, 2 chicken wings, 2 skins, 1 minced meat, and 1 thigh, but it was not observed in internal organs and bone samples (Table 2.3).

### **2.3.2. Identification of the isolates by MALDI-TOF MS analysis**

Tables 2.1 and 2.4 display the best match scores ranging from 2.112 to 2.511 of the MALDI-TOF MS analysis for *L. monocytogenes* isolates from different years. Figure 2.1 shows the PCA dendrogram of 17 isolates in 2022, split into four clusters upon protein similarity in MALDI-TOF MS profiles. There were 6 isolates (35.29 %), 4 (23.53 %), 4 (23.53 %), and 3 (17.65 %) in each of the four clusters, I through IV. The isolates (5PEC and 5SEC) in cluster-I, (25PEC and 25SEC), and (28PEC and 28SEC) in cluster-II had high MALDI-TOF MS similarity and shared the same serotype, AMR pattern, and source. The isolates (45PEC and 45SEC) in cluster-I and (55PEC and 55SEC) in cluster-III originated from the same source. The isolates 83PEC and 54SEC from the same cluster-IV shared the same serotype and AMR characteristics.

Figure 2.2 depicts the PCA dendrogram of 36 isolates from various years, which were divided into six clusters (I–VI). Isolates (16FO, S18HO, 12HO, S41HC, 54PEC) had the same serotype (1/2b) and AMR patterns (MPIPC, CFX, FOM), while isolates (48FA and 6HA) had serotype 1/2b and AMR patterns (MPIPC, CFX). Furthermore, some of the isolates from the same clusters (50FO and 68HA in cluster-V, 59HO and

55HA in cluster-VI) possessed the same serotype, AMR patterns, source, and year. The isolates 2FA and S24FC shared the same serotype (1/2b) and AMR patterns (MIPIC, CFX, and FOM) in MALDI-TOF MS cluster VI.

### **2.3.3. Serotyping of the isolates**

Based on serotype investigation of 17 *L. monocytogenes* isolates, serotypes 1/2b, 3a, 3b, and 1/2a were found to be 41.2, 29.4, 23.5, and 5.9 % respectively (Table 2.4).

### **2.3.4. Antimicrobial susceptibility of the isolates**

Four AMR patterns (a) CFX (b) MIPIC, CFX (c) CFX, FOM, and (d) MIPIC, CFX, FOM were observed in 17 isolates from 2022 (Table 2.4). Antimicrobial susceptibility profiles were calculated depending on 12 different isolates since they were isolated from the same samples that shared the same serotypes and AMR patterns. The antibiogram of the isolates is shown in Table 2.5. The AMR profiles including MIC<sub>50</sub> and MIC<sub>90</sub> of the isolates from 2022 are displayed in Table 2.6. Most of the isolates were susceptible to multiple antibiotics except intermediate resistance to cefmetazole (75 %), and resistance to ceftiofur (100 %), oxacillin (41.7 %), and fosfomycin (41.7 %). For multidrug resistance (MDR), only 2 isolates (16.7 %) were resistant to 3 antibiotics (Table 2.5c).

### **2.3.5 Comparison of occurrence, serotyping, and AMR of *L. monocytogenes* isolates in 2012, 2017, and 2022**

As shown in Fig. 2.3, the prevalence of *L. monocytogenes* isolated from raw chicken samples in 2022 (10.6 %, 9/85 samples) was significantly ( $P < 0.05$ ) lower than those in 2017 (24.0 %, 12/50) and 2012 (52.9 %, 45/85). The serotype distributions of the isolates in different years indicated that serotypes 1/2b, 3a, 3b and 1/2a were 41.2, 29.4, 23.5, and 5.9 % in 2022; serotypes 1/2b and 1/2a were 51.7 and 48.3 % in 2017; and serotypes 1/2b, 1/2a, 4b, and 1/2c were 73.9, 21.5, 3.1, and 1.5 % in 2012 respectively. The pathogenic serotypes 1/2a and 1/2b responsible for more than 95 %

of human listeriosis decreased over time, and 4b was not detected in 2022. Non-pathogenic serotypes 3a and 3b were commonly found only in 2022 isolates (Fig. 2.4).

The changes in AMR of the isolates from the recent 5-year were demonstrated in Fig. 2.5. The isolates in different years showed susceptibility to various tested antibiotics. However, 100 % in 2022 and 2017, and 98.7 % in 2012 were highly resistant to cefoxitin, followed by 72 % in 2012, 82.6 % in 2017, and 41.7 % in 2022 to oxacillin, and 57.3 % in 2012, 95.7 % in 2017 and 41.7% in 2022 to fosfomycin respectively. Furthermore, clindamycin (8 %) and flomoxef (2.7 %) resistance were detected in 2012 isolates, as well as clindamycin (17.4 %) and linezolid (4.3 %) resistance in 2017, but these antibiotic resistances were not found in 2022 (Fig. 2.5A). Figure 2.5B indicates that isolates in 2012 were resistant to one (12 %), two (40 %), three (40 %), and four (6.7 %) antibiotics, whereas those in 2017 were resistant to one (3.5 %), two (10.3 %), three (72.4 %), four (3.0 %), and five (3.5 %) medicines. However, the isolates obtained in 2022 demonstrated resistance to one (33.3 %), two (50.0 %), and three (16.7 %) antibiotics. In 2022, the MDR rate for *L. monocytogenes* was 16.7%, significantly lower ( $P < 0.05$ ) than in 2017 (82.6 %) and 2012 (46.7 %) isolates (Fig. 2.5C).

### **2.3.6. Comparison of virulence genes possession and biofilm-forming ability of *L. monocytogenes* isolates in 2012, 2017, and 2022**

All four virulence genes were detected in different years of the isolates except for the *clpC* and *inlA* genes in 2017 (S15FC) and the *clpC* gene in 2022 (83PEC).

Figure 2.6A shows the median value (interquartile range) of biofilm mass indicated 0.17 (0.10, 0.25) in 2022, which were significantly ( $P < 0.05$ ) weaker than 0.26 (0.13, 0.34) in 2017, and 0.23 (0.08, 0.33) in 2012. The biofilm formation abilities of the 2012 isolates were estimated as weak (8.3 %), moderate (50 %), and strong (41.7 %); those of the 2017 isolates were found to be moderate (41.7 %) and strong (58.3 %); and those of the 2022 isolates were found to be weak (8.3 %), moderate (75 %), and strong (16.7 %) (Fig. 2.6B).

## 2.4. Discussion

The study related to *L. monocytogenes* contamination in foods has been lacking in Japan since 2017. This study is the first report to compare the pathogenicity in virulence gene detection and biofilm-producing capability of the *L. monocytogenes* isolates in 5-year differences. The incidence of *L. monocytogenes* in 2022 was 10.6 % (9/85) of raw chicken samples. This finding was consistent with the contamination range (8.7-15.1 %) of raw chicken that was recently investigated in various nations including 8.7% in China, 11.1 % in Ethiopia, 13 % in Brazil, and 15.1 % in South Africa (Cavalcanti et al., 2022; Diriba et al., 2021; Kaptchouang Tchatchouang et al., 2022; Liu et al., 2020b). However, our result was greater than that of 3.9 % of poultry in Poland (Skowron et al., 2020), 1.9%-5.7 % of chicken meat in Morocco (Bouymajane et al., 2021) but lower than that of 56 % of poultry in Spain (Panera-Martínez et al., 2022). The variances in the prevalence of *L. monocytogenes* between this study and other investigations could be attributed to differences in sampling procedures, seasonal and geographical fluctuations, and differing sanitary conditions during food preparation and storage (Bouymajane et al., 2021). In a 5-year difference surveillance, the contamination rate of *L. monocytogenes* contamination in 2022 was significantly lower ( $P < 0.05$ ) than those in 2012 (52.9 %, 45/85) and 2017 (24 %, 12/50). The yearly trend of declining contamination rates of *L. monocytogenes* in Japan could be linked to improved hygienic conditions in poultry processing facilities as well as temperature control during transport and storage. Other studies also concurred that the *L. monocytogenes* infection rate in ready-to-eat meat and poultry products had decreased globally, including in the United States (Mamber et al., 2020; Sampedro et al., 2022).

MALDI-TOF MS analysis provides a fast and accurate way to identify bacteria (Thouvenot et al., 2018). In the current investigation, MALDI-TOF MS accurately identified all the isolates as *L. monocytogenes* at the species level, with a score of  $> 2.0$ . The PCA dendrogram of the isolates, particularly 17 strains from 2022, revealed that some

of the isolates included in the same cluster by MALDI-TOF MS were identical in serotype, source, year of isolation, and antibiotic resistance profile (Figs. 2.1 and 2.2). This result demonstrated that *L. monocytogenes* strains isolated from raw chickens were successfully recognized and clustered into a group of closely related strains using PCA analysis of MALDI-TOF MS data. It was claimed that PCA analysis of MALDI-TOF MS data from bacterial strains could be relevant in epidemiological studies on infectious diseases.

According to our findings, serotypes 1/2b and 1/2a were most isolated from raw chickens in various years, while serotypes 3a and 3b were only discovered in 2022. Serotypes 4b and 1/2c were identified in 2012, but not in 2017 or 2022. Wang et al. (2017) found that 90 % of the isolates belonged to serotypes 1/2a and 1/2b according to their proclivity to multiply or survive in foods. Shimojima et al. (2016) also noted that these serotypes are common in a variety of foods in Japan. Moreover, human listeriosis-related serotypes, 1/2a and 1/2b are most common in food, and 4b is in clinical cases (Bouymajane et al., 2021; Buchanan et al., 2017; Cavalcanti et al., 2022). These results suggested that the epidemiologically relevant serotypes 1/2a and 1/2b were reduced in 2022 compared to 2012 and 2017, indicating public health risk of listeriosis in Japan seems lower than in other countries.

The pathogenicity levels of *L. monocytogenes* were determined in virulence gene detection and the biofilm-forming ability of the isolates. The *hlyA* and *plcA* genes were detected in all isolates in different years using the primer sequences designed in the current investigation. The listeriolysin O encoding gene (*hlyA*) is used to detect the virulence of *L. monocytogenes* (Liu et al., 2012; Mohamed et al., 2016). In our earlier investigation, we employed primer sequences generated by Liu et al. (2012) to detect *hlyA* in 2017 isolates, and only 58.6 % (17/29) of the isolates tested positive due to spontaneous mutations (Maung et al., 2019). However, all isolates could be detected for the *hlyA* gene when I used the primer sequence designed in this study. As a result, the *hlyA* and *plcA* primer sequences used in this experiment were suitable for

amplifying the genes of *L. monocytogenes* from various years, which may be beneficial for detecting *L. monocytogenes* and virulence genes in future research. Furthermore, *inlA* and *clpC* were found in many isolates obtained throughout a range of years. These findings are in line with research from other countries, including Turkey (AI et al., 2022), Morocco (Bouymajane et al., 2021), Brazil (Iwa and Okoh, 2020), and Poland (Wiśniewski et al., 2022).

According to Wang et al. (2017), the development of biofilm varies based on the types of strain, nutrients of the medium, and environment. In this study, the biofilm-forming ability of the isolates in different years was carried out using the same conditions. All the isolates from various years could produce biofilms, however, the 2022 isolates exhibited notably reduced biofilm formation ( $P < 0.05$ ) in comparison to the isolates from 2012 and 2017. Wiśniewski et al. (2022) documented that *L. monocytogenes*' capacity to form biofilms can boost their survival in food and food processing environments, complicating decontamination and increasing the risk of listeriosis. These findings imply that the isolates from 2022 are less pathogenic than the isolates from earlier batches.

The isolates in 5 different years were commonly resistant to cefoxitin, oxacillin, and fosfomycin. These resistant antibiotics suppress the peptidoglycan formation in bacterial cell walls (Maung et al., 2019; Panera-Martínez et al., 2022). Most of the 2022 isolates were highly resistant to cefoxitin, followed by oxacillin and fosfomycin, which were lower than the 2017 and 2012 isolates. Additionally, 2022 isolates had a significantly ( $P < 0.05$ ) decreased MDR rate compared to 2017 and 2012. These findings contrast with recent studies in other nations including Morocco, South Africa, the United States, and Spain which showed high resistance to various antibiotics in *L. monocytogenes* (Kaptchouang Tchatchouang et al., 2022; Kayode and Okoh, 2022; Panera-Martineaz et al., 2022). This can be justified by advances in public health knowledge, understanding of AMR, and antimicrobial use in healthcare, nursing care,

food, livestock production, and aquaculture under the guidelines of the Japanese Government's National Action Plan on Antimicrobial Resistance (2016-2020). Noritake and Hodin (2022) confirmed that these guidelines effectively lowered total antimicrobial usage nationwide. Furthermore, food additives and other alternative antimicrobials may be recommended in Japan's food and processing facilities to help prevent *L. monocytogenes* antimicrobial resistance in foods.

## 2.5. Summary

This study examined the prevalence, serotype, MALDI-TOF MS characterization, antimicrobial resistance, virulence gene detection, and biofilm formation of *Listeria monocytogenes* isolated from raw chickens in 2022. The profiles of these isolates were compared with those of isolates from 2012 and 2017. In the investigation in 2022, 9 out of 85 chicken samples (10.6 %) were positive, and 17 *L. monocytogenes* were detected. The serotype distributions of 1/2b, 3a, 3b, and 1/2a indicated 41.2 %, 29.4 %, 23.5 %, and 5.9 % respectively. The isolates in various years were successfully identified and clustered using PCA dendrograms of MALD-TOF MS analysis. In the AMR detection, all isolates were susceptible to most of the tested antibiotics except ceftiofur, oxacillin, and fosfomycin. In a 5-year difference surveillance, the *L. monocytogenes* occurrence in 2022 (10.6 %) was significantly lower ( $P < 0.05$ ) than those in 2017 (24 %) and 2012 (52.9 %). The epidemiologically important serotypes 1/2a, 1/2b, and 4b decreased over time. The MDR rate in 2022 (16.7 %) was significantly lower than those in 2017 (82.6 %) and 2012 (46.7 %). Furthermore, *hlyA*, *plcA*, *clpC*, and *inlA* virulence genes were detected among 36 isolates from different years. Most of the isolates in different years harbored 4 virulence genes. The isolates in 2022 exhibited significantly ( $P < 0.05$ ) weaker biofilm formation than in 2012 and 2017. Despite the low levels of contamination in chicken flesh and AMR of the isolates, virulent *L. monocytogenes* contamination in food should be recognized.

**Table 2.1.** Conventional and MALDI-TOF MS identification, serotype, ribotype, and antimicrobial resistance patterns of *L. monocytogenes* isolates in 2012 and 2017

| No.           | Isolate | Source      | Conventional method     | MALDI-TOF MS            |             | Serotype | Ribotype          | AMR patterns               |
|---------------|---------|-------------|-------------------------|-------------------------|-------------|----------|-------------------|----------------------------|
|               |         |             |                         | Organism                | Score value |          |                   |                            |
| 2012 Isolates |         |             |                         |                         |             |          |                   |                            |
| 1             | 2FA     | Minced meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.494       | 1/2b     | ECORI 422-249-S-4 | MPIPC, CFX, FOM            |
| 2             | 4FA     | Thigh       | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.282       | 1/2b     | ECORI 422-62-S-7  | MPIPC, CFX, FOM            |
| 3             | 6HA     | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.302       | 1/2b     | ECORI 422-245-S-2 | MPIPC, CFX                 |
| 4             | 8HO     | Wing        | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.256       | 1/2b     | ECORI 422-260-S-2 | MPIPC, CFX, FOM            |
| 5             | 11HO    | Minced meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.396       | 1/2a     | ECORI 422-257-S-2 | MPIPC, CFX, FOM            |
| 6             | 12HO    | Thigh       | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.301       | 1/2b     | ECORI 422-257-S-2 | MPIPC, CFX, FOM            |
| 7             | 21FA    | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.4         | 1/2b     | ECORI 422-261-S-3 | MPIPC, CFX                 |
| 8             | 48FA    | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.248       | 1/2b     | ECORI 422-240-S-3 | MPIPC, CFX                 |
| 9             | 50FO    | Minced meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.301       | 1/2a     | ECORI 422-242-S-3 | CFX                        |
| 10            | 55HA    | Minced meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.351       | 1/2a     | ECORI 422-247-S-8 | MPIPC, CFX                 |
| 11            | 59HO    | Minced meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.356       | 1/2a     | ECORI 422-244-S-8 | MPIPC, CFX                 |
| 12            | 68HA    | Minced meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.315       | 1/2a     | ECORI 422-242-S-3 | CFX                        |
| 2017 Isolates |         |             |                         |                         |             |          |                   |                            |
| 1             | S4FO    | Broiler     | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.342       | 1/2a     | ECORI 422-320-S-2 | MPIPC, CFX, FOM            |
| 2             | S8HC    | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.39        | 1/2a     | ECORI 422-317-S-5 | MPIPC, CFX, CLDM, LZD, FOM |
| 3             | S15FC   | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.424       | 1/2a     | ECORI 422-63-S-6  | CFX, FOM                   |
| 4             | S16FO   | Wing        | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.424       | 1/2b     | ECORI 422-62-S-7  | MPIPC, CFX, FOM            |
| 5             | S18HO   | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.3         | 1/2b     | ECORI 422-318-S-8 | MPIPC, CFX, FOM            |
| 6             | S24FC   | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.112       | 1/2b     | ECORI 422-75-S-3  | MPIPC, CFX, FOM            |
| 7             | S25FC   | Minced meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.398       | 1/2b     | ECORI 422-320-S-6 | MPIPC, CFX, CLDM, FOM      |
| 8             | S31HO   | Thigh       | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.358       | 1/2a     | ND                | MPIPC, CFX, FOM            |
| 9             | S38HC   | Thigh       | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.327       | 1/2a     | ECORI 422-320-S-6 | MPIPC, CFX, CLDM, FOM      |
| 10            | S39HC   | Wing        | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.198       | 1/2b     | ECORI 422-62-S-7  | CFX                        |
| 11            | S41HC   | Skin        | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.466       | 1/2b     | ND                | MPIPC, CFX, FOM            |
| 12            | S42HC   | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.511       | 1/2b     | ND                | MPIPC, CFX, FOM            |

ND= not detected

MPIPC: Oxacillin, CFX: Cefoxitin, FOM: Fosfomycin, CLDM: Clindamycin, LZD: Linezolid

**Table 2.2.** Primer sequences used for the detection of virulence genes

| Target gene | Primer sequence (5'-3')                                      | Target size (bp) | References           |
|-------------|--------------------------------------------------------------|------------------|----------------------|
| <i>hlyA</i> | F: GCATTGATTTGCCAGGTATG<br>R: TTTCTGCATTCACTCCAAGC           | 399              | This study*          |
| <i>plcA</i> | F: TGATTATCGGATCCAACCAC<br>R: GTTTGTTTTTCGGGGAAGTC           | 447              | This study*          |
| <i>clpC</i> | F: TCTTGGTATTAGTTTGAATAAAGCTC<br>R: TCAAACGTACTTTAGAACCAGATT | 833              | Honjoh et al. (2008) |
| <i>inlA</i> | F: TTTTCTATAATAACAAGGTAAGTGAC<br>R: CTGTATAGCTATTGGCGCTAT    | 820              | Honjoh et al. (2008) |

\*Designed based on nucleotide sequences from NCBI database ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)).

**Table 2.3.** Occurrence of *L. monocytogenes* in raw chicken and viscera samples

| No.   | Parts of samples     | No. of collected samples (n) | No. (%) of positive samples | Occurrence (%) |
|-------|----------------------|------------------------------|-----------------------------|----------------|
| 1     | Breast meat          | 17                           | 3 (17.6)                    | 3.5            |
| 2     | Minced/ chopped meat | 13                           | 1 (7.7)                     | 1.2            |
| 3     | Thigh                | 12                           | 1 (8.3)                     | 1.2            |
| 4     | Wing                 | 9                            | 2 (22.2)                    | 2.4            |
| 5     | Liver and heart      | 11                           | 0 (0.0)                     | 0.0            |
| 6     | Skin                 | 8                            | 2 (25)                      | 2.4            |
| 7     | Fillet               | 7                            | 0 (0.0)                     | 0.0            |
| 8     | Gizzard              | 4                            | 0 (0.0)                     | 0.0            |
| 9     | Ovary and oviduct    | 2                            | 0 (0.0)                     | 0.0            |
| 10    | Bone                 | 2                            | 0 (0.0)                     | 0.0            |
| Total |                      | 85                           | 9                           | 10.6           |

**Table 2.4.** Conventional and MALDI-TOF MS identification, serotype, and antimicrobial resistance patterns of *L. monocytogenes* isolates in 2022

| No. | Isolate ** | Source      | Conventional method     | MALDI-TOF MS            |             | Serotype | AMR patterns    |
|-----|------------|-------------|-------------------------|-------------------------|-------------|----------|-----------------|
|     |            |             |                         | Organism                | Score value |          |                 |
| 1   | 5PEC*      | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.344       | 3a       | CFX             |
| 2   | 5SEC       | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.204       | 3a       | CFX             |
| 3   | 25PEC*     | Skin        | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.355       | 1/2b     | MPIPC, CFX      |
| 4   | 25SEC      | Skin        | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.474       | 1/2b     | MPIPC, CFX      |
| 5   | 26PEC*     | Thigh       | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.43        | 3b       | CFX             |
| 6   | 26SEC      | Thigh       | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.342       | 3b       | CFX             |
| 7   | 28PEC*     | Wing        | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.284       | 3a       | MPIPC, CFX      |
| 8   | 28SEC      | Wing        | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.289       | 3a       | MPIPC, CFX      |
| 9   | 45PEC*     | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.257       | 3a       | MPIPC, CFX      |
| 10  | 45SEC*     | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.355       | 1/2a     | CFX             |
| 11  | 54PEC*     | Wing        | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.452       | 1/2b     | MPIPC, CFX, FOM |
| 12  | 54SEC*     | Wing        | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.147       | 1/2b     | CFX, FOM        |
| 13  | 55PEC*     | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.318       | 3b       | CFX             |
| 14  | 55SEC*     | Breast meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.373       | 1/2b     | CFX, FOM        |
| 15  | 81PEC*     | Skin        | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.329       | 3b       | MPIPC, CFX, FOM |
| 16  | 83PEC*     | Minced meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.236       | 1/2b     | CFX, FOM        |
| 17  | 83SEC      | Minced meat | <i>L. monocytogenes</i> | <i>L. monocytogenes</i> | 2.43        | 1/2b     | CFX, FOM        |

\*12 different isolates in 2022 used for detection of virulence genes and biofilm forming ability

CFX: Cefoxitin, MPIPC: Oxacillin, FOM: Fosfomicin

\*\* The names of the isolated *L. monocytogenes* were designed according to their sample number (1-85) and enrichment cultures (primary enrichment culture, PEC and secondary enrichment culture, SEC).

**Table 2.5.** Phenotypic antibiogram profile with minimum inhibitory concentration values of *L. monocytogenes* isolated in 2022

|     |         | MIC values (µg/mL) |            |           |             |          |          |            |           |             |           |              |             |            |             |           |            |                   |              |              |
|-----|---------|--------------------|------------|-----------|-------------|----------|----------|------------|-----------|-------------|-----------|--------------|-------------|------------|-------------|-----------|------------|-------------------|--------------|--------------|
| No. | Isolate | Oxacillin          | Ampicillin | Cefazolin | Cefmetazole | Flomoxef | Imipenem | Gentamycin | Arbekacin | Minocycline | Cefoxitin | Erythromycin | Clindamycin | Vancomycin | Teicoplanin | Linezolid | Fosfomycin | Sulfamethoxazole- | Trimethoprim | Levofloxacin |
| 1   | 5PEC    | 2                  | 0.25       | 1         | 32          | 8        | 0.25     | 0.25       | 0.25      | 2           | >16       | 0.12         | 1           | 1          | 0.5         | 2         | 32         | 9.5/0.5           | 1            |              |
| 2   | 5SEC    | 2                  | 0.25       | 1         | 32          | 8        | 0.25     | 0.25       | 0.25      | 2           | >16       | 0.12         | 1           | 1          | 0.5         | 2         | 32         | 9.5/0.5           | 1            |              |
| 3   | 25PEC   | 4                  | 0.25       | 2         | 32          | 8        | 0.25     | 0.5        | 0.25      | 2           | >16       | 0.12         | 0.25        | 1          | 0.5         | 2         | 32         | 9.5/0.5           | 1            |              |
| 4   | 25SEC   | 4                  | 0.25       | 2         | 32          | 8        | 0.25     | 0.5        | 0.5       | 2           | >16       | 0.12         | 0.25        | 1          | 0.5         | 2         | 32         | 9.5/0.5           | 1            |              |
| 5   | 26PEC   | 2                  | 0.25       | 2         | 32          | 8        | 0.25     | 0.25       | 0.5       | 2           | >16       | 0.12         | 0.5         | 1          | 0.5         | 2         | 32         | 9.5/0.5           | 1            |              |
| 6   | 26SEC   | 2                  | 0.25       | 2         | 32          | 8        | 0.25     | 0.25       | 0.5       | 2           | >16       | 0.12         | 0.5         | 1          | 0.5         | 2         | 32         | 9.5/0.5           | 1            |              |
| 7   | 28PEC   | 4                  | 0.25       | 2         | 32          | 8        | 0.25     | 0.25       | 0.25      | 2           | >16       | 0.12         | 1           | 1          | 0.5         | 2         | 32         | 9.5/0.5           | 1            |              |
| 8   | 28SEC   | 4                  | 0.25       | 2         | 32          | 8        | 0.25     | 0.25       | 0.25      | 2           | >16       | 0.25         | 1           | 1          | 0.5         | 2         | 32         | 9.5/0.5           | 1            |              |
| 9   | 45PEC   | 4                  | 0.25       | 2         | 32          | 8        | 0.25     | 0.25       | 0.25      | 2           | >16       | 0.12         | 1           | 1          | 0.5         | 2         | 32         | 9.5/0.5           | 1            |              |
| 10  | 45SEC   | 2                  | 0.12       | 1         | 16          | 8        | 0.25     | 0.25       | 0.25      | 2           | >16       | 0.25         | 1           | 1          | 0.5         | 2         | 32         | 9.5/0.5           | 1            |              |
| 11  | 54PEC   | 4                  | 0.25       | 1         | 16          | 8        | 0.25     | 0.25       | 0.5       | 2           | >16       | 0.25         | 1           | 1          | 0.5         | 2         | 128        | 9.5/0.5           | 1            |              |
| 12  | 54SEC   | 2                  | 0.25       | 1         | 16          | 8        | 0.25     | 0.25       | 0.5       | 2           | >16       | 0.25         | 2           | 1          | 0.5         | 2         | 128        | 9.5/0.5           | 1            |              |
| 13  | 55PEC   | 2                  | 0.25       | 2         | 32          | 8        | 0.25     | 0.25       | 0.25      | 2           | >16       | 0.12         | 0.5         | 1          | 0.5         | 2         | 32         | 9.5/0.5           | 1            |              |
| 14  | 55SEC   | 2                  | 0.25       | 2         | 32          | 8        | 0.25     | 0.5        | 0.25      | 2           | >16       | 0.12         | 0.5         | 1          | 0.5         | 2         | 128        | 9.5/0.5           | 2            |              |
| 15  | 81PEC   | 4                  | 0.25       | 2         | 32          | 8        | 0.25     | 0.25       | 0.25      | 2           | >16       | 0.25         | 1           | 1          | 0.5         | 2         | 128        | 9.5/0.5           | 0.5          |              |
| 16  | 83PEC   | 2                  | 0.5        | 2         | 32          | 8        | 0.25     | 0.25       | 0.25      | 2           | >16       | 0.25         | 2           | 1          | 0.5         | 2         | 128        | 9.5/0.5           | 1            |              |
| 17  | 83SEC   | 2                  | 0.5        | 2         | 32          | 8        | 0.25     | 0.25       | 0.25      | 2           | >16       | 0.25         | 2           | 1          | 0.5         | 2         | 128        | 9.5/0.5           | 1            |              |


|  |              |
|--|--------------|
|  | Susceptible  |
|  | Intermediate |
|  | Resistance   |

**Table 2.6.** Antimicrobial resistance profiles of *L. monocytogenes* strains isolated in 2022


| Antimicrobial agents          | Concentrations (µg/mL)      | MIC <sub>50</sub> (µg/mL) | MIC <sub>90</sub> (µg/mL) | Number of Isolates (%) |        |          |
|-------------------------------|-----------------------------|---------------------------|---------------------------|------------------------|--------|----------|
|                               |                             |                           |                           | S                      | I      | R        |
| Oxacillin                     | 0.12, 0.25, 0.5, 1, 2, 4    | 2                         | 4                         | 7 (58.3)               | -      | 5 (41.7) |
| Ampicillin                    | 0.12, 0.25, 0.5, 4, 8, 16   | 0.25                      | 0.25                      | 12 (100)               | -      | -        |
| Cefazolin                     | 0.5, 1, 2, 4, 8, 16         | 2                         | 2                         | 12 (100)               | -      | -        |
| Cefmetazole                   | 1, 2, 4, 8, 16, 32          | 32                        | 32                        | 3 (25)                 | 9 (75) | -        |
| Flomoxef                      | 0.5, 1, 2, 4, 8, 16         | 8                         | 8                         | 12 (100)               | -      | -        |
| Imipenem                      | 0.25, 0.5, 1, 2, 4, 8       | 0.25                      | 0.25                      | 12 (100)               | -      | -        |
| Gentamycin                    | 0.25, 0.5, 1, 2, 4, 8       | 0.25                      | 0.5                       | 12 (100)               | -      | -        |
| Arbekacin                     | 0.25, 0.5, 1, 2, 4, 8       | 0.25                      | 0.5                       | 12 (100)               | -      | -        |
| Minocycline                   | 2, 4, 8                     | 2                         | 2                         | 12 (100)               | -      | -        |
| Cefoxitin                     | 4, 8, 16                    | >16                       | >16                       | -                      | -      | 12 (100) |
| Erythromycin                  | 0.12, 0.25, 0.5, 1, 2, 4    | 0.12                      | 0.25                      | 12 (100)               | -      | -        |
| Clindamycin                   | 0.06, 0.12, 0.25, 0.5, 1, 2 | 1                         | 2                         | 12 (100)               | -      | -        |
| Vancomycin                    | 0.5, 1, 2, 4, 8, 16         | 1                         | 1                         | 12 (100)               | -      | -        |
| Teicoplanin                   | 0.5, 1, 2, 4, 8, 16         | 0.5                       | 0.5                       | 12 (100)               | -      | -        |
| Linezolid                     | 0.25, 0.5, 1, 2, 4, 8       | 2                         | 2                         | 12 (100)               | -      | -        |
| Fosfomycin                    | 32, 64, 128                 | 32                        | 128                       | 7 (58.3)               | -      | 5 (41.7) |
| Sulfamethoxazole-Trimethoprim | 9.5/0.5, 19/1, 38/2         | 0.5                       | 0.5                       | 12 (100)               | -      | -        |
| Levofloxacin                  | 0.25, 0.5, 1, 2, 4          | 1                         | 1                         | 12 (100)               | -      | -        |

MIC- Minimum Inhibitory Concentration


S- Susceptible, I- Intermediate, R- Resistance




**Figure 2.1.** A principal component analysis (PCA) dendrogram of MALDI-TOF MS analysis for 17 *L. monocytogenes* in 2022. Strains are grouped into four clusters (numbered I–IV) by PCA analysis.




**Figure 2.2.** A principal component analysis (PCA) dendrogram of MALDI-TOF MS analysis for 36 *L. monocytogenes* strains in 2012, 2017, and 2022. Strains are grouped into six clusters (numbered I–VI) by PCA analysis.




**Fig. 2.3.** Changes of occurrence of *L. monocytogenes* isolated in 2012, 2017, and 2022. Different letters (a-c) signify significant differences,  $P < 0.05$ .



**Fig. 2.4.** Changes of serotype distribution of *L. monocytogenes* isolated in 2012, 2017, and 2022.



**Fig. 2.5.** Changes of antimicrobial resistance profiles of *L. monocytogenes* isolated in 2012, 2017, and 2022. (A) Rate of *L. monocytogenes* resistant to antibiotics tested [MIPIC- Oxacillin, ABPC- Ampicillin, CEZ- Cefazolin, CMZ- Cefmetazole, FMOX- Flomoxef, IPM- Imipenem, GM- Gentamycin, ABK- Arbekacin, MINO- Minocycline, CFX- Cefoxitin, EM- Erythromycin, CLDM- Clidamycin, VCM- Vancomycin, TEIC- Teicoplanin, LZD- Linezolid, FOM- Fosfomycin, ST- Sulfomethoxazole-Trimethoprim, LVFX- Levofloxacin] (B) *L. monocytogenes* distribution in number of resistant antimicrobials (C) Multidrug resistance rate of *L. monocytogenes*. The letters (a-c) show a significant difference at  $P < 0.05$ .



**Fig. 2.6.** Changes of biofilm formation capability of *L. monocytogenes* isolated in 2012, 2017, and 2022. (A) Biofilm mass (OD<sub>595</sub>) of the isolates in different years. Whiskers extend to minimum and maximum values, and the horizontal line and the dot in the box represent median and mean values, respectively. The letters (a-c) show a significant difference at  $P < 0.05$ . (B) Biofilm formation intensity in different years of isolates.

## **Chapter 3. Isolation and characterization of bacteriophages specific to *Listeria monocytogenes***

### **3.1. Introduction**

*Listeria monocytogenes* is a Gram-positive foodborne pathogen, widely distributed in soil, water, farms, industrial plants, and various food sources. It can cause listeriosis infection with the highest mortality rate of about 20-30 % among foodborne outbreaks (Santativongchai et al., 2023). *Listeria* infections can lead to several problems, with fatality rates of 50 %, 70 %, and 80 % for sepsis, meningitis, and maternal-fetal infections, respectively (Pushkareva and Ermolaeva, 2010; Shamloo et al., 2019). Due to the misuse and overuse of antibiotics for various purposes, establishing antimicrobial resistance (AMR) in foodborne bacteria has become a global public health issue. If the AMR is not tackled now, the predicted death rate will climb to 10 million and economic losses of over \$100 trillion by 2050 (Elsayed et al., 2023). Therefore, efforts to find appropriate alternative antibiotics have increased interest in recent years.

Bacteriophages or phages are bacterial viruses that have been considered promising antibacterial agents. Lytic phages are utilized securely and successfully because they solely interact with the target host bacteria and are not harmful to humans or animals (Garvey, 2020). They are also useful in phage-based biosensors, which are used to rapidly, precisely, and specifically identify hazardous bacteria in environmental samples (Marzban et al., 2022). Furthermore, they are effective as bio-decontamination agents against harmful bacteria in hospitals, livestock, and food supply systems (Gamachu and Debalo, 2022).

The control strategies of *L. monocytogenes* by using the potential bacteriophages in fruits, ready-to-eat foods, milk, and cheese have been studied previously (Guenther and Loessner, 2011; Leverentz et al., 2003; Rodríguez-Rubio et al., 2015). Some

countries, including the United States, Switzerland, and Canada, permit the use of phages in food production. *Listeria* phage-based products such as Listex™ P100 (bacteriophage P100), and ListShield™ (a mixture of six different bacteriophages) are available in commercial (Scattolini et al., 2021). Additionally, there has been an increase in research on the use of phages against pathogenic bacteria in food processing environments and clinical settings to eliminate and prevent the formation of biofilms (Sulakvelidze, 2011).

Many phages are limited in their ability to lyse specific bacterial species, making them less useful as a wide biocontrol for bacterial infections in the food sector (Zhou et al., 2020). Therefore, this chapter aimed to isolate the specific bacteriophages against *L. monocytogenes* and to characterize the isolated bacteriophages phenotypically and genotypically.

## **3.2. Materials and methods**

### **3.2.1. Bacterial strains and culture conditions**

The bacterial strains used in this study are shown in Table 3.1. Bacterial cells were prepared by streaking the frozen stock (−80 °C) onto tryptic soy agar (TSA, Becton, Dickinson and Company, Sparks, MD, USA) and incubated overnight at 30 °C. Then, a single colony was picked and inoculated into 5 mL of Brain Heart Infusion broth (BHI, Becton, Dickinson and Company, Sparks, MD, USA). After incubation at 30 °C for 18-24 h, the cultures were used for subsequent experiments.

### **3.2.2. Isolation, purification, and propagation of bacteriophages**

For the isolation of bacteriophages, 65 raw chicken meats and visceral samples were bought from supermarkets in Fukuoka, and 15 cattle farm samples including raw milk, faeces, compost, soil, and bedding were collected from the cattle farm in Kyushu University. Ten *L. monocytogenes* strains with varied serotypes, ribotypes, and AMR patterns, isolated from different sources, were employed as host strains (Table 3.1).

Briefly, each sample (50 g) was inoculated with an equivalent mixture (100  $\mu$ L) of 10 bacterial suspensions, homogenized with 100 mL of Luria Bertani broth (Becton, Dickinson and Company, Sparks, MD, USA) supplemented with 10 mmol/L  $\text{CaCl}_2$  in a sterile stomacher bag, and cultured at 30 °C for 24 h. The culture (10 mL) was centrifuged at  $12,000 \times g$  for 20 min at 4 °C, and the supernatant was filtered through a membrane filter with 0.22- $\mu$ m pore size (Merck Millipore, Ireland). As a preliminary step to isolate phages, spot assays were used to screen the filtrates. The overnight culture of each strain (100  $\mu$ L) was mixed with 4 mL of molten top agar (Luria Bertani broth containing 0.5 % agar) with 1 mmol/L  $\text{CaCl}_2$ , maintained at 55 °C, and poured onto a TSA plate. After that, 10  $\mu$ L of the filtrates were spotted on the bacterial lawn plate, dried, and incubated at 30 °C for 24 h. The filtrate that had shown clear plaque was used to isolate the individual phage using the plaque assay. The filtrate (100  $\mu$ L) was mixed with the same volume of host cell suspension and left at 30 °C for 1 h. The mixture (200  $\mu$ L) was added to top agar (4 mL), poured onto a TSA plate, and kept at 30 °C for 24 h.

For the purification of phages, a single plaque was picked and suspended in 1 mL of saline magnesium (SM) buffer (0.05 M Tris-HCl buffer, 0.008 M  $\text{MgSO}_4$ , 0.1 M NaCl, and 0.01 % gelatin). The phage suspension was 10-fold serially diluted with the same buffer. The diluted phage suspension (100  $\mu$ L) was mixed with its host culture (100  $\mu$ L) in 4 mL top agar. Then, the mixture was immediately poured onto a TSA plate, and kept overnight at 30 °C for plaque formation. This step was repeated at least 3 times to ensure the purity of the phages.

For the propagation of phages, the purified phage suspensions ( $10^4$ - $10^6$  PFU/ mL) were mixed with their host strains, added in 4 mL top agar, and poured onto TSA plates, then incubated at 30 °C for 24 h. The SM buffer (5 mL) was added to the dense plaque plates and shaken overnight at room temperature (25 °C). The suspensions were collected by centrifugation at  $12,000 \times g$  at 4 °C for 20 min. The supernatants were

filtered, and the filtrates were stored at 4 °C as phage stocks ( $10^8$ - $10^{10}$  PFU/mL) for further experiment.

### **3.2.3. Host range determination of isolated phages**

The host ranges of the isolated phages against 21 *L. monocytogenes* strains, 8 *Listeria* spp., and other bacterial strains (Tables 3.1, 3.4, and 3.5) were determined by spot assay. Bacterial lawns were prepared by spreading 100 µL of each bacterial culture on TSA plates, and then 10 µL of phage suspensions ( $10^8$  PFU/mL) were spotted onto the plate and maintained at 30 °C for 24 h. The lytic spectra were interpreted as (+) clear lysis, (±) turbid, and (-) no lysis.

### **3.2.4. Morphological observation of plaques**

According to host range determination, 3 different phages: vB\_LmoS-PLM9, which was isolated from chicken chopped meat; vB\_LmoS-PLM26 from cattle faeces; and vB\_LmoS-PLM34 from chicken skin were selected and observed their morphological differences from the plaque assay plates.

### **3.2.5. Transmission electron microscopy (TEM) observation**

The widest host bacteriophage vB\_LmoS-PLM34 was observed with TEM. The phage stock ( $10^{10}$  PFU/mL) was placed onto carbon-coated grids, stained with 2 % uranyl acetate, and visualized at a voltage of 100 kV using Hitachi TEM H-7650 (Hitachi Co., Ltd., Japan).

### **3.2.6. Temperature and pH stability tests**

The stability tests were performed for 3 different phages. For temperature stability, 1 mL of phage suspension in SM buffer at the final concentration ( $10^8$  PFU/mL) was placed in a 1.5 mL Eppendorf tube and incubated from 4 to 90 °C for 1 h using a mini cooling dry bath incubator, MC-0203 (Major Science Co., Ltd., Taiwan). For pH stability, 100 µL of phage suspension ( $10^9$  PFU/mL) was mixed with 900 µL of pH

values ranging from 2 to 10 of SM buffer and incubated at 30 and 4 °C for 24 h. After that, the viable phage counts were determined using plaque assay.

### **3.2.7. Genomic DNA sequencing and bioinformatic analysis**

The genomic DNA of 3 phages was extracted using a High Pure Viral Nucleic Kit (Roche, Mannheim, Germany) according to the manufacturer's instructions. The whole genomic sequencing was performed using the Illumina HiSeq system, read sequences were assembled using DFAST version 1.2.18, and the completed sequences were annotated using Prokka 1.14.6 (Seemann, 2014). Open reading frames (ORF) were predicted using the NCBI nucleotide and protein BLAST databases. The RESfinder-3.1 server (Zankari et al., 2012) and VirulenceFinder-2.0 server (Joensen et al., 2014) were used to search for antibiotic resistance and virulence factors genes.

### **3.2.8. Determination of latent period and burst size**

The one-step growth curve of lytic phage vB\_LmoS-PLM9 was performed using the protocol by Zhao et al. (2023). The target host strain of phage vB\_LmoS-PLM9, *L. monocytogenes* 193 was used in this experiment. Briefly, bacterial culture (900 µL) was mixed with phage suspension (100 µL) to obtain a multiplicity of infection (MOI) of 0.01 and incubated at 30 °C for 15 min to allow phage adsorption. The mixture was centrifuged at  $12,000 \times g$  for 5 min. Then, the pellet was resuspended in 10 mL of pre-warmed BHI broth and incubated at 30 °C with shaking for 150 min. The sample (200 µL) was withdrawn every 10 min, centrifuged, and then the supernatant was recovered and analyzed using a plaque assay. The latent period was determined as the time interval from infection to the initial release of phage progeny. The burst size was calculated by dividing the number of phages at the end of the rise period by the number of phages at the beginning of the rise period.

### **3.3. Results**

#### **3.3.1. Isolation of *L. monocytogenes* specific phages**

Nine phages (named PLM1-PLM9) targeting *L. monocytogenes* 193 (serotype 4b) and 2 phages (PLM31 and PLM34) targeting *L. monocytogenes* 174 (serotype 1/2a) were isolated from raw chicken samples (Table 3.2). From the cattle farm samples, 8 phages (PLM10-PLM17) were isolated using the host strain *L. monocytogenes* 193 (serotype 4b), 5 phages (PLM26-PLM30) against *L. monocytogenes* ATCC15313<sup>T</sup>, and 2 phages (PLM32 and PLM33) against *L. monocytogenes* 174 (serotype 1/2a) as described in Table 3.3.

#### **3.3.2. Host range of isolated phages**

The lytic spectra of the isolated phages are shown in Tables 3.4 and 3.5. The phages (PLM1-PLM9 and PLM10-PLM17) showed similar lytic spectra (41.4 %), phages (PLM26-PLM30) were able to lyse (37.9-51.7 %), and phages (PLM31-34) exhibited lytic activities (89.7-96.6 %). All phages were active against *L. monocytogenes* and other *Listeria* spp., such as *L. innocua*, *L. seeligeri*, *L. welshimeri*, and *L. grayi*, but not against *L. ivanovii* and other bacterial genera.

#### **3.3.3. Morphology of plaques**

Phage vB\_LmoS-PLM9 formed a wide and clear plaque (2.5-3 mm) with a clear boundary. Phages vB\_LmoS-PLM26 and vB\_LmoS-PLM34 formed medium-size plaques (1-1.3 mm) and pin-size plaques (0.5-0.6 mm).

#### **3.3.4. Morphology of isolated phage**

The TEM picture of the phage vB\_LmoS-34 is shown in Fig. 3.1. This phage was characterized as a member of the *Siphoviridae* family under the *Caudovirilae* order, presenting an icosahedral head (diameter ~ 60 nm) and a long and noncontractile tail (length ~ 230 nm).

### 3.3.5. Temperature and pH stability

Phages vB\_LmoS-PLM9 and vB\_LmoS-PLM 26 were stable at temperatures ranging from 4 to 50 °C but gradually declined as temperatures increased from 60 to 90 °C. Phage vB\_LmoS-PLM34 was stable at 4–40 °C, but its activity reduced at 50 °C and was not identified at 60–90 °C (Fig. 3.2A). The titers of all phages were not changed at pH from 3 to 10 at 4 °C for 24 h, while they were stable at pH from 4 to 10 at 25 °C for 24 h (Fig. 3.2B, C, and D).

### 3.3.6. Genetic characterization of phages

A genome map of phage vB\_LmoS-PLM9 is shown in Fig. 3.3. The nucleotide sequence of vB\_LmoS-PLM9 was registered in the Gene bank under the accession number OR371505. This phage was a circular double-stranded DNA genome composed of 38,345 bp with 36 % G+C content. A total of 62 ORFs were predicted in the genome, of which 32 (51.6 %) were related to known functions and 30 (48.4 %) were assigned to hypothetical functions. The genome did not contain tRNA, antibiotic resistance, virulence, or toxin genes. Phage vB\_LmoS-PLM9 had an N-acetylmuramoyl-L-alanine amidase endolysin gene. The genome annotation results are presented in Table 3.6. These proteins were classified into five groups: (i) phage structure and packing, (ii) DNA replication, (iii) host lysis, (iv) hypothetical proteins, and (v) additional functions (Fig. 3.3). The BLAST search indicated that the genomic DNA of vB\_LmoS-PLM9 had high sequence identity with those of *Listeria* phage vB\_LmoS\_188 (query cover 66 %; identity 96.45 %; accession number NC\_028871.1) and *Listeria* phage PSU-VKH-LP019 (query cover 77 %; identity 92.49 %; accession number MH341451.1).

A genome map of phage vB\_LmoS-PLM26 is also shown in Fig. 3.4. The nucleotide sequence of vB\_LmoS-PLM26 was registered in the Gene bank under the accession number OP926971. It had a circular double-stranded DNA genome

composed of 41,221 bp with 35 % G+C content. A total of 62 ORFs were predicted in the genome, of which 35 (59.3 %) were related to known functions and 24 (40.7 %) were assigned to hypothetical functions. Phage vB\_LmoS-PLM26 contained peptidoglycan l-alanyl-d-glutamate endopeptidase endolysin gene. And the genome did not contain tRNA, antibiotic resistance, virulence, or toxin genes. The genome annotation results are presented in Table 3.7. The BLAST search indicated that the genomic DNA of vB\_LmoS-PLM26 had high sequence identity with those of *Listeria* phage LP-101 (query cover 84 %; identity 93.49 %; accession number NC\_024387.1) and *Listeria* phage LP-P111 (query cover 70 %; identity 91.93 %; accession number OP779214.1).

As illustrated in Fig. 3.5, phage vB\_LmoS-PLM34 had a circular double-stranded DNA genome of 32,895 bp with 37 % G+C content. A total of 53 ORFs were predicted in the genome, of which 35 (66 %) were related to known functions and 18 (34 %) were assigned to hypothetical functions. Phage vB\_LmoS-PLM34 also contained a gene encoding lysin with N-acetylmuramoyl-L-alanine amidase activity, and the genome did not contain tRNA, antibiotic resistance, virulence, or toxin genes. The genome annotation results are presented in Table 3.8. The nucleotide sequence of vB\_LmoS-PLM34 was also registered in the Gene bank under the accession number OP926972. The BLAST search indicated that the genomic DNA of phage vB\_LmoS-PLM34 had somewhat similar sequences with those of *Listeria* phage A118 (query cover 5 %; identity 96.62 %; accession number NC\_003216.1) and *Listeria* phage A500 (query cover 4 %; identity 82.91 %; accession number NC\_00981.1).

### **3.3.7. Latent period and burst size of a lytic phage vB\_LmoS-PLM9**

As shown in Fig. 3.6, the one-step growth curve of phage vB\_LmoS-PLM9 indicated a latent period of 70 min and a burst size of  $51.2 \pm 2.1$  PFU/cell.

### 3.4. Discussion

Bacteriophages have recently been identified as potential antibacterial agents in the food sector due to their ability to kill dangerous microorganisms (Zhou et al., 2020). However, phage-based biocontrol approaches have a severely limited antibacterial spectrum because most phages are generally exclusive to a bacterial strain or species, and occasionally to a genus (Hagens and Loessner, 2010). Therefore, a phage capable of infecting various target bacterial strains still needs to be discovered as the best candidate for developing a phage-based biocontrol strategy.

In this study, bacteriophages were isolated from the same set of raw chicken samples used for *L. monocytogenes* isolation in previous Chapter 2. Since chicken meat is the most consumable meat and abundantly sold with varieties of brands in supermarkets, we used raw meat samples to isolate naturally, environmentally friendly, and beneficial phages. Cattle farm samples including raw milk, faeces, compost, pasture soil, and bedding were also used to isolate the phages because phages are naturally abundant in livestock environments. A total of 11 phages from various parts of raw chicken samples and 15 phages from cattle farm samples were isolated by targeting the 3 different *L. monocytogenes*' host strains no. 193 (serotype 4b), no. 174 (serotype 1/2a), and standard strain ATCC15313<sup>T</sup>. The titrations of all phages in this study were  $3.5 \times 10^8 - 1.7 \times 10^{10}$  PFU/mL, which were consistent with many studies, phage lysates were between  $10^6$  and  $10^{11}$  PFU/mL (Stephenson, 2016; Marzban et al., 2022). Most of the isolated phages in this investigation showed lytic activities against *L. innocua*, *L. seeligeri*, *L. welshimeri*, and *L. grayi*, as well as *L. monocytogenes*. A similar study by Zhou et al. (2020) found that the *Listeria* phage vB\_LmoM-SH3-3 can lyse *L. monocytogenes*, *L. innocua*, and *L. welshimeri*. Despite other *Listeria* spp. lacking pathogenic characteristics, they might nevertheless be sources of virulence and resistance-associated genes. Gómez et al. (2014) documented pathogenic bacteria may be able to acquire resistance genes from the reservoir of resistance genes formed by *L.*

*innocua*. In this instance, broad-host-range phages will have a wider range of applications.

According to host range determination and plaque morphology, the broadest host range phage vB\_LmoS-PLM34, followed by vB\_LmoS-PLM9 and vB\_LmoS-PLM26 were selected for further characterization. Temperature and pH are generally regarded to be the key factors influencing phage activity in the food environment. Phages typically become inactive at high temperatures, but some phages have been shown to survive temperatures as high as 60 °C. Previous studies reported that *Listeria* phages were stable at pH ranging from 4 to 10 (Byun et al., 2022; Deniz Ayaz and Cufaoglu, 2016). These findings agree with our results. Phage vB\_LmoS-PLM34 was stable at temperatures between 4 and 40 °C, while phages vB\_LmoS-PLM9 and vB\_LmoS-PLM26 were relatively stable at temperature range from 4 to 50 °C. Furthermore, all three phages remained stable at pH levels ranging from 4 to 10, indicating their efficacy in various foods processed under different conditions.

Genomic sequencing analysis indicated that all 3 phages were circular and double-stranded DNAs. All the phages did not contain tRNA, virulence, and antimicrobial resistance genes. However, phages vB\_LmoS-PLM26 and vB\_LmoS-PLM34 contained lysogeny genes, while phage vB\_LmoS-PLM9 did not. Therefore, phage vB\_LmoS-PLM9 seems to be a lytic phage, suggesting it can be safely used in food applications. Nevertheless, 3 different phages possessed the important features that their genomes encoded with lytic proteins such as endolysin and holin. Phage vB\_LmoS-PLM9 and vB\_LmoS-PLM34 genomes encoded N-acetylmuramoyl-l-alanine amidases, whereas phage vB\_LmoS-PLM26 genome encoded peptidoglycan l-alanyl-d-glutamate endopeptidase. These phage-derived lysins will be expressed into recombinant proteins, and the mechanism by which the phage rapidly lyses bacterial cells will be examined in our future study. The genetic engineering of lysogenic phage to be promising virulent phage should also be investigated.

### 3.5. Summary

This chapter investigated the isolation and characterization of bacteriophages specific to *L. monocytogenes*. Eleven phages from raw chicken samples and 15 phages from cattle farm samples were isolated. All the isolated phages exhibited lytic activities against *L. monocytogenes* as well as *L. innocua*, *L. seeligeri*, *L. welshimeri*, and *L. grayi*. The TEM observation of the widest host range phage vB\_LmoS-PLM34 showed an icosahedral head (diameter ~ 60 nm) and a long and noncontractile tail (length ~ 230 nm) under the *Siphoviridae* family. Phages vB\_LmoS-PLM9 and vB\_LmoS-PLM26 indicated high-temperature stability at 4-50 °C, while vB\_LmoS-PLM9 was 4-40 °C. All 3 phages were stable at pH ranging from 4 to 10. Genomic sequencing analysis revealed that phage vB\_LmoS-Plm9 was a lytic phage however, phages vB\_LmoS-PLM26 and vB\_LmoS-PLM34 were lysogenic phages. All phages lacked tRNA, virulence, or antimicrobial resistance genes and were composed of endolysin and holin. Phages vB\_LmoS-PLM9 and vB\_LmoS-PLM34 encoded N-acetylmuramoyl-l-alanine amidases while phage vB\_LmoS-PLM26 encoded peptidoglycan l-alanyl-d-glutamate endopeptidase. One-step growth curve analysis of lytic phage vB\_LmoS-PLM9 with MOI of 0.01 indicated a latent period of 70 min and a burst size of  $51.2 \pm 2.1$  PFU/cell. Therefore, this study was successfully investigated in isolating and characterizing bacteriophages against *L. monocytogenes*, specifically three different phages.

**Table 3.1.** Bacterial strains used in this study

| Bacterial strains                                    | Serotype                                                                                 | Ribotype          | Antimicrobial resistance patterns | Source                    |
|------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------|-----------------------------------|---------------------------|
| <i>L. monocytogenes</i> S8HC*                        | 1/2a                                                                                     | ECORI 422-90-S-1  | MPIPC,CFX,CLDM,LZD,FOM            | Breast                    |
| <i>L. monocytogenes</i> S4HO                         | 1/2a                                                                                     | ECORI 422-75-S-3  | MPIPC,CFX,CLDM,FOM                | Broiler                   |
| <i>L. monocytogenes</i> S25FC*                       | 1/2b                                                                                     | ECORI 422-318-S-8 | MPIPC,CFX,CLDM,FOM                | Minced meat               |
| <i>L. monocytogenes</i> S38HC*                       | 1/2a                                                                                     | ECORI 422-320-S-6 | MPIPC,CFX,CLDM,FOM                | Thigh                     |
| <i>L. monocytogenes</i> S24FC                        | 1/2b                                                                                     | ECORI 422-75-S-3  | MPIPC,CFX,FOM                     | Breast                    |
| <i>L. monocytogenes</i> S31FC                        | 1/2a                                                                                     | ND                | MPIPC,CFX,FOM                     | Thigh                     |
| <i>L. monocytogenes</i> 8FO*                         | 1/2b                                                                                     | ECORI 422-260-S-4 | MPIPC,FMOX,CFX,FOM                | Fillet                    |
| <i>L. monocytogenes</i> 76HA                         | 1/2a                                                                                     | ECORI 422-246-S-5 | MPIPC,FMOX,CFX,FOM                | Wing drummette            |
| <i>L. monocytogenes</i> 11FA                         | ND                                                                                       | ECORI 422-62-S-1  | MPIPC,CFX,CLDM,FOM                | Minced                    |
| <i>L. monocytogenes</i> 37HA                         | ND                                                                                       | ECORI 422-258-S-2 | MPIPC,CFX,CLDM,FOM                | Minced                    |
| <i>L. monocytogenes</i> 38FO                         | ND                                                                                       | ECORI 422-265-S-7 | MPIPC,CFX,CLDM,FOM                | Thigh fillet              |
| <i>L. monocytogenes</i> 11HO                         | 1/2a                                                                                     | ECORI 422-258-S-2 | MPIPC,CFX,FOM                     | Minced                    |
| <i>L. monocytogenes</i> 12HA                         | 1/2b                                                                                     | ECORI 422-258-S-5 | MPIPC,CFX,FOM                     | Thigh                     |
| <i>L. monocytogenes</i> 26FA*                        | 4b                                                                                       | ECORI 422-253-S-8 | MPIPC,CFX,CLDM                    | Thigh                     |
| <i>L. monocytogenes</i> 56HO                         | 1/2c                                                                                     | ECORI 422-244-S-3 | MPIPC,FOM                         | Thigh                     |
| <i>L. monocytogenes</i> 152*                         | 1/2c                                                                                     | ECORI 422-64-S-5  | CFX                               | Beef                      |
| <i>L. monocytogenes</i> 174*                         | 1/2a                                                                                     | ECORI 422-72-S-1  | CFX                               | Human cerebrospinal fluid |
| <i>L. monocytogenes</i> 178*                         | 1/2b                                                                                     | ECORI 422-63-S-6  | CFX                               | Human blood               |
| <i>L. monocytogenes</i> 185                          | 4b                                                                                       | ECORI 422-78-S-3  | CFX, FOM                          | Human cerebrospinal fluid |
| <i>L. monocytogenes</i> 193*                         | 4b                                                                                       | ECORI 422-78-S-3  | CFX, FOM                          | Minced pork               |
| <i>L. monocytogenes</i> ATCC 15313 <sup>T</sup> *    | American Type Culture Collection (USA)                                                   |                   |                                   |                           |
| <i>L. innocua</i> ATCC 33090                         | American Type Culture Collection (USA)                                                   |                   |                                   |                           |
| <i>L. innocua</i> LIS31                              | Obihiro University of Agriculture and Veterinary Medicine, Japan                         |                   |                                   |                           |
| <i>L. ivanovii</i> ATCC 19119                        | American Type Culture Collection (USA)                                                   |                   |                                   |                           |
| <i>L. seeligeri</i> ATCC 35967                       | American Type Culture Collection (USA)                                                   |                   |                                   |                           |
| <i>L. seeligeri</i> LIS34                            | Obihiro University of Agriculture and Veterinary Medicine, Japan                         |                   |                                   |                           |
| <i>L. welshimeri</i> ATCC 35897                      | American Type Culture Collection (USA)                                                   |                   |                                   |                           |
| <i>L. welshimeri</i> LIS36                           | Obihiro University of Agriculture and Veterinary Medicine, Japan                         |                   |                                   |                           |
| <i>L. grayi</i> ATCC 25401                           | American Type Culture Collection (USA)                                                   |                   |                                   |                           |
| <i>Bacillus cereus</i> JCM152                        | Japan Collection of Microorganisms (RIKEN Saitama, Japan)                                |                   |                                   |                           |
| <i>Staphylococcus aureus</i> ATCC 25923              | American Type Culture Collection (USA)                                                   |                   |                                   |                           |
| <i>Enterococcus faecalis</i> JCM 7783                | Japan Collection of Microorganisms (RIKEN Saitama, Japan)                                |                   |                                   |                           |
| <i>Clostridium perfringens</i> JCM 1290 <sup>T</sup> |                                                                                          |                   |                                   |                           |
| <i>Salmonella</i> Typhimurium NBRC 12529             | National Institute of Technology and Evaluation Biological Resource Centre, Chiba, Japan |                   |                                   |                           |
| <i>Salmonella</i> Enteritidis NBRC 3313              |                                                                                          |                   |                                   |                           |

*L. monocytogenes* strains were selected depend on different serotype, ribotype, and AMR patterns isolated from different sources

\**L. monocytogenes* strains used for screening of bacteriophages isolation

**Table 3.2.** *L. monocytogenes* phages isolated from raw chicken samples

| No. | Phage name | Sample code | Sources                   | Titer (PFU/mL)       | Host strain                                |
|-----|------------|-------------|---------------------------|----------------------|--------------------------------------------|
| 1   | PLM1       | CM-4        | Chicken wing              | $1.7 \times 10^{10}$ | <i>L. monocytogenes</i> 193, serotype 4b   |
| 2   | PLM2       | CM-6        | Chicken ovary and oviduct | $7.9 \times 10^9$    |                                            |
| 3   | PLM3       | CM-7        | Chicken thigh cartilage   | $1.7 \times 10^{10}$ |                                            |
| 4   | PLM4       | CM-8        | Chicken thigh fillet      | $4.9 \times 10^9$    |                                            |
| 5   | PLM5       | CM-9        | Chicken liver             | $8.2 \times 10^9$    |                                            |
| 6   | PLM6       | CM-21       | Chicken chopped meat      | $6.1 \times 10^9$    |                                            |
| 7   | PLM7       | CM-59       | Chicken breast (sasami)   | $5.8 \times 10^9$    |                                            |
| 8   | PLM8       | CM-60       | Chicken skin              | $2.6 \times 10^9$    |                                            |
| 9   | PLM9       | CM-61       | Chicken chopped meat      | $9.5 \times 10^9$    |                                            |
| 10  | PLM31      | CM-9        | Chicken liver             | $7.0 \times 10^8$    | <i>L. monocytogenes</i> 174, serotype 1/2a |
| 11  | PLM34      | CM-32       | Chicken skin              | $1.2 \times 10^9$    |                                            |

**Table 3.3.** *L. monocytogenes* phages isolated from cattle farm samples

| No. | Phage name | Sample code | Sources      | Titer (PFU/mL)       | Host strain                                        |
|-----|------------|-------------|--------------|----------------------|----------------------------------------------------|
| 1   | PLM10      | F-1         | Raw milk     | $1.2 \times 10^{10}$ | <i>L. monocytogenes</i> 193,<br>serotype 4b        |
| 2   | PLM11      | F-3         | Raw milk     | $5.1 \times 10^9$    |                                                    |
| 3   | PLM12      | F-5         | Faeces       | $9.2 \times 10^9$    |                                                    |
| 4   | PLM13      | F-8         | Compost      | $1.0 \times 10^{10}$ |                                                    |
| 5   | PLM14      | F-10        | Pasture soil | $8.4 \times 10^9$    |                                                    |
| 6   | PLM15      | F-12        | Pasture soil | $6.1 \times 10^9$    |                                                    |
| 7   | PLM16      | F-14        | Bedding      | $1.4 \times 10^{10}$ |                                                    |
| 8   | PLM17      | F-15        | Bedding      | $1.5 \times 10^{10}$ |                                                    |
| 9   | PLM26      | F-5         | Faeces       | $5.7 \times 10^9$    | <i>L. monocytogenes</i><br>ATCC 15313 <sup>T</sup> |
| 10  | PLM27      | F-7         | Compost      | $3.2 \times 10^9$    |                                                    |
| 11  | PLM28      | F-10        | Pasture soil | $4.2 \times 10^8$    |                                                    |
| 12  | PLM29      | F-14        | Compost      | $7.5 \times 10^9$    |                                                    |
| 13  | PLM30      | F-6         | Faeces       | $3.5 \times 10^8$    |                                                    |
| 14  | PLM32      | F-7         | Compost      | $8.8 \times 10^8$    | <i>L. monocytogenes</i> 174,<br>serotype 1/2a      |
| 15  | PLM33      | F-10        | Pasture soil | $1.9 \times 10^9$    |                                                    |

**Table 3.4.** Lytic spectra of isolated phages from raw chicken samples

| No                         | Bacterial strains                                 | PLM1 | PLM2 | PLM3 | PLM4 | PLM5 | PLM6 | PLM7 | PLM8 | PLM9 | PLM31 | PLM34 |
|----------------------------|---------------------------------------------------|------|------|------|------|------|------|------|------|------|-------|-------|
| 1                          | <i>L. monocytogenes</i> S8HC*                     | -    | -    | -    | -    | -    | -    | -    | -    | -    | ±     | ±     |
| 2                          | <i>L. monocytogenes</i> S4HO                      | ±    | ±    | ±    | ±    | ±    | ±    | ±    | ±    | +    | ±     | +     |
| 3                          | <i>L. monocytogenes</i> S25FC*                    | -    | -    | -    | -    | -    | -    | -    | -    | -    | ±     | ±     |
| 4                          | <i>L. monocytogenes</i> S38HC*                    | -    | -    | -    | -    | -    | -    | -    | -    | -    | +     | +     |
| 5                          | <i>L. monocytogenes</i> S24FC                     | -    | -    | -    | -    | -    | -    | -    | -    | -    | ±     | ±     |
| 6                          | <i>L. monocytogenes</i> 31FC                      | -    | -    | -    | -    | -    | -    | -    | -    | -    | ±     | +     |
| 7                          | <i>L. monocytogenes</i> 8FO*                      | -    | -    | -    | -    | -    | -    | -    | -    | -    | +     | +     |
| 8                          | <i>L. monocytogenes</i> 76HA                      | +    | +    | +    | +    | +    | +    | +    | +    | +    | +     | +     |
| 9                          | <i>L. monocytogenes</i> 11FA                      | +    | +    | +    | ±    | ±    | +    | +    | ±    | +    | +     | +     |
| 10                         | <i>L. monocytogenes</i> 37HA                      | -    | -    | -    | -    | -    | -    | -    | -    | -    | +     | +     |
| 11                         | <i>L. monocytogenes</i> 38FO                      | ±    | +    | +    | +    | +    | ±    | +    | +    | +    | +     | +     |
| 12                         | <i>L. monocytogenes</i> 11HO                      | -    | -    | -    | -    | -    | -    | -    | -    | -    | +     | +     |
| 13                         | <i>L. monocytogenes</i> 12HA                      | -    | -    | -    | -    | -    | -    | -    | -    | -    | +     | +     |
| 14                         | <i>L. monocytogenes</i> 26FA*                     | -    | -    | -    | -    | -    | -    | -    | -    | -    | -     | -     |
| 15                         | <i>L. monocytogenes</i> 56HO                      | -    | -    | -    | -    | -    | -    | -    | -    | -    | +     | +     |
| 16                         | <i>L. monocytogenes</i> 152*                      | -    | -    | -    | -    | -    | -    | -    | -    | -    | +     | +     |
| 17                         | <i>L. monocytogenes</i> 174*                      | -    | -    | -    | -    | -    | -    | -    | -    | -    | +     | +     |
| 18                         | <i>L. monocytogenes</i> 178*                      | -    | -    | -    | -    | -    | -    | -    | -    | -    | +     | +     |
| 19                         | <i>L. monocytogenes</i> 185                       | +    | +    | +    | +    | +    | +    | +    | +    | +    | ±     | +     |
| 20                         | <i>L. monocytogenes</i> 193*                      | +    | +    | +    | +    | +    | +    | +    | +    | +    | +     | +     |
| 21                         | <i>L. monocytogenes</i> ATCC 15313 <sup>T</sup> * | -    | -    | -    | -    | -    | -    | -    | -    | -    | +     | +     |
| 22                         | <i>L. innocua</i> ATCC 33090                      | +    | +    | +    | +    | +    | +    | +    | +    | +    | +     | +     |
| 23                         | <i>L. innocua</i> LIS31                           | +    | +    | +    | +    | +    | +    | +    | +    | +    | ±     | ±     |
| 24                         | <i>L. ivanovii</i> ATCC 19119                     | -    | -    | -    | -    | -    | -    | -    | -    | -    | -     | -     |
| 25                         | <i>L. seeligeri</i> ATCC 35967                    | +    | +    | +    | +    | +    | +    | +    | +    | +    | ±     | ±     |
| 26                         | <i>L. seeligeri</i> LIS34                         | -    | -    | -    | -    | -    | -    | -    | -    | -    | +     | +     |
| 27                         | <i>L. welshimeri</i> ATCC 35897                   | +    | +    | +    | +    | +    | +    | +    | +    | +    | ±     | ±     |
| 28                         | <i>L. welshimeri</i> LIS36                        | +    | +    | +    | +    | +    | +    | +    | +    | +    | ±     | ±     |
| 29                         | <i>L. grayi</i> ATCC 25401                        | +    | +    | +    | +    | +    | +    | +    | +    | +    | -     | ±     |
| (+) clear lysis            |                                                   | 10   | 11   | 11   | 10   | 10   | 10   | 11   | 10   | 12   | 16    | 19    |
| (±) turbid                 |                                                   | 2    | 1    | 1    | 2    | 2    | 2    | 1    | 2    | 0    | 10    | 8     |
| Total no. of lysed strains |                                                   | 12   | 12   | 12   | 12   | 12   | 12   | 12   | 12   | 12   | 26    | 27    |
| (%)                        |                                                   | 41.4 | 41.4 | 41.4 | 41.4 | 41.4 | 41.4 | 41.4 | 41.4 | 41.4 | 89.7  | 93.1  |

\*Bacterial strains used for screening of bacteriophages isolation

(+) clear lysis, (±) turbid, (-) No lysis

All of the phages are inactive against *Staphylococcus aureus* ATCC 25923, *Bacillus cereus* JCM152, *Enterococcus faecalis* JCM 7783, *Clostridium perfringens* JCM 1290T, *Salmonella* Typhimurium NBRC 12529, *Salmonella* Enteritidis NBRC 3313.

**Table 3.5.** Lytic spectra of isolated phages from cattle farm samples

| N o.                       | Bacterial strains                                 | PLM10 | PLM11 | PLM12 | PLM13 | PLM14 | PLM15 | PLM16 | PLM17 | PLM26 | PLM27 | PLM28 | PLM29 | PLM30 | PLM32 | PLM33 |
|----------------------------|---------------------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 1                          | <i>L. monocytogenes</i> S8HC*                     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | +     | +     |
| 2                          | <i>L. monocytogenes</i> S4HO                      | ±     | +     | +     | ±     | +     | +     | ±     | ±     | +     | +     | +     | +     | +     | +     | +     |
| 3                          | <i>L. monocytogenes</i> S25FC*                    | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | ±     | ±     |
| 4                          | <i>L. monocytogenes</i> S38HC*                    | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | +     | +     |
| 5                          | <i>L. monocytogenes</i> S24FC                     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | ±     | ±     |
| 6                          | <i>L. monocytogenes</i> 31FC                      | -     | -     | -     | -     | -     | -     | -     | -     | +     | -     | -     | ±     | -     | +     | +     |
| 7                          | <i>L. monocytogenes</i> 8FO*                      | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | +     | +     |
| 8                          | <i>L. monocytogenes</i> 76HA                      | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     |
| 9                          | <i>L. monocytogenes</i> 11FA                      | ±     | +     | +     | ±     | +     | +     | +     | +     | +     | +     | +     | +     | +     | ±     | +     |
| 10                         | <i>L. monocytogenes</i> 37HA                      | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | +     | +     |
| 11                         | <i>L. monocytogenes</i> 38FO                      | +     | +     | +     | ±     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     |
| 12                         | <i>L. monocytogenes</i> 11HO                      | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | +     | +     |
| 13                         | <i>L. monocytogenes</i> 12HA                      | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | +     | +     |
| 14                         | <i>L. monocytogenes</i> 26FA*                     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     |
| 15                         | <i>L. monocytogenes</i> 56HO                      | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | +     | +     |
| 16                         | <i>L. monocytogenes</i> 152*                      | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | +     | +     |
| 17                         | <i>L. monocytogenes</i> 174*                      | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | +     | +     |
| 18                         | <i>L. monocytogenes</i> 178*                      | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | +     | +     |
| 19                         | <i>L. monocytogenes</i> 185                       | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | ±     | +     |
| 20                         | <i>L. monocytogenes</i> 193*                      | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     |
| 21                         | <i>L. monocytogenes</i> ATCC 15313 <sup>T</sup> * | -     | -     | -     | -     | -     | -     | -     | -     | +     | ±     | ±     | +     | -     | +     | +     |
| 22                         | <i>L. innocua</i> ATCC 33090                      | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     |
| 23                         | <i>L. innocua</i> LIS31                           | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     |
| 24                         | <i>L. ivanovii</i> ATCC 19119                     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | -     | ±     | -     |
| 25                         | <i>L. seeligeri</i> ATCC 35967                    | +     | +     | +     | +     | +     | +     | +     | +     | ±     | -     | -     | ±     | -     | ±     | ±     |
| 26                         | <i>L. seeligeri</i> LIS34                         | -     | -     | -     | -     | -     | -     | -     | -     | ±     | -     | -     | ±     | -     | +     | +     |
| 27                         | <i>L. welshimeri</i> ATCC 35897                   | +     | +     | +     | +     | +     | +     | +     | +     | +     | ±     | +     | +     | +     | ±     | ±     |
| 28                         | <i>L. welshimeri</i> LIS36                        | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | ±     | ±     |
| 29                         | <i>L. grayi</i> ATCC 25401                        | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | +     | ±     | ±     |
| (+) clear lysis            |                                                   | 10    | 12    | 12    | 9     | 12    | 12    | 11    | 11    | 13    | 10    | 11    | 12    | 11    | 19    | 21    |
| (±) turbid                 |                                                   | 2     | 0     | 0     | 3     | 0     | 0     | 0     | 1     | 2     | 2     | 1     | 3     | 0     | 9     | 6     |
| Total no. of lysed strains |                                                   | 12    | 12    | 12    | 12    | 12    | 12    | 12    | 12    | 15    | 12    | 12    | 15    | 11    | 28    | 27    |
| (%)                        |                                                   | 41.4  | 41.4  | 41.4  | 41.4  | 41.4  | 41.4  | 41.4  | 41.4  | 51.7  | 41.4  | 41.4  | 51.7  | 37.9  | 96.6  | 93.1  |

\*Bacterial strains used for screening of bacteriophages isolation

(+) clear lysis, (±) turbid, (-) No lysis

All of the phages are inactive against *Staphylococcus aureus* ATCC 25923, *Bacillus cereus* JCM152, *Enterococcus faecalis* JCM 7783, *Clostridium perfringens* JCM 1290T, *Salmonella* Typhimurium NBRC 12529, *Salmonella* Enteritidis NBRC 3313.

**Table 3.6.** Annotation of phage vB\_LmoS-PLM9 genome

| ORF | Position<br>(5'-3') | Length<br>(bp) | No. of<br>amino acids | Size<br>(kDa) | Predicted function                             |
|-----|---------------------|----------------|-----------------------|---------------|------------------------------------------------|
| 1   | 23-256              | 234            | 77                    | 9.4           | hypothetical protein                           |
| 2   | 253-450             | 198            | 65                    | 8             | hypothetical protein                           |
| 3   | 589-1947            | 1359           | 452                   | 53.2          | recombinase family protein                     |
| 4   | 2012-2719           | 708            | 235                   | 26.2          | hypothetical protein                           |
| 5   | 2740-3462           | 723            | 240                   | 27.6          | hypothetical protein                           |
| 6   | 3478-3696           | 219            | 72                    | 7.8           | zinc ribbon domain-containing protein          |
| 7   | 3752-3919           | 168            | 55                    | 6.5           | hypothetical protein                           |
| 8   | 4076-4558           | 483            | 160                   | 18.5          | helix-turn-helix transcriptional regulator     |
| 9   | 4707-4958           | 252            | 83                    | 9.5           | helix-turn-helix transcriptional regulator     |
| 10  | 4962-5156           | 195            | 64                    | 7.3           | hypothetical protein                           |
| 11  | 5168-5434           | 267            | 88                    | 9.9           | hypothetical protein                           |
| 12  | 5434-5595           | 162            | 53                    | 6.1           | hypothetical protein                           |
| 13  | 5588-5830           | 243            | 80                    | 9.2           | hypothetical protein                           |
| 14  | 5894-6664           | 771            | 256                   | 29.1          | phage repressor protein/ antirepressor Ant     |
| 15  | 6787-7320           | 534            | 177                   | 19.8          | hypothetical protein                           |
| 16  | 7317-7532           | 216            | 71                    | 8.4           | hypothetical protein                           |
| 17  | 7640-7828           | 189            | 62                    | 7.3           | gp45 family putative tail fiber system protein |
| 18  | 8060-9019           | 960            | 319                   | 36.7          | phage exonuclease                              |
| 19  | 9019-9834           | 816            | 271                   | 30.6          | recombinase RecT                               |
| 20  | 9854-10,786         | 933            | 310                   | 36.9          | DnaD domain-containing protein                 |
| 21  | 10,783-10,950       | 168            | 55                    | 6.4           | hypothetical protein                           |
| 22  | 10,965-11,249       | 285            | 94                    | 11.3          | hypothetical protein                           |
| 23  | 11,246-11,455       | 210            | 69                    | 8.1           | hypothetical protein                           |
| 24  | 11,452-12,060       | 609            | 202                   | 23.3          | YopX family protein                            |
| 25  | 12,057-12,425       | 369            | 122                   | 14.2          | hypothetical protein                           |
| 26  | 12,422-12,598       | 177            | 58                    | 6.6           | hypothetical protein                           |
| 27  | 12,585-13,028       | 444            | 147                   | 17            | hypothetical protein                           |
| 28  | 13,029-13,202       | 174            | 57                    | 6.4           | hypothetical protein                           |
| 29  | 13,199-13,618       | 420            | 139                   | 15.7          | hypothetical protein                           |
| 30  | 13,618-14,100       | 483            | 160                   | 17.8          | single-stranded DNA-binding protein            |
| 31  | 14,132-14,437       | 306            | 101                   | 11.7          | response regulator                             |
| 32  | 14,540-14,944       | 405            | 134                   | 15.5          | endodeoxyribonuclease                          |
| 33  | 15,089-15,244       | 156            | 51                    | 5.7           | DUF3954 domain-containing protein              |
| 34  | 15,332-15,904       | 573            | 190                   | 22.3          | sigma-70 family RNA polymerase sigma factor    |
| 35  | 16,186-16,413       | 228            | 75                    | 8.4           | hypothetical protein                           |
| 36  | 16,453-17,193       | 741            | 246                   | 27.7          | terminase small subunit                        |
| 37  | 17,186-18,505       | 1320           | 439                   | 50.5          | terminase large subunit                        |
| 38  | 18,520-20,076       | 1557           | 518                   | 58.8          | hypothetical protein                           |

**Table 3.6. *Cont.***

| ORF | Position<br>(5'-3') | Length<br>(bp) | No. of<br>amino acids | Size<br>(kDa) | Predicted function                                    |
|-----|---------------------|----------------|-----------------------|---------------|-------------------------------------------------------|
| 39  | 20,081-21,124       | 1044           | 347                   | 40.8          | minor capsid protein                                  |
| 40  | 21,219-21,773       | 555            | 184                   | 21            | BREX-1 system adenine-specific DNA-methyltransferase  |
| 41  | 21,796-22,668       | 873            | 290                   | 32.1          | hypothetical protein                                  |
| 42  | 22,682-22,837       | 156            | 51                    | 6             | hypothetical protein                                  |
| 43  | 22,838-23,191       | 354            | 117                   | 12.6          | hypothetical protein                                  |
| 44  | 23,191-23,556       | 366            | 121                   | 13.6          | hypothetical protein                                  |
| 45  | 23,546-23,863       | 318            | 105                   | 12            | HK97 gp10 family phage protein                        |
| 46  | 23,860-24,231       | 372            | 123                   | 14.2          | hypothetical protein                                  |
| 47  | 24,236-24,922       | 687            | 228                   | 23.6          | Ig-like domain-containing protein                     |
| 48  | 24,972-25,403       | 432            | 143                   | 16.2          | hypothetical protein                                  |
| 49  | 25,508-25,711       | 204            | 67                    | 7.7           | Gp15 family bacteriophage protein                     |
| 50  | 25,716-30,521       | 4806           | 1601                  | 174.3         | tail tape measure protein                             |
| 51  | 30,525-31,349       | 825            | 274                   | 31.2          | tail family protein                                   |
| 52  | 31,362-32,375       | 1014           | 337                   | 37.7          | phage tail protein                                    |
| 53  | 32,372-33,400       | 1029           | 342                   | 37.9          | hypothetical protein                                  |
| 54  | 33,397-34,470       | 1074           | 357                   | 39.2          | BppU family phage baseplate upper protein             |
| 55  | 34,467-34,808       | 342            | 113                   | 12.5          | hypothetical protein                                  |
| 56  | 34,808-34,954       | 147            | 48                    | 5.6           | XkdX family protein                                   |
| 57  | 34,982-35,356       | 375            | 124                   | 14.7          | gp23 protein                                          |
| 58  | 35,369-35,647       | 279            | 92                    | 9.7           | holin                                                 |
| 59  | 35,650-36,519       | 870            | 289                   | 33.2          | N-acetylmuramoyl-L-alanine amidase                    |
| 60  | 36,544-36,960       | 417            | 138                   | 15.4          | hypothetical protein                                  |
| 61  | 37,239-37,742       | 504            | 167                   | 19.8          | DUF4065 domain-containing protein                     |
| 62  | 37,739-38,131       | 393            | 130                   | 15.2          | type II toxin-antitoxin system PemK/ Maz family toxin |

**Table 3.7.** Annotation of phage vB\_LmoS-PLM26 genome

| ORF | Position<br>(5'-3') | Length<br>(bp) | No. of<br>amino acids | Size<br>(kDa) | Predicted function                               |
|-----|---------------------|----------------|-----------------------|---------------|--------------------------------------------------|
| 1   | 1-1644              | 1644           | 547                   | 63.3          | terminase large subunit                          |
| 2   | 1656-2786           | 1131           | 376                   | 43.5          | portal protein                                   |
| 3   | 2783-3580           | 798            | 265                   | 28.6          | Clp protease                                     |
| 4   | 3607-4758           | 1152           | 383                   | 42.5          | major capsid protein                             |
| 5   | 4765-4935           | 171            | 56                    | 6.6           | hypothetical protein                             |
| 6   | 4945-5244           | 300            | 99                    | 11.5          | gp6-like head-tail connector protein             |
| 7   | 5228-5593           | 366            | 121                   | 13.8          | head-tail adapter protein                        |
| 8   | 5590-5991           | 402            | 133                   | 14.8          | hypothetical protein                             |
| 9   | 5988-6371           | 384            | 127                   | 14.6          | DUF3168 domain-containing protein                |
| 10  | 6393-6980           | 588            | 195                   | 21.1          | tail protein                                     |
| 11  | 7052-7384           | 333            | 110                   | 13.2          | hypothetical protein                             |
| 12  | 7435-7584           | 150            | 49                    | 5.9           | hypothetical protein                             |
| 13  | 7600-12,525         | 4926           | 1641                  | 174.8         | tail tape measure protein                        |
| 14  | 12,518-14,167       | 1650           | 549                   | 62            | tail protein                                     |
| 15  | 14,180-16,474       | 2295           | 764                   | 87            | tail protein                                     |
| 16  | 16,464-17,555       | 1092           | 363                   | 39.5          | carbohydrate-binding protein CenC                |
| 17  | 17,603-18,046       | 444            | 147                   | 16.5          | hypothetical protein                             |
| 18  | 18,025-18,441       | 417            | 138                   | 15.3          | hypothetical protein                             |
| 19  | 18,462-18,728       | 267            | 88                    | 9.8           | holin                                            |
| 20  | 18,725-19,435       | 711            | 236                   | 25.8          | Peptidoglycan L-alanyl-D-glutamate endopeptidase |
| 21  | 19,590-20,162       | 573            | 190                   | 22.3          | hypothetical protein                             |
| 22  | 20,230-20,679       | 450            | 149                   | 17.2          | anti-CRISPR protein AcrIIA1                      |
| 23  | 20,684-21,055       | 372            | 123                   | 14.2          | anti-CRISPR protein AcrIIA2                      |
| 24  | 21,089-21,466       | 378            | 125                   | 14.6          | anti-CRISPR protein AcrIIA3                      |
| 25  | 21,796-22,005       | 210            | 69                    | 7.9           | hypothetical protein                             |
| 26  | 22,447-22,680       | 234            | 77                    | 9.3           | hypothetical protein                             |
| 27  | 22,677-22,868       | 192            | 63                    | 7.8           | hypothetical protein                             |
| 28  | 23,063-24,217       | 1155           | 384                   | 44.9          | integrase                                        |
| 29  | 24,350-24,922       | 573            | 190                   | 21.3          | hypothetical protein                             |
| 30  | 24,974-25,426       | 453            | 150                   | 17.9          | ImmA/IrrE family metallo-endopeptidase           |
| 31  | 25,443-25,766       | 324            | 107                   | 12.4          | helix-turn-helix transcriptional regulator       |
| 32  | 26,166-26,369       | 204            | 67                    | 7.8           | YozE family protein                              |
| 33  | 26,436-26,627       | 192            | 63                    | 7.1           | helix-turn-helix transcriptional regulator       |
| 34  | 26,649-26,891       | 243            | 80                    | 9.5           | hypothetical protein                             |
| 35  | 26,894-27,079       | 186            | 61                    | 7.5           | hypothetical protein                             |
| 36  | 27,182-27,304       | 123            | 40                    | 4.9           | hypothetical protein                             |
| 37  | 27,314-27,466       | 153            | 50                    | 5.5           | hypothetical protein                             |
| 38  | 27,829-28,059       | 231            | 76                    | 9             | hypothetical protein                             |
| 39  | 28,345-28,560       | 216            | 71                    | 8.1           | hypothetical protein                             |

**Table 3.7. *Cont.***


| ORF | Position<br>(5'-3') | Length<br>(bp) | No. of<br>amino acids | Size<br>(kDa) | Predicted function                       |
|-----|---------------------|----------------|-----------------------|---------------|------------------------------------------|
| 40  | 28,638-29,189       | 552            | 183                   | 21.6          | DUF1642 domain-containing protein        |
| 41  | 29,248-29,763       | 516            | 171                   | 19.7          | hypothetical protein                     |
| 42  | 29,942-30,412       | 471            | 156                   | 18.6          | DUF1642 domain-containing protein        |
| 43  | 30,413-30,835       | 423            | 140                   | 16.4          | hypothetical protein                     |
| 44  | 30,832-31,005       | 174            | 57                    | 6.6           | hypothetical protein                     |
| 45  | 31,002-31,385       | 384            | 127                   | 14.2          | hypothetical protein                     |
| 46  | 31,387-31,866       | 480            | 159                   | 18.4          | Siphovirus Gp157 family protein          |
| 47  | 31,886-32,575       | 690            | 229                   | 26.1          | AAA family ATPase                        |
| 48  | 32,753-33,895       | 1143           | 380                   | 43.3          | DEAD/DEAH box helicase                   |
| 49  | 33,920-34,405       | 486            | 161                   | 18.4          | DUF669 domain-containing protein         |
| 50  | 34,428-36,701       | 2274           | 757                   | 87.2          | phage/plasmid primase, P4 family         |
| 51  | 37,036-37,350       | 315            | 104                   | 11.7          | VRR-NUC domain-containing protein        |
| 52  | 37,418-37,996       | 579            | 192                   | 22.2          | putative phage-related protein (DUF3310) |
| 53  | 37,997-38,152       | 156            | 51                    | 5.8           | hypothetical protein                     |
| 54  | 38,214-38,441       | 228            | 75                    | 9.2           | hypothetical protein                     |
| 55  | 38,454-38,879       | 426            | 141                   | 16.7          | DUF722 domain-containing protein         |
| 56  | 38,977-39,720       | 744            | 247                   | 29.2          | endonuclease domain-containing protein   |
| 57  | 40,180-40,506       | 327            | 108                   | 12.2          | hypothetical protein                     |
| 58  | 40,506-40,820       | 315            | 104                   | 12.8          | HNH endonuclease                         |
| 59  | 40,926-4            | 300            | 99                    | 11.5          | terminase small subunit                  |

**Table 3.8.** Annotation of phage vB\_LmoS-PLM34 genome


| ORF | Position<br>(5'-3') | Length<br>(bp) | No. of<br>amino acids | Size<br>(kDa) | Predicted function                             |
|-----|---------------------|----------------|-----------------------|---------------|------------------------------------------------|
| 1   | 27-389              | 363            | 120                   | 14.1          | HNH endonuclease                               |
| 2   | 386-712             | 327            | 108                   | 12.4          | hypothetical protein                           |
| 3   | 809-940             | 132            | 43                    | 5.1           | hypothetical protein                           |
| 4   | 983-1315            | 333            | 110                   | 12.7          | hypothetical protein                           |
| 5   | 1331-1873           | 543            | 180                   | 21.3          | integrase                                      |
| 6   | 1870-2388           | 519            | 172                   | 19.9          | RNA polymerase subunit sigma                   |
| 7   | 2459-2629           | 171            | 56                    | 6.8           | hypothetical protein                           |
| 8   | 2635-2874           | 240            | 79                    | 9.4           | hypothetical protein                           |
| 9   | 2895-3374           | 480            | 159                   | 17.5          | single-stranded DNA-binding protein            |
| 10  | 3374-3955           | 582            | 193                   | 22.4          | DUF3310 domain-containing protein              |
| 11  | 3955-4203           | 249            | 82                    | 9.7           | DUF3850 domain-containing protein              |
| 12  | 4224-4607           | 384            | 127                   | 14.6          | preprotein translocase subunit YajC            |
| 13  | 4604-5065           | 462            | 153                   | 18.1          | hypothetical protein                           |
| 14  | 5062-5250           | 189            | 62                    | 7             | SAM-benzoic acid carboxyl<br>methyltransferase |
| 15  | 5263-5973           | 711            | 236                   | 27            | hypothetical protein                           |
| 16  | 5973-6374           | 402            | 133                   | 15.4          | YopX family protein                            |
| 17  | 6371-6673           | 303            | 100                   | 11.1          | hypothetical protein                           |
| 18  | 6677-7396           | 720            | 239                   | 27.7          | DUF2786 domain-containing protein              |
| 19  | 7411-7587           | 177            | 58                    | 6.8           | hypothetical protein                           |
| 20  | 7584-8000           | 417            | 138                   | 15.6          | hypothetical protein                           |
| 21  | 7997-8353           | 357            | 118                   | 13.6          | MerR family transcriptional regulator          |
| 22  | 8355-9269           | 915            | 304                   | 35.7          | phage replication initiation protein           |
| 23  | 9329-9442           | 114            | 37                    | 4.1           | hypothetical protein                           |
| 24  | 9442-9768           | 327            | 108                   | 12.8          | DUF771 domain-containing protein               |
| 25  | 9866-10,057         | 192            | 63                    | 7.5           | hypothetical protein                           |
| 26  | 10,167-10,307       | 141            | 46                    | 5.3           | helix-turn-helix domain-containing<br>protein  |
| 27  | 10,273-10,557       | 285            | 94                    | 10.8          | hypothetical protein                           |
| 28  | 10,600-11,070       | 471            | 156                   | 18            | ImmA/IrrE family metallo-endopeptidase         |
| 29  | 11,125-11,838       | 714            | 237                   | 26.4          | hypothetical protein                           |
| 30  | 11,860-13,011       | 1152           | 383                   | 44.8          | integrase                                      |
| 31  | 13,013-13,123       | 111            | 36                    | 4.4           | hypothetical protein                           |
| 32  | 13,161-13,348       | 186            | 61                    | 7.3           | hypothetical protein                           |
| 33  | 13,328-14,176       | 849            | 282                   | 31.2          | N-acetylmuramoyl-L-alanine amidase             |
| 34  | 14,173-14,466       | 294            | 97                    | 10.4          | holin                                          |
| 35  | 14,470-14,835       | 366            | 121                   | 14.5          | conserved phage protein                        |
| 36  | 14,874-15,935       | 1062           | 353                   | 38.2          | minor structural protein                       |
| 37  | 15,928-18,219       | 2292           | 763                   | 84.6          | tail protein                                   |
| 38  | 18,225-20,468       | 2244           | 747                   | 84.6          | tail protein                                   |

**Table 3.8. *Cont.***


| ORF | Position<br>(5'-3') | Length<br>(bp) | No. of<br>amino acids | Size<br>(kDa) | Predicted function                     |
|-----|---------------------|----------------|-----------------------|---------------|----------------------------------------|
| 39  | 20,461-24,534       | 4074           | 1357                  | 146.8         | phage tail length tape-measure protein |
| 40  | 24,678-24,773       | 96             | 31                    | 3.6           | hypothetical protein                   |
| 41  | 24,857-25,204       | 348            | 115                   | 13.2          | hypothetical protein                   |
| 42  | 25,294-25,869       | 576            | 191                   | 21            | major tail protein                     |
| 43  | 25,890-26,288       | 399            | 132                   | 15.3          | hypothetical protein                   |
| 44  | 26,291-26,656       | 366            | 121                   | 13.6          | HK97 gp10 family phage protein         |
| 45  | 26,650-26,970       | 321            | 106                   | 12.5          | hypothetical protein                   |
| 46  | 26,940-27,278       | 339            | 112                   | 12.9          | head-tail connector protein            |
| 47  | 27,327-28,496       | 1170           | 389                   | 43.4          | major capsid protein                   |
| 48  | 28,560-29,126       | 567            | 188                   | 21            | head maturation protease               |
| 49  | 29,123-30,358       | 1236           | 411                   | 45.8          | portal protein                         |
| 50  | 30,361-30,561       | 201            | 66                    | 7.1           | DUF1056 family protein                 |
| 51  | 30,568-32,319       | 1752           | 583                   | 67.5          | terminase large subunit                |
| 52  | 32,288-32,815       | 528            | 175                   | 20.5          | terminase small subunit                |
| 53  | 32,791-32,889       | 99             | 32                    | 3.6           | hypothetical protein                   |




**Fig. 3.1.** Transmission electron micrograph of phage vB\_LmoS-PLM34.




**Fig. 3.2.** (A) Temperature stability of phages vB\_LmoS-PLM9, vB\_LmoS-PLM26, and vB\_LmoS-PLM34. (B) pH stability of phage vB\_LmoS-PLM9. (C) pH stability of phage vB\_LmoS-PLM26. (D) pH stability of phage vB\_LmoS-PLM34. The error bars show the mean  $\pm$  S.D. of the three replicates.




**Fig. 3.3.** Genome map of *Listeria* phage vB\_LmoS-PLM9. GenBank accession number is OR371505. Arrows: Blue- phage structure and packaging, Orange- DNA replication, Red- host lysis, Purple- hypothetical protein, Black- additional functions.



**Fig. 3.4.** Genome map of *Listeria* phage vB\_LmoS-PLM26. GenBank accession number is OP926971. Arrows: Blue- phage structure and packaging, Orange- DNA replication, Red- host lysis, Yellow- Integrase, Purple- hypothetical protein, Black- additional functions.



**Fig. 3.5.** Genome map of *Listeria* phage vB\_LmoS-PLM34. GenBank accession number is OP926972. Arrows: Blue- phage structure and packaging, Orange- DNA replication, Red- host lysis, Yellow- Integrase, Purple- hypothetical protein, Black- additional functions.



**Fig. 3.6.** One-step growth curve of phage vB\_LmoS-PLM9.

## **Chapter 4. Evaluation of plant-based essential oils and their application in single or combined with phage vB\_LmoS-PLM9 against pathogenic *Listeria monocytogenes* in broth and milk**

### **4.1. Introduction**

A foodborne *L. monocytogenes* is a serious bacterium and causes listeriosis in humans and animals. Among the 13 serotypes, serotype 4b accounts for between 30 and 50 percent of sporadic human listeriosis cases globally (Akhtar et al., 2017; Kawacka et al., 2020). The contamination of *L. monocytogenes* in meat, fish, vegetables, and milk and milk products, remains a severe threat to the global food safety problem (Elafify et al., 2022). Hence, applicable techniques are promoted to control *L. monocytogenes* infection in foods.

Antimicrobial resistance (AMR) is becoming an increasingly concerning problem for global public health, prompting a rise in studies exploring antimicrobial substitutes. Bacteriophages (phages) are viruses that target specific bacteria without causing harm to humans, and they are gaining popularity as potential biocontrol agents against foodborne pathogens like *L. monocytogenes*, with numerous studies applying them to various food products (Akhtar et al., 2017; Byun et al., 2022). In certain nations, particularly in the United States, phage-based products like ListShield™ and Listex™ P100 are employed to combat *L. monocytogenes* (Byun et al., 2022; Perera et al., 2015).

Essential oils (EOs) are natural chemicals derived from various parts of plants. They have strong antimicrobial and antioxidant properties and have been recognized as potential agents against microorganisms (Paudel et al., 2019; Van Haute et al., 2017). Most EOs are classified as GRAS and can even be used as decontaminants (Cui et al., 2016; Somrani et al., 2020). Cinnamon bark (*Cinnamomum zeylanicum*) and Cinnamon cassia (*Cinnamomum cassia*) are both referred to as "Cinnamon" and they are part of the same "Lauraceae" family and "*Cinnamomum*" genus, however they are distinct plant species. Cinnamon bark (C.b) has a lighter color, flavor, and scent than cinnamon

cassia (C.c). Cinnamaldehyde, the primary constitute of cinnamon oil, has a broad antibacterial spectrum that protects against spoilage microorganisms and foodborne pathogens (Brnawi et al., 2019; Paudel et al., 2019; Zhang et al., 2016).

The combination of several antibacterial agents presents a new method for expanding the range of antimicrobial effectiveness, addressing AMR, and increasing the effectiveness of antibacterial activity by leveraging synergistic effects (Corrêa et al., 2021; Duc et al., 2018). The potential synergistic effect between phage and EOs may impede the development of phage-resistant bacteria and diminish the potent, distinct aroma of the oil (Corrêa et al., 2021; Ni et al., 2020). This chapter aims to evaluate eight kinds of EOs against various *Listeria* spp. and to investigate the most effective EOs in single and combined with phage vB\_LmoS-PLM9 against pathogenic *L. monocytogenes* in broth and milk.

## **4.2. Materials and methods**

### **4.2.1. Preparation of bacterial culture**

The pathogenic *L. monocytogenes* strain no.193 (serotype 4b) isolated from minced pork and well-characterized in our Laboratory (Chapters 2 and 3) was used for this experiment. Bacterial strain from  $-80^{\circ}\text{C}$  frozen stock was streaked onto TSA and cultured in 5 mL of BHI broth overnight at  $30^{\circ}\text{C}$ . The culture was used for further experiments.

### **4.2.2. Preparation of bacteriophage vB\_LmoS-PLM9**

The isolated bacteriophage vB\_LmoS-PLM9 in our Laboratory (Chapter 3) was used in this experiment. This phage showed lytic activity against different species of *Listeria* including *L. monocytogenes*. Strain no.193 was used to refresh the phage suspension since it was the target host strain for phage isolation. The fresh phage stock (approximately  $10^{10}$  PFU/mL) was prepared using the double-layer agar method. Briefly, 100  $\mu\text{L}$  phage ( $10^4$  PFU/mL) and 100  $\mu\text{L}$  host cell were added in 4 mL of LB

top agar containing 1 mmol/L CaCl<sub>2</sub>, then the mixture was poured onto TSA. After keeping at 30 °C for 24 h, the phage was collected by adding 5 ml aliquots of saline magnesium (SM) buffer onto the top of dense-plaque plates. After shaking at 25 °C overnight, the top agar layer was scraped and centrifuged. The supernatant was filtered and maintained as a phage stock at 4°C until use.

#### **4.2.3. Preparation of EOs**

Eight 100 % pure EOs; cinnamon bark (C.b), cinnamon cassia (C.c), clove, lemon grass, ginger, turmeric, basil, and lemon were bought from iHerb (NowFoods, Japan). To prepare the 4 and 10 % (v/v) stock oil solutions, 0.5 % (w/v) Tween 80 (FIJIFILM, Wako Pure Chemical Corporation, Japan) was used. These stock solutions were then diluted in BHI broth to create working solutions.

#### **4.2.4. Antibacterial activity of EOs**

Disc diffusion test was used to determine the antibacterial activities of 10 % of 8 EOs against *Listeria* spp., including *L. monocytogenes* 193 (Table 4.1). One hundred microliters of bacteria at a density of 10<sup>6</sup> or 10<sup>8</sup> CFU/mL were spread using a sterilized cotton swab onto Muller Hinton agar. Subsequently, 6 mm paper discs (Whatman™, China) were positioned on the plate. Then, 10 µL of 10 % EO was added to the disc and kept at 4 °C for 30 min to ensure better adsorption before being kept at 30 °C for 24 h. Sterilized broth and Gentamycin disc (30 µg/mL, BD BBL™ Sensi-Disc™, USA) were used for controls. The zone diameters (mm) were measured to interpret the degree of inhibition. All experiments were performed in triplicates.

Following the antibacterial test on various EOs, the strong anti-listerial activities of C.b, C.c, and clove were used for further experiments. The minimum inhibitory concentration (MIC) values of EOs (4-0.015 %) against *L. monocytogenes* 193 (10<sup>6</sup> or 10<sup>8</sup> CFU/mL) were investigated using the broth microdilution method (CLSI, 2021). The negative control utilized was sterilized broth. The cells from transparent wells were

10-fold serially diluted with phosphate buffer saline (PBS). The dilution (100  $\mu$ L) was spread onto TSA plates to determine the MBC values.

#### **4.2.5. Determination of phage activity in the presence of EOs**

The survivability of phage was assessed in the presence of various EO concentrations (0.03, 0.0625, 0.125, 0.25, 0.5, and 1 %). The phage suspension (180  $\mu$ L) was mixed with EOs (20  $\mu$ L), which was kept at 4 °C for 24 h. Phage titer was determined using a plaque assay.

#### **4.2.6. Determination of viability of *L. monocytogenes* treated with phage and/or EOs in broth**

In broth at 30 °C, single and combined phage (MOI 10) and C.b or C.c at 1/3 or 1/2  $\times$  MIC value (0.02 or 0.03 %) were applied. Moreover, phage (MOI 1) and/or clove oil at 1/2 or 1  $\times$  MIC value (0.125 or 0.25 %) was used. The bacterial suspension (500  $\mu$ L) was prepared in BHI broth (4 mL) to obtain the cell at  $10^6$  CFU/mL. An equal volume of phage and/or EOs (500  $\mu$ L) was added for treatment groups and sterilized broth for control. Samples were taken every 2 h and thinned out with PBS. The viability was checked by the plate count method on TSA.

#### **4.2.7. Determination of viability of *L. monocytogenes* treated with phage and/or EOs in milk**

In this trial, commercially available 100 % pasteurized milk including fat content of 3.5 % or more, was purchased from the supermarket. For sample preparation, 500  $\mu$ L of bacterial culture was contaminated into 4 mL of milk to attain  $10^5$  CFU/mL. Then, 500  $\mu$ L of phage and/or EOs alone and in combination was added to the artificially contaminated milk and stored at 30 °C for 24 h and 4 °C for 7 d. Only broth was employed for the control sample. At 30 °C, phage (MOI = 100), C.b or C.c (0.0625 % or 0.125 %), and clove oil (0.5 %) were used, and the viable counts were checked every 2 h. At 4 °C, phage (MOI = 100), C.b or C.c (0.125 %), and clove oil (0.5 %) were

treated, and the viable counts were determined every single day.

#### **4.2.8. Statistical analysis**

Analysis of variance (ANOVA) followed by post-hoc least significant difference (LSD) pairwise multiple comparison test was performed to assess significant differences between essential oils groups. Student's t-test was utilized to ascertain statistically significant differences between control and treatment groups. Differences were considered statistically significant when  $P < 0.05$ .

### **4.3. Results**

#### **4.3.1. Antibacterial activity of EOs against *L. monocytogenes***

Table 4.1 shows that 10 % of C.b, C.c, clove, and lemongrass oils presented anti-listerial efficiencies, but others did not. Among eight EOs, C.b and C.c oils indicated the widest inhibition zone, then clove and lemongrass oils against different species of *Listeria* including *L. monocytogenes* 193.

#### **4.3.2. MIC and MBC values of EOs against *L. monocytogenes***

The MIC values of C.b and C.c were found to be 0.0625 % at  $10^6$  CFU/mL and 0.125 % at  $10^8$  CFU/mL. The MBC of C.b and C.c were 0.125 % at  $10^6$  CFU/mL and 0.25 % at  $10^8$  CFU/mL. For the clove oil, the MIC values were 0.25 % at  $10^6$  CFU/mL and 0.5 % at  $10^8$  CFU/mL, and the MBC were 0.5 % at  $10^6$  CFU/mL and 1 % at  $10^8$  CFU/mL (Table 4.2).

#### **4.3.3. Effects of EOs on phage survivability**

Figure 4.1 demonstrates the titers of phage vB\_LmoS-PLM9 remained constant when exposed to C.b, C.c, or clove oils in concentrations between 0.03 to 1 % at 4 °C for 24 h.

#### 4.3.4. Effects of phage and/or EOs against *L. monocytogenes* in broth

In applications of phage and/or C.b or C.c at 30 °C, viable cells were reduced by 3.2 log after 10 h and resistant cells regrew after 24 h in phage therapy at MOI of 10 compared to the control. The surviving cells were decreased by 1.7 and 1.1 log at 10 h in a single treatment of  $1/2 \times \text{MIC}$  (0.02 %) of C.b/ C.c but regrew later. Phage (MOI = 10) plus 0.02 % C.b/ C.c reduced surviving cells by approximately 2 log at 4 h, and continuously suppressed the regrowth till 10 h, and then reached the same level at 24 h (Fig. 4.2A). The treatment of 0.03 % of C.b/ C.c retarded the growth of cells up to 24 h. Combined phage (MOI = 10) and 0.03 % C.b/ C.c was highly effective compared to individual ones, reducing the viable cells by 3 log at 24 h incubation (Fig. 4.2B).

Fig.4.3 shows the application of individual and combined phage and clove oil at 30 °C. The surviving cells were decreased by a maximum of 2.7 log in phage treatment at MOI of 1 after 8 h but regrowth was similar to control later time. Clove oil at 0.125 % reduced the cell viability by 1.1 log at 2 h and continued to decline for 24 h. Combining phage (MOI of 1) with clove oil (0.125 %) reduced surviving cells by 3.6 log after 10 h compared to the initial cell counts of the control sample and was undetectable at 24 h. These results showed that combined therapy was more effective than the single one. Moreover, the bacterial cells were not detected in the treatments with  $1 \times \text{MIC}$  value (0.25 %) clove oil alone or combined with phage after 2 h (Fig. 4.3).

#### 4.3.5. Effects of phage and/or EOs against *L. monocytogenes* in milk

The applications of single and combined phage and C.b or C.c in milk are demonstrated in Fig. 4.4. At 30 °C, phage alone (MOI = 100) decreased the cell survivability by 1.4 log at 2 h but reached the level as the control after 24 h. In C.b or C.c oil (0.0625 %) alone, the surviving cells were reduced by 1.5 log at 10 h but later regrew to the same level as the control. Phage (MOI 100) plus 0.0625 % C.b/ C.c treatments decreased the cell growth by approximately 1.5 log at 2 h and 3.7 log at 10

h respectively (Fig. 4.4A). Both cinnamon oil treatments at 0.125 % controlled the initial cell counts up to 24 h. However, surviving cells were lowered by 2.3 and 1.5 log at 2 h and prohibited the resistant cells in phage (MOI = 100) plus 0.125 % C.b/ C.c (Fig. 4.4B). At 4 °C, phage alone at MOI 100 lowered surviving cells by approximately 1 log at 1 d and was stable until the end of the trial. In single 0.125 % of both cinnamon oils, viable cells were inhibited for 7 d. Phage at MOI 100 united with C.b/ C.c (0.125 %) gradually decreased the viable counts from 1 d and arrived under detection levels at 4 and 5 d, respectively (Fig. 4.4C).

The use of phage and/or clove oil in milk at 30 and 4 °C shown in Fig. 4.5. At 30 °C, clove oil (0.5 %) treatment did not show an obvious effect on the survivability of *L. monocytogenes*. However, viable cells were reduced by 2.7 log at 4 h and 3.4 log at 10 h when compared with the growth of the control sample, but resistant bacteria grew at 24 h in phage (MOI of 100) plus 0.5 % clove oil (Fig. 4.5A). At 4 °C, phage treatment (MOI = 100) decreased the viable counts after 1 d, although 0.5 % clove oil did not show the effect. Combining phage at MOI of 100 and 0.5 % clove oil reduced viable numbers by 1.7 log at 1 d and 3.5 log at 7 d (Fig. 4.5B).

#### 4.4. Discussion

Recently, phage application has been proposed as a promising strategy to control foodborne infections, including *L. monocytogenes*. Phage combined with other antibacterial substances is becoming increasingly popular due to the establishment of phage-resistant mutants in single-phage therapy (Lima et al., 2019; Pinheiro et al., 2019). Many researchers have worked on phage cocktails, phage and antibiotics, phage and nisin, phage and carvacrol, etc. to combat phage-resistant bacteria (Cufaoglu and Ayaz, 2019; Duc et al., 2020; Lopes et al., 2018; Noor Mohammadi et al., 2022b). Corrêa et al. (2021) reported *L. monocytogenes* and *Salmonella* Enteritidis were effectively reduced by binding cinnamon oil and phenolic acid. Additionally, commercial phage (SALMONELEX) combined with thymol or carvacrol exhibited

synergism against *Salmonella* in chicken as reported by Moon et al. (2020).

In this investigation, eight different EOs at 10 % were employed to assess anti-listerial activity. The most potent effects were observed in C.b and C.c oils, following clove and lemongrass oils against different *Listeria* spp., including *L. monocytogenes* (Table. 4.1). Similar findings reported by dos Santos et al. (2022) cinnamon oil indicated the strongest antibacterial efficiency to *L. monocytogenes* when they tested with 10 % of five EOs (dos Santos et al., 2022). Tomićić et al. (2018) also reported that cinnamon oils showed the highest anti-listerial efficiency among tested various essential oils including cinnamon, dill, clove, mentha, red thyme, rosemary, sage, and summer savory. Mahfuzul Hoque et al. (2008) and Paudel et al. (2019) documented that cinnamon and clove EOs are potential antimicrobial substances for use in food. Cinnamon and clove oils compose cinnamaldehyde and eugenol, which have potential antimicrobial properties to Gram +ve and -ve pathogens. Other studies have indicated that cinnamaldehyde hindered ATPase, caused damage to cell membranes, and impeded cytokinesis. On the other hand, eugenol facilitated the permeabilization of cell membranes through its interaction with proteins (Hyldgaard et al., 2012; Rogiers et al. 2017; Somrani et al., 2020).

The MIC values for cinnamon oils (0.0625 %) in the current study were found to be lower compared to earlier studies: 0.1 % (Somrani et al., 2020), 0.5 % (Brnawi et al., 2018), 1-10 % (dos Santos et al., 2022), and 1.25-2.5 % (Mahfuzul Hoque et al., 2008). Prior research reported by Mahfuzul Hoque et al. (2008) that MIC values of clove oil ranged from 2.5 to 5 %, which was higher than the values (0.25 %) found in this investigation. These discrepancies are most likely attributable to the various strains and methodologies used in numerous research. Furthermore, the active component of EOs varied based on the regions where the plants were grown and the parts of the plant used for extraction, along with the extraction techniques employed, all these factors could influence the values (Martins et al., 2016; Somrani et al., 2020).

Combining two antimicrobial substances enhances the activity of combating pathogenic bacteria if they exert synergism. This research investigated that combined phage vB\_LmoS-PLM9 and cinnamon or clove oils showed more effectiveness against *L. monocytogenes* than individual ones. The usage of different concentrations of EOs alone varied the inhibition degrees against *L. monocytogenes*. Phage (MOI = 10) + C.b or C.c (0.03 %), and phage (MOI = 1) + clove oil (0.125 %) exhibited high efficacy in reducing the surviving cells and suppressing the resistant cell growth in broth. Similarly, phages and other antimicrobial agents can work together to inhibit the development of phage-resistant mutants (Ni et al., 2020). The precise mechanism of the anti-listerial activity of phage and EOs should be further researched.

Cinnamon or clove EOs have been researched in previous studies for their potential use in milk and dairy products (Brnawi et al., 2018; Cui et al., 2016; Elafify et al., 2022). Natural plant extracts are used as fragrance and flavor enhancers in the fluid milk industry due to the growing trend of introducing new aromas and flavors. Since ancient times, the dairy industry has employed plant EOs to flavor food and beverages. Milk drinks flavored with cinnamon, clove, and other spices are popular, especially in Spain and Latin American countries (Cava et al., 2007). However, using high volumes of essential oils might alter the aroma of food products, which may be unacceptable to some consumers. This study investigated the combining phage and C.b, C.c, or clove oils by using lower concentrations to control pathogenic *L. monocytogenes* in milk. Phage (MOI of 100) mixed with C.b or C.c (0.125 %) lowered cell numbers at 2 h and inhibited regrowth cells at 30 °C, while those decreased surviving cells at 1 d and arrived at less than detection limit at 4 or 5 d at 4 °C. In the treatment of phage (MOI 100) plus clove oil (0.5 %), the viable counts were reduced at 4 h but some resistant bacteria regrew at 24 h at 30 °C, whereas those were reduced at 1 d, and then gradually decreased until the end of 7 days trail. The first report demonstrated that combining phage with cinnamon or clove oils has bacteriostatic and bactericidal effects against *L. monocytogenes*.

in milk. More research will be done on the antibacterial efficacy of combining phage and EOs against *L. monocytogenes*, especially in various solid foods.

#### 4.5. Summary

This chapter examined the antibacterial activity of eight different EOs against *Listeria* spp. including *L. monocytogenes*. The most effective C.b and C.c had MIC and MBC values of 0.0625 % and 0.125 %, respectively, whereas the values for clove oil were 0.25 % and 0.5 %. Single and combined applications of phage vB\_LmoS-PLM9 and C.b, C.c, or clove oils were investigated in broth and milk. Single treatment of phage reduced the viable cells after 2 h, but regrowth at 24 h of storage at 30 °C. The survival cell was inhibited when treated with phage in milk at 4 °C. The number of viable cells was inhibited or reduced in treatments with EO alone, depending on the concentrations used. However, mixed phage (MOI 10) and C.b/ C.c (0.03 %), and phage (MOI 1) and clove oil (0.125 %) decreased the viability of bacterial cells and prevented the regrowth cells *in vitro* at 30 °C. Mixing phage (MOI 100) and C.b/ C.c (0.125 %) or clove oil (0.5 %) reduced the survival cells and inhibited the resistant cell growth in milk, particularly at 4 °C. These findings suggested that phage plus EOs might be an effective method for controlling *L. monocytogenes* in milk.

**Table 4.1.** Anti-listerial activity of EOs at 10 % by disc diffusion assay at 30 °C

| No. | <i>Listeria</i> spp.                            | Zone diameter (Mean $\pm$ S.D. mm) |                             |                             |                             |
|-----|-------------------------------------------------|------------------------------------|-----------------------------|-----------------------------|-----------------------------|
|     |                                                 | Cinnamon bark                      | Cinnamon cassia             | Clove                       | Lemon grass                 |
| 1   | <i>L. monocytogenes</i> 193*                    | 26.7 $\pm$ 1.2 <sup>c</sup>        | 21.7 $\pm$ 1.5 <sup>b</sup> | 9.7 $\pm$ 1.2 <sup>a</sup>  | 9.7 $\pm$ 0.6 <sup>a</sup>  |
| 2   | <i>L. monocytogenes</i> ATCC 15313 <sup>T</sup> | 25.5 $\pm$ 0.9 <sup>c</sup>        | 30.2 $\pm$ 0.8 <sup>d</sup> | 8.2 $\pm$ 0.3 <sup>a</sup>  | 12.0 $\pm$ 1.0 <sup>b</sup> |
| 3   | <i>L. innocua</i> ATCC 33090                    | 32.0 $\pm$ 1.0 <sup>b</sup>        | 32.7 $\pm$ 0.6 <sup>b</sup> | 10.3 $\pm$ 0.6 <sup>a</sup> | 9.7 $\pm$ 0.6 <sup>a</sup>  |
| 4   | <i>L. innocua</i> LIS31                         | 24.3 $\pm$ 0.6 <sup>c</sup>        | 28.2 $\pm$ 0.8 <sup>d</sup> | 7.7 $\pm$ 0.6 <sup>a</sup>  | 9.7 $\pm$ 0.6 <sup>b</sup>  |
| 5   | <i>L. ivanovii</i> ATCC 19119                   | 30.3 $\pm$ 0.6 <sup>b</sup>        | 29.3 $\pm$ 0.6 <sup>b</sup> | 8.7 $\pm$ 0.6 <sup>a</sup>  | 10.0 $\pm$ 1.0 <sup>a</sup> |
| 6   | <i>L. seeligeri</i> ATCC 35967                  | 31.3 $\pm$ 0.6 <sup>b</sup>        | 33.7 $\pm$ 2.5 <sup>b</sup> | 11.7 $\pm$ 1.5 <sup>a</sup> | 11.7 $\pm$ 1.2 <sup>a</sup> |
| 7   | <i>L. seeligeri</i> LIS34                       | 30.3 $\pm$ 0.6 <sup>b</sup>        | 33.8 $\pm$ 0.9 <sup>c</sup> | 10.7 $\pm$ 0.6 <sup>a</sup> | 10.7 $\pm$ 0.6 <sup>a</sup> |
| 8   | <i>L. welshimeri</i> ATCC 35897                 | 24.3 $\pm$ 1.5 <sup>b</sup>        | 24.7 $\pm$ 0.6 <sup>b</sup> | 9.7 $\pm$ 0.6 <sup>a</sup>  | 10.7 $\pm$ 0.6 <sup>a</sup> |
| 9   | <i>L. welshimeri</i> LIS36                      | 23.6 $\pm$ 1.5 <sup>b</sup>        | 22.0 $\pm$ 2.0 <sup>b</sup> | 0                           | 11.3 $\pm$ 0.6 <sup>a</sup> |
| 10  | <i>L. grayi</i> ATCC 25401                      | 20.0 $\pm$ 1.0 <sup>b</sup>        | 25.7 $\pm$ 1.5 <sup>c</sup> | 9.8 $\pm$ 0.8 <sup>a</sup>  | 10.7 $\pm$ 1.2 <sup>a</sup> |


No inhibition was observed in 10 % ginger, turmeric, basil, and lemon.

\*Host strain of phage vB\_LmoS-PLM9


<sup>a-c</sup> Different superscript letters indicate significant differences ( $P < 0.05$ ) among EOs in each row

**Table 4.2.** MIC and MBC values of EOs

| EOs             | 10 <sup>6</sup> CFU/mL |         | 10 <sup>8</sup> CFU/mL |         |
|-----------------|------------------------|---------|------------------------|---------|
|                 | MIC (%)                | MBC (%) | MIC (%)                | MBC (%) |
| Cinnamon bark   | 0.0625                 | 0.125   | 0.125                  | 0.25    |
| Cinnamon cassia | 0.0625                 | 0.125   | 0.125                  | 0.25    |
| Clove           | 0.25                   | 0.5     | 0.5                    | 1       |




**Fig. 4.1.** Phage activity in treatments of C.b, C.c, and clove oils. Phage ( $5 \times 10^9$  PFU/mL) was utilized in the presence of cinnamon bark and cassia oils, while phage ( $5 \times 10^8$  PFU/mL) was employed in clove oil. Mean  $\pm$  S.D. ( $n = 3$ ).



**Fig. 4.2.** Effects of phage vB\_LmoS-PLM9 and/or C.b or C.c (A) 0.02% and (B) 0.03% against *L. monocytogenes* in broth at 30 °C. Mean  $\pm$  S.D. ( $n = 3$ ).


(A) Symbols:  $\circ$ , Control;  $\bullet$ , Phage (MOI=10);  $\square$ , 0.02% C.b;  $\triangle$ , 0.02% C.c;  $\blacksquare$ , Phage (MOI=10) + 0.02% C.b;  $\blacktriangle$ , Phage (MOI=10) + 0.02% C.c.

(B) Symbols:  $\circ$ , Control;  $\bullet$ , Phage (MOI=10);  $\square$ , 0.03% C.b;  $\triangle$ , 0.03% C.c;  $\blacksquare$ , Phage (MOI=10) + 0.03% C.b;  $\blacktriangle$ , Phage (MOI=10) + 0.03% C.c.



**Fig. 4.3.** Effects of phage vB\_LmoS-PLM9 and/or clove oil against *L. monocytogenes* in broth at 30 °C. Mean  $\pm$  S.D. ( $n = 3$ ).


Symbols: ○, Control; ●, Phage (MOI=1); △, 0.125% Clove oil; □, 0.25% Clove oil; ▲, Phage (MOI=1) + 0.125% Clove oil; ■, Phage (MOI=1) + 0.25% Clove oil.



**Fig. 4.4.** Effects of phage vB\_LmoS-PLM9 and/or C.b or C.c against *L. monocytogenes* in milk at (A and B) 30 °C, and (C) 4 °C. Mean  $\pm$  S.D. ( $n = 3$ ).

(A) Symbols: ○, Control; ●, Phage (MOI=100); □, 0.0625% C.b; △, 0.0625% C.c; ■, Phage (MOI=100) + 0.0625% C.b; ▲, Phage (MOI=100) + 0.0625% C.c.

(B and C) Symbols: ○, Control; ●, Phage (MOI=100); □, 0.125% C.b; △, 0.125% C.c; ■, Phage (MOI=100) + 0.125% C.b; ▲, Phage (MOI=100) + 0.125% C.c.



**Fig. 4.5.** Effects of phage vB\_LmoS-PLM9 and/or clove oil against *L. monocytogenes* in milk at (A) 30 °C, and (B) 4 °C. Mean  $\pm$  S.D. ( $n = 3$ ).

Symbols:  $\circ$ , Control;  $\bullet$ , Phage (MOI=100);  $\square$ , 0.5% Clove oil;  $\blacksquare$ , Phage (MOI=100) + 0.5% Clove oil.

## **Chapter 5. Control of pathogenic *Listeria monocytogenes* on various solid foods and its biofilm by using bacteriophage vB\_LmoS-PLM9 and/or cinnamon bark and clove oils**

### **5.1. Introduction**

Food contaminated by serious pathogens is a major risk to our socioeconomic and healthcare systems. The consumption of contaminated food causes 600 million illnesses and 420,000 deaths per year worldwide (WHO, 2022). *L. monocytogenes* is a ubiquitous environmental microorganism that can survive in high salt concentrations, low temperatures, and low pH. It can cause listeriosis outbreaks with a 20-30 % mortality rate, which are linked to the consumption of contaminated ready-to-eat foods, meat and meat products, milk and milk products, seafood, and vegetables (Duze et al., 2021; Hossain et al., 2022). Additionally, this bacterium can form biofilms, which spread harmful and spoiling microorganisms to food and food processing environments. Zhu et al. (2022) have reported that microbial biofilm formation is a severe concern in the food industry and causes over 60 % of foodborne outbreaks. Since food safety is one of the primary goals of the “One Health” approach, controlling the contamination and biofilm capability of *L. monocytogenes* is crucial in the food sector.

The use of promising natural and eco-friendly antimicrobial agents, such as bacteriophages, bacteriocin, enzymes, and compounds extracted from plants, has been reported recently in response to the serious worldwide public health issue of antibiotic resistance (Bai et al., 2023). Bacteriophages (phages) are viruses that infect specific target bacterial serotypes or strains. The ability of phage-host interactions ensures the target bacteria without disrupting the food’s typical microbiota (Stone et al., 2020). Single wide-host range phage or phage cocktails have been employed as effective antimicrobial agents to combat *L. monocytogenes* contamination and associated biofilm in food or food processing environments (Akhtar et al., 2017; Byun et al., 2022; Soni

and Nannapaneni, 2010). However, most previous research revealed that using phages to eradicate a high population of biofilm was unsuccessful due to the host's development of resistance to the phage and the biofilms' ability to persist on phage-treated biotic and abiotic surfaces (Byun et al., 2022).

Essential oils and their components have been demonstrated as promising natural antimicrobial agents to inhibit foodborne pathogens including *L. monocytogenes* (Hossain et al., 2022; dos Santos et al., 2022; Zhang et al., 2020; Zhu et al., 2022). Cinnamon oil is the most common spice extracted from cinnamon bark (*Cinnamomum zeylanicum*), which exhibits antibacterial and antioxidant properties (Żukowska and Durczyńska, 2024). It has been used as a preservative to extend the microbial shelf life of foods (Van Haute et al., 2017). It also effectively prevents biofilm growth of pathogenic and spoilage bacteria due to its active components, cinnamaldehyde, cinnamate, and cinnamic acid (Vasconcelos et al., 2018; Liu et al., 2020a; Zhu et al., 2022). Clove oil (*Eugenia caryophyllus*) is a non-toxic, biodegradable, and broad-spectrum antimicrobial agent. Its main component, eugenol, is effective for bacteriostasis and anti-biofilm (Hossain et al., 2022; Zhang et al., 2020).

The combination of natural antimicrobial agents from plants and microorganisms can minimize effective concentrations, costs, and sensory effects if they work synergistically (Corrêa et al., 2021; Hossain et al., 2022; Moon et al., 2020). Combining phage and cinnamon or clove oil had significant benefits in suppressing the survivability of *L. monocytogenes* in milk as described in Chapter 4 (Maung et al., 2024), however, more research is required to utilize phage and essential oil in diverse foods for advanced applications in the food sector. Therefore, this chapter investigated the biocontrol of pathogenic *L. monocytogenes* on solid food matrices and its biofilms using single and combined phage vB\_LmoS-PLM9 and cinnamon or clove oil.

## **5.2. Materials and methods**

### **5.2.1. Preparation of *L. monocytogenes* culture**

The pathogenic serotype 4b strain, *Listeria monocytogenes* no.193 was used in this experiment. This bacterium was isolated from minced pork and well-characterized in our Laboratory (Chapter 2). The bacterial cell was prepared by streaking the frozen stock (−80 °C) onto a TSA plate for 24 h and cultured in 5 mL BHI broth overnight at 30 °C. The fresh culture was used for further trials.

### **5.2.2. Preparation of bacteriophage vB\_LmoS-PLM9**

The isolated *Listeria* phage vB\_LmoS-PLM9 was used in this study. The potential phage vB\_LmoS-PLM9 was isolated from chopped chicken meat using the target host *L. monocytogenes* no.193. The phenotypic and genotypic characterization of this phage was described in Chapter 3. The fresh phage stock solution was prepared using the described propagation method in Chapter 4. In brief, 100 µL phage suspension ( $10^4$  PFU/mL) was mixed with 100 µL host culture in 4 mL of top agar with 1 mmol/L CaCl<sub>2</sub>, plated on TSA, and maintained at 30 °C for 24 h. The SM buffer (5 mL) was added to dense-plaque assay plates and left at room temperature (25 °C) overnight with shaking. The phage suspension was centrifuged, and then the supernatant was filtered and kept as phage stock ( $10^{10}$  PFU/mL) at 4 °C until use.

### **5.2.3. Preparation of EOs**

As documented in Chapter 4, cinnamon bark (cinnamon) and clove essential oils purchased from iHerb (NowFoods, Japan) were dissolved in 0.5 % (v/v) Tween 80 to prepare 4 % stock. Working solutions were prepared by diluting the stock solution with BHI broth or 0.5 % Tween 80.

#### **5.2.4. Determination of viability of *L. monocytogenes* treated with phage and/or cinnamon oil on ham, boneless skinless chicken meat, smoked salmon, and natural cheese**

The food models such as ham, boneless skinless chicken meat, smoked salmon, and natural cheese purchased from supermarkets in Fukuoka were used in this experiment. For the treatments on ham, chicken meat, and natural cheese, phage ( $5 \times 10^8$  PFU/mL) and cinnamon oil (0.5 or 1 %) were applied. The concentrations of phage ( $10^9$  PFU/mL) and cinnamon oil (0.125 or 0.25 %) were used to apply on smoked salmon. Briefly, samples were cut into 2 cm  $\times$  2 cm pieces and exposed to ultraviolet (UV) radiation for 30 min to reduce surface contamination. The samples were artificially contaminated with *L. monocytogenes* suspension (100  $\mu$ L) to achieve  $10^4$  CFU/piece. After 30 min, 100  $\mu$ L of phage and/or cinnamon suspension was spread to the surface of the contaminated samples and then stored at 30 °C for 24 h and 4 °C for 5 days. Sterilized broth was expended for the control sample. At 2, 4, 6, and 24 h at 30 °C and every single day at 4 °C, samples were taken, homogenized in 10 mL of PBS, serially diluted in PBS, and overlaid on CHROMagar™ *Listeria* (CHROMagar, Paris, France). The viable cells were counted after incubation at 30 °C for 24 h.

#### **5.2.5. Determination of viability of *L. monocytogenes* treated with phage and/or cinnamon oil on ham and salmon fillet**

In the application of phage and/or clove oil on ham and salmon fillets, treatments of phage ( $10^9$  PFU/mL) and clove oil (1 or 2 %) were used. The samples were prepared as described in Section 5.2.4, and the viable cell numbers were detected at 30 °C for 2, 4, 6, 24 h, and 4 °C every day for 5 d using CHROMagar.

#### **5.2.6. Determination of viability of *L. monocytogenes* treated with phage and/or cinnamon oil in mixed salad and coleslaw**

In these food trials, the effectiveness of phage and/or essential oil against *L. monocytogenes* in mixed salad and coleslaw was performed at a low temperature of 4 °C. For single treatment, phage ( $10^8$  PFU/mL), cinnamon (1 %), and clove (2 %) were applied. For phage plus essential oils treatments, phage ( $10^8$  PFU/mL) and half concentrations of cinnamon (0.5 %) or clove (1 %) were formulated. Sample preparation was performed using the procedure by Lewis et al. (2019). Briefly, samples were prepared by weighing 10 g each in a sterilized stomacher bag and keeping them under UV for 30 min. After that, 100  $\mu$ L diluted bacterial suspension (approximately  $10^6$  CFU/mL) was contaminated in the prepared sample. One milliliter of phage suspension was diluted in SM buffer, 1 mL of cinnamon or clove oil solution was diluted in 0.5 % Tween 80 for single treatments, whereas 500  $\mu$ L of phage and 500  $\mu$ L of essential oil for combined treatments were added to the contaminated samples. The SM buffer and 0.5 % Tween 80 were added as a control. All the prepared samples with or without treatments were kept in zip-lock bags and maintained at 4 °C for 5 d. Samples were extracted every day, homogenized in 9 mL of PBS, and diluted with PBS, and then cell viability was determined on CHROMagar.

#### **5.2.7. Determination of biofilm of *L. monocytogenes* after the treatment with phage and/or cinnamon and clove oils**

The biofilm development assay was carried out in a 96-well polystyrene microplate (Violamo, Japan) following the procedure reported by Miyamoto et al. (2011). *L. monocytogenes* 193 was cultivated in BHI broth overnight, shaking at 120 rpm and 30 °C. The overnight culture was diluted with broth to produce an OD<sub>660</sub> of 0.7. Two hundred microliters of diluted suspensions were inoculated to each well of microtiter plates and incubated at 30 °C for 24 h to form biofilm.

Time-kill experiment of single and combined phage and cinnamon or clove oil

against *L. monocytogenes* biofilms' removal was carried out as described by Duc et al. (2023). Following the formation of biofilms, the planktonic cells were removed by pipetting, and the wells were cleaned twice with sterile water before being treated with phage ( $5 \times 10^9$  PFU/mL) and cinnamon (0.125 %) or clove oil (0.25 %). For the control, the broth was inoculated instead of the treatment. After incubating at 30 °C for 0, 2, 4, 6, and 24 h, the supernatants were gently removed, and the wells were raised twice with sterile water. After adding 200 µL of PBS to each well, biofilm cells were collected by scratching the surface with pipette tips and continuously resuspending. The obtained suspensions were diluted with PBS, and viable counts were examined by the conventional plating method on CHROMagar.

#### 5.2.8. Statistical analysis

Data were calculated as mean  $\pm$  standard deviation from triplicate experiments. The student's t-test was used to identify significant differences ( $P < 0.05$ ) between the control and treatment groups.

### 5.3. Results

#### 5.3.1. Effects of phage and/or cinnamon oil on the viability of pathogenic *L. monocytogenes* on ham, boneless skinless chicken meat, smoked salmon, and natural cheese

The applications on ham are shown in Fig. 5.1. At 30 °C, the viable cells were reduced by approximately 1 log at 2 h and 2.3 log at 24 h incubation in the phage-treated sample. Survival cells decreased when cinnamon oil was treated alone compared to the control group. However, the combined therapy with phage and cinnamon oil was more effective than the single treatment. *L. monocytogenes* viable counts were lowered by approximately 2.5 log at 6 h, and cell growth was inhibited by 4.2 log at 24 h in the presence of phage and 1 % cinnamon oil (Fig. 5.1A). At 4 °C, a single phage treatment lowered around 1.3 log at 1 d, whereas cinnamon oil (0.5 or 1 %) alone had no

discernible impact. The combination of phage and cinnamon oil (1 %) reduced surviving cells by 2.3 log at 1 d and continuously inhibited by suppressing the regrowth cells under initial cell counts (Fig. 5.1B).

The applications on boneless skinless chicken meat are displayed in Fig. 5.2. At 30 °C, viable cells were reduced by 1 and 0.7 log after 6 h of phage and cinnamon oil treatment alone, respectively. However, phage combined with 0.5 or 1 % cinnamon oil lowered viable numbers by about 1.3 log and 2.3 log, respectively, after 6 and 24 h of incubation compared to the growth of the control sample. The combined treatment of phage and 1 % cinnamon oil immediately reduced approximately 1 log after 2 h (Fig. 5.2A). Figure 5.2B also shows that the combined phage and cinnamon oil treatments were more effective than single treatments at 4 °C. The viable cells were reduced by approximately 1.2 and 1.4 log at 1 d in combined phage and 0.5 or 1 % cinnamon oil. The survival cell counts were decreased by approximately 2.9 log in the combined phage and 0.5 % cinnamon oil after 5 d storage, whereas they were lowered and reached under a detection level in the combined phage and 1 % cinnamon oil.

The effects on smoked salmon at 30 °C are shown in Fig. 5.3. The viability of *L. monocytogenes* was reduced by approximately 1 log after 2 h incubation in phage treatment. Cinnamon oil treatment did not affect viable counts at 0.125 or 0.25 %. No additional effects were observed on the viability of *L. monocytogenes* treated with combined phage and cinnamon oil.

Figure 5.4 indicates the efficiency of phage and/or cinnamon oil against *L. monocytogenes* on natural cheese at 4 °C. The viable counts of *L. monocytogenes* in the phage-treated sample were reduced immediately compared to the control, but not in the 0.5 or 1 % cinnamon oil-treated sample. The surviving cells were decreased by 1.8 log at 2 d in combining phage and 0.5 % cinnamon oil treatment, and by 2 log at 1 d in combining phage and 1 % cinnamon oil, demonstrating that the combination treatments were more effective than the single ones.

### **5.3.2. Effects of phage and/or clove oil on the viability of pathogenic *L. monocytogenes* on ham and salmon fillet**

The applications of phage and/or clove oil on ham at 30 °C, the phage-treated ham sample indicated that the viable cells were reduced by about 1.1 log and 1.7 log after 2 and 24 h of incubation compared to the control. Although the viable counts of *L. monocytogenes* were not significantly reduced in clove oil-treated samples at 2 h, they were reduced by 1.6 log and 1.9 log in 1 and 2 % clove oil-treated samples at 24 h. The survival cells were reduced at a maximum of 2.3 log at 6 h and 3.6 log at 24 h in combined treatment with phage and 2 % clove oil, whereas they were decreased by 1.6 log at 6 h and 2.8 log at 24 h in the combined phage and 1 % clove oil (Fig. 5.5A). At 4 °C, phage treatment reduced the viable cells by 1.5 log at 1 d and continuously inhibited cell growth until 5 d. Clove oil therapy with 2 % inhibited bacterial cell development for 1 to 3 d. Nevertheless, combined treatments were more effective than single ones. When *L. monocytogenes* was treated with phage and clove oil (1 or 2 %), their vitality steadily declined and nearly reached the lowest detection limit at 4 and 5 d (Fig. 5.5B).

On salmon fillet, the viable cells were reduced by 1.1, 0.6, and 0.9 log in the single treatment of phage, 1 %, and 2 % of clove oil after 4 h at 30 °C. These results indicated lower effects than the viability of *L. monocytogenes* reduced by 1.3 and 1.5 log in phage combined with 1 and 2 % clove oil after 4 h incubation (Fig. 5.6A). At 4 °C, a reduction of viable cells was observed by 1.1 log in treatment of combined phage and 2 % clove oil at 2 d, however, no significant effects were found in other therapies (Fig. 5.6B).

### **5.3.3. Effects of phage and/or cinnamon and clove oils on the viability of pathogenic *L. monocytogenes* in mixed salad and coleslaw**

In the mixed salad trial, the sample treated with phage alone decreased small numbers of cells at 3 d. The viable cells were immediately reduced by approximately 1

log CFU/g in the 2 % clove oil treatment, but it had no effect in the 1 % cinnamon oil treatment. The combined phage and 0.5 % cinnamon oil reduced the surviving cells by about 1 log at 1 d and continuously inhibited the regrowth of cells. Combined phage and clove oil (2 %) had the greatest impact, reducing viable counts by 1.5 log CFU/g at 2 d and steadily falling to nearly an undetectable level after 4 d (Fig. 5.7A).

Similar results showed that combination treatments were more beneficial than individual ones in the coleslaw food trial at 4 °C. Combined phage and half concentration of cinnamon oil (0.5 %) treatment reduced survival cells by about 1 log at 1 d and 1.5 log at 2 d, then continuously prevented regrowth cells, which were more effective than 1 % cinnamon oil treatment alone. In 2 % clove oil treatment, survival cells were reduced only by about 1 log at 1 d and inhibited the regrowth of cells over a 5-d period. However, combining phage and half concentration of clove oil (1 %) was more effective by reducing the viable counts to 2.3 log CFU/g at 2 d and limiting the resistance cell populations till the end of the experiment (Fig. 5.7B).

#### **5.3.4. Effects of phage and/or cinnamon oil on removal of *L. monocytogenes* biofilm**

The effect of phage vB\_LmoS-PLM9 and/or cinnamon oil on the removal of biofilms is shown in Fig. 5.8A. The biofilm cells were reduced by approximately 1.5 log CFU/well after 2 h incubation in the phage treatment alone. The treatment of cinnamon oil (0.125 %) alone did not show an obvious effect until 6 h but it reduced by 1.8 log at 24 h when compared with the control. In phage plus 0.25 % cinnamon oil, biofilm cells were decreased by 1.5 log at 2 h, 2 log at 4 h, and 4.4 log at 24 h compared to the biofilm cells well without treatment.

#### **5.3.5. Effects of phage and/or clove oil on removal of *L. monocytogenes* biofilm**

Fig. 5.8B illustrates the effects of phage vB\_LmoS-PLM9 and clove oil in an individual or combination on removing *L. monocytogenes* biofilms. The biofilm cells were decreased by approximately 1.4 log CFU/well after 2 h and continuously inhibited

after 24 h in phage treatment alone, while those were not observed in 0.25 % clove oil alone. The combination of phage and 0.25 % clove oil was more effective than the treatment alone, which decreased the biofilm cells by approximately 3.2 log after 4 h compared to the initial cell counts and suppressed the regrowth cell populations.

#### 5.4. Discussion

*Listeria monocytogenes* contamination in various foods and their biofilm formation capability are serious food safety problems for consumers and the food industry. The development of natural alternative antimicrobial agents has become a top focus in research since foodborne bacteria are resistant to antibiotics. According to this purpose, our earlier study in Chapter 4 isolated a potential phage vB\_LmoS-PLM9, evaluated the effective essential oils including cinnamon and clove oils, and determined their effects in single and combined therapy against *L. monocytogenes* in milk. However, we still need to do more research to control this pathogen which may lead to the food safety approach. Therefore, this study aimed to investigate the biocontrol of pathogenic *L. monocytogenes* in various solid food matrices such as ham, salmon, chicken meat, natural cheese, mixed salad, and coleslaw, and its biofilms using phage, cinnamon, and clove oil alone or in combination.

Controlling *L. monocytogenes* on the ham food model using commercial phages such as Listex™ P100 and ListShield™ (Gutiérrez et al., 2017) and essential oils including cinnamon oil (dos Santos et al., 2022) have been reported previously. Using high concentrations (3, 5, and 10 %) of cinnamon oil could inhibit the growth of *L. monocytogenes* on ham, however, it may not be acceptable for some consumers due to sensory factors (dos Santos et al., 2022). To reduce sensory impacts using a lower dosage of essential oils, a combination of two antibacterial agents is increasing in interest. Furthermore, there was no report of combining phage and essential oil therapy against *L. monocytogenes* on ham. In this study, ham treated with phage alone reduced the viable counts of *L. monocytogenes* at 2 h but some resistance cells grew back after

24 h at 30 °C. At 4 °C, the phage treatment reduced viable cells at 1 d and inhibited until 5 d. Single cinnamon or clove oil treatments showed their effects relied on tested concentrations. Although we did not find the surviving cells reduction in treatments of cinnamon oil (0.5 or 1 %) and clove oil (1 %) alone, the viable cells were decreased when treated with clove oil (2 %) at 4 °C. However, the combined phage and cinnamon or clove oil reduced *L. monocytogenes* vitality and limited the populations of resistant cells compared with treatment alone, especially at 4 °C storage. These results suggested that the phage combined with essential oil treatment could be a solution to suppress the phage resistance mutants and lessen the sensory effects of essential oil by using lower concentrations on ham.

The phage and cinnamon or clove oils were also applied to the smoked salmon. The viable cells were reduced at 2 h in the phage-treated sample, while they did not show any effects in the cinnamon oil-treated sample. The combined phage and cinnamon oil did not observe any additional effects to inhibit the *L. monocytogenes*. Moosavi-Nasab et al. (2019) reported similar findings, stating that cinnamon oil had no antibacterial impact on vacuum- or modified atmosphere-packaged salmon. Van Haute et al. (2017) also found no antimicrobial effectiveness when cinnamon oil was applied to salmon. And, only a few viable cells were reduced in the treatment of 2 % clove oil interaction with phage. These results may be due to the abundance of lipids in salmon, resulting in the distribution of active chemicals of essential oils to the salmon lipid phase. Other variables may be necessary to activate the antibacterial activity of essential oil and phage on salmon.

Chicken meat is the most consumable and important vehicle for public health concerns worldwide. Applications of phage against *Salmonella*, *E. coli*, and *C. perfringens* were previously reported in our laboratory (Duc et al., 2020; Noor Mohammadi et al., 2022a; Zhao et al., 2023), however, it has not been studied yet against *L. monocytogenes* using specific *Listeria* phage. Plant-based essential oils and

their compounds including cinnamon and clove oils alone against *L. monocytogenes* in chicken meats were documented in other studies (Mahfuzul Hoque et al., 2008; Noori et al., 2018; Shahbazi et al., 2018; Raeisi et al., 2016; Yousefi et al., 2020). Only one report observed a combination of commercial phage (SALMONELEX) and essential oils against *Salmonella* in chicken meat (Moon et al., 2020). This study examined using phage and cinnamon oil alone or in combination to combat *L. monocytogenes* in boneless skinless chicken meat. The maximum viable counts were reduced after 6 h at 30 °C and 3 d at 4 °C in phage-treated samples. The treatment of 1 % cinnamon oil was more effective at a low temperature (4 °C) than storage at 30 °C. However, bacterial cell reduction was not observed in the treatment of 0.5 % cinnamon oil in both temperatures. Nonetheless, the combined therapy with phage and cinnamon oil indicated better effectiveness than the single treatment, especially at 4 °C. The survival cell counts were reduced immediately at 1 d in both combined treatments. And they were continuously decreased in phage combined with 0.5 % cinnamon oil while reduced to a lower detection level in phage combined with 1 % cinnamon oil at 5 d trial. These findings suggested that combined phage and cinnamon oil could be an effective and promising anti-listerial treatment for chicken meat.

A listeriosis outbreak was caused by contaminated natural cheese, as reported in Japan in 2001 (Makino et al., 2005). Cheese contains rich nutrients, which makes bacteria and fungi more likely to become contaminated. Khorshidian et al. (2018) reported that several essential oils can be used as natural antimicrobial agents to combat foodborne pathogens in cheese and extend the shelf-life. However, negative effects on organoleptic properties were observed if they applied high concentrations of essential oils. Therefore, this study investigated phage plus lower concentrations of cinnamon oil against *L. monocytogenes* in natural cheese at 4 °C. Phage alone instantly reduced viable cell counts, however, cinnamon oil (0.5 or 1 %) alone had no effect. The combined treatment of phage and cinnamon oil immediately reduced the survival cells

and inhibited the resistance cell populations until 5 d. These results may be helpful for consumer safety without any sensory impacts.

Similar results were observed when we applied the phage and/or cinnamon or clove oil in mixed salad and coleslaw food models. At 4 °C storage for 5 d, phage and half concentrations of cinnamon (0.5 %) or clove (1 %) oil treatments were more effective than single ones. Similar results were reported by Lewis et al. (2019) that the combined use of commercial phage (P100) and Nisaplin was more effective than single use in coleslaw stored at 4 °C during a 10-d period. Most of the results in this study indicated that the combined phage and essential oil therapy was more effective than the phage or essential alone. This may be due to phage and active components of essential oils may exert synergism to inhibit bacterial cells and prevent the resistance cell populations. Leistner and Gorris. (1995) also documented that hurdle technology should be employed often to remove or control pathogens by combining multiple preservation methods.


Biofilm formation is a severe problem in the food industry and is difficult to prevent. Many studies are approaching to inhibit or eradicate the *L. monocytogenes* biofilms by using phages or phage cocktails (Byun et al., 2022; Soni and Nannapaneni, 2010) and various essential oils such as *Cinnamon zeylanicum* and *Thymbra capitata* (Maggio et al., 2023), oregano (Tahric et al., 2023), lavender (Han et al., 2022), garlic (Liu et al., 2024), and clove oil (Zhang et al., 2020). Furthermore, a combination of two antimicrobial agents is being developed to provide greater results in combating pathogenic biofilms. Nisin and essential oil components such as thymol and eugenol (Hossain et al., 2022), nisin and plant extracts (Santativongchai et al., 2023) against *L. monocytogenes* biofilms, as well as bacteriophage and carvacrol against *Pseudomonas syringae* and *actinidiae* biofilms (Ni et al., 2020) have been effectively employed. The results in this study are in agreement with those previous reports for the removal of preformed biofilms. The phage alone with high MOI also showed a reduction of

preformed biofilm cells. The use of sub-inhibitory concentrations of cinnamon or clove oil did not show obvious effects in single therapies, however, those combined with phage had better effectiveness in destroying preformed biofilms. These preliminary findings in controlling the preformed pathogenic *L. monocytogenes* biofilms using phage interacted with cinnamon or clove oil could be useful in the ongoing investigation of controlling biofilms in the food industry.


## 5.5. Summary

This chapter investigated the effects of single and combined phage and cinnamon or clove oil against pathogenic *L. monocytogenes* in various solid food matrices and their biofilm removal. The treatments of the phage plus cinnamon oil (0.5 or 1 %) or clove oil (1 or 2 %) reduced the survival cell counts of *L. monocytogenes* on ham but not salmon. The combined phage and 1 % cinnamon oil treatment reduced the number of surviving cells in chicken meat more than the individual treatments, especially at 4 °C storage. In natural cheese at 4 °C, phage alone and phage combined with cinnamon oil treatments reduced the viable cell counts, however, cinnamon oil (0.5 or 1 %) alone did not show any effects. In mixed salad and coleslaw trials at a low temperature, phage + 1 % clove oil and phage + 0.5 % cinnamon oil treatments were more effective than others. On the other hand, the combined treatments of phage and 0.125 % cinnamon oil or 0.25 % clove oil have shown high effectiveness in inhibiting preformed biofilms compared to individual treatments. These results suggested that combined phage and cinnamon or clove oil is a promising candidate to control *L. monocytogenes* in various foods and their biofilms.

**(A) 30 °C**




**(B) 4 °C**




**Fig. 5.1.** Effects of phage vB\_LmoS-PLM9 and cinnamon bark oil alone or in combination on the viability of *L. monocytogenes* on ham at (A) 30 °C, and (B) 4 °C. Mean  $\pm$  S.D. ( $n = 3$ ).

Symbols: ○, Control; ●, Phage ( $5 \times 10^8$  PFU/mL); △, 0.5 % C.b; □, 1 % C.b; ▲, Phage ( $5 \times 10^8$  PFU/mL) + 0.5 % C.b; ■, Phage ( $5 \times 10^8$  PFU/mL) + 1 % C.b.




**Fig. 5.2.** Effects of phage vB\_LmoS-PLM9 and cinnamon bark oil alone or in combination on the viability of *L. monocytogenes* on boneless skinless chicken meat at (A) 30 °C, and (B) 4 °C. Mean  $\pm$  S.D. ( $n = 3$ ).

Symbols:  $\circ$ , Control;  $\bullet$ , Phage ( $5 \times 10^8$  PFU/mL);  $\triangle$ , 0.5 % C.b;  $\square$ , 1 % C.b;  $\blacktriangle$ , Phage ( $5 \times 10^8$  PFU/mL) + 0.5 % C.b;  $\blacksquare$ , Phage ( $5 \times 10^8$  PFU/mL) + 1 % C.b.




**Fig. 5.3.** Effects of phage vB\_LmoS-PLM9 and cinnamon bark oil alone or in combination on the viability of *L. monocytogenes* on smoked salmon at 30 °C. Mean  $\pm$  S.D. ( $n = 3$ ).

Symbols: ○, Control; ●, Phage ( $10^9$  PFU/mL); △, 0.125 % C.b; □, 0.25 % C.b; ▲, Phage ( $10^9$  PFU/mL) + 0.125 % C.b; ■, Phage ( $10^9$  PFU/mL) + 0.25 % C.b.




**Fig. 5.4.** Effects of phage vB\_LmoS-PLM9 and cinnamon bark oil alone or in combination on the viability of *L. monocytogenes* on natural cheese at 4 °C. Mean  $\pm$  S.D. ( $n = 3$ ).

Symbols: ○, Control; ●, Phage ( $5 \times 10^8$  PFU/mL); △, 0.5 % C.b; □, 1 % C.b; ▲, Phage ( $5 \times 10^8$  PFU/mL) + 0.5 % C.b; ■, Phage ( $5 \times 10^8$  PFU/mL) + 1 % C.b.




**Fig. 5.5.** Effects of phage vB\_LmoS-PLM9 and clove oil alone or in combination on the viability of *L. monocytogenes* on ham at (A) 30 °C, and (B) 4 °C. Mean  $\pm$  S.D. ( $n = 3$ ).

Symbols: ○, Control; ●, Phage ( $10^9$  PFU/mL); △, 1 % Clove oil; □, 2 % Clove oil; ▲, Phage ( $10^9$  PFU/mL) + 1 % Clove oil; ■, Phage ( $10^9$  PFU/mL) + 2 % Clove oil.




**Fig. 5.6.** Effects of phage vB\_LmoS-PLM9 and clove oil alone or in combination on the viability of *L. monocytogenes* on salmon fillet at (A) 30 °C, and (B) 4 °C. Mean  $\pm$  S.D. ( $n = 3$ ).

Symbols:  $\circ$ , Control;  $\bullet$ , Phage ( $10^9$  PFU/mL);  $\triangle$ , 1 % Clove oil;  $\square$ , 2 % Clove oil;  $\blacktriangle$ , Phage ( $10^9$  PFU/mL) + 1 % Clove oil;  $\blacksquare$ , Phage ( $10^9$  PFU/mL) + 2 % Clove oil.



**Fig. 5.7.** Effects of phage vB\_LmoS-PLM9 and cinnamon bark or clove oil alone or in combination on the viability of *L. monocytogenes* at a low temperature, 4 °C storage (A) mixed salad, and (B) coleslaw. Mean  $\pm$  S.D. ( $n = 3$ ).

Symbols: ○, Control; ●, Phage ( $10^8$  PFU/mL); △, 1 % C.b; □, 2 % Clove oil; ▲, Phage ( $10^8$  PFU/mL) + 0.5 % C.b; ■, Phage ( $10^8$  PFU/mL) + 1 % Clove oil.



**Fig. 5.8.** (A) Effects of phage vB\_LmoS-PLM9 and cinnamon bark oil alone or in combination on removing 24 h-preformed biofilms at 30 °C. Mean  $\pm$  S.D. ( $n = 3$ ).

Symbols: ○, Control; ●, Phage ( $5 \times 10^9$  PFU/mL); □, 0.125% C.b.; ■, Phage ( $5 \times 10^9$  PFU/mL) + 0.125% C.b.

(B) Effects of phage vB\_LmoS-PLM9 and clove oil alone or in combination on removing 24 h-preformed biofilms at 30 °C. Mean  $\pm$  S.D. ( $n = 3$ ).

Symbols: ○, Control; ●, Phage ( $5 \times 10^9$  PFU/mL); □, 0.25% Clove oil; ■, Phage ( $5 \times 10^9$  PFU/mL) + 0.25% Clove oil.

## Chapter 6. Conclusions

Food safety has become an important public health concern worldwide due to the emergence of microbial foodborne pathogens. *L. monocytogenes* is a severe food poisoning pathogen, widely disseminated in our environment, which may easily infect food. It causes several listeriosis outbreaks in humans and animals, with high mortality rates due to consuming contaminated foods. Additionally, controlling biofilms in this pathogen on food and food-contact surfaces is essential since biofilm-associated infections have been linked to over 65 % of serious health problems. Due to increasing antimicrobial resistance, developing promising alternative antimicrobial agents to combat foodborne pathogens is critically necessary. Bacteriophage is a bacterial virus abundant in nature and possesses many advantages such as high host specificity, low cost, and no harmful effect on humans. According to previous studies, the bacteriophage is a potential antibacterial agent that can be used safely in foods. Plant-based essential oils have antimicrobial and antioxidant properties; therefore, they are used for bacteriostasis, bactericidal, and anti-biofilm in the food industry. Nevertheless, it is important to pay great attention to the combination of antibacterial agents derived from plants and microorganisms, as this may help to avoid the regrowth of resistant bacteria and require lower concentrations of each agent. Therefore, this study was conducted to characterize the antimicrobial-resistant *L. monocytogenes* isolated from food and investigate their biocontrol using specific bacteriophage and essential oils in a single or combination.

In Chapter 2, *L. monocytogenes* was isolated from 85 raw chicken and viscera samples collected from supermarkets in Fukuoka in 2022. Nine samples (10.6 %) were positive, and 17 strains were isolated. Characterization in serotyping indicated serotypes 1/2b (41.2 %), 3a (29.4 %), 3b (23.5 %), and 1/2a (5.9 %) respectively. All the isolates were identified and clustered by MALDI-TOF mass spectrometry. Antimicrobial susceptibility testing demonstrated the isolates were sensitive to several

antibiotics except cefoxitin, oxacillin, and fosfomycin. In the comparison of 5-year differences surveillance, the incidence of *L. monocytogenes* in 2022 was significantly ( $P < 0.05$ ) lower than those in 2017 (24 %) and 2012 (52.9 %), and pathogenic serotype distributions decreased over time. Antimicrobial resistance (AMR) and multi-drug resistance rates of isolates in 2022 were reduced compared to those in 2017 and 2012. The virulence genes (*hlyA*, *plcA*, *clpC*, and *inlA*) were harbored in most isolates in 5-year intervals. The biofilm mass in 2022 isolates was significantly ( $P < 0.05$ ) weaker than previous isolates. Although rates of detection from chicken meat and AMR of the isolates were not high, virulent *L. monocytogenes* contamination in foods still should pay attention.

Chapter 3 demonstrated the isolation and characterization of bacteriophages against *L. monocytogenes*. Eleven phages from raw chicken samples and 15 phages from Kyushu University's cattle farm samples were isolated. According to host range determination, most phages exhibited lytic activity against *L. monocytogenes*, *L. innocua*, *L. seeligeri*, *L. welshimeri*, and *L. grayi*. Characterization of three selected phages was performed. All the phages were stable at pH (4-10), and temperatures (4-50 °C), except for phage vB\_LmoS-PLM34, which only survived up to 40 °C. The transmission electron microscopy of the broadest host range phage vB\_LmoS-PLM34 showed an icosahedral head (diameter ~ 60 nm) and noncontractile tail (length ~ 230 nm) that belongs to the *Siphoviridae* family. The whole genomic DNA sequencing analysis demonstrated all 3 phages have no genes for tRNA, virulence, or antimicrobial resistance genes but endolysin genes. Phages vB\_LmoS-PLM9 and vB\_LmoS-PLM34 had N-acetylmuramoyl-l-alanine amidases, whereas phage vB\_LmoS-PLM26 had peptidoglycan l-alanyl-d-glutamate endopeptidase endolysins. However, only phage vB\_LmoS-PLM9 was a lytic phage since it did not have lysogenic-related genes. Its latent period (70 min) and burst size ( $51.2 \pm 2.1$  PFU/cell) were observed. These results

indicated that bacteriophages against *L. monocytogenes* were isolated and characterized phenotypically and genotypically.

In Chapter 4, eight essential oils including cinnamon bark, cinnamon cassia, clove, lemongrass, ginger, basil, turmeric, and lemon were evaluated for their antibacterial efficiency. Cinnamon bark and cinnamon cassia exhibited the strongest anti-listerial activities, followed by clove and lemongrass oils against *L. monocytogenes*, and various *Listeria* spp. were observed when tested at 10 %. The MIC and MBC values of both cinnamon bark and cassia oils were 0.0625 and 0.125 %, respectively, and those of clove oil were 0.25 and 0.5 %, respectively. The application of essential oils and/or phage vB\_LmoS-PLM9 alone and in combination was investigated in broth and milk. The combined applications were highly effective compared to single ones. In broth at 30 °C, the survival cells of *L. monocytogenes* were decreased, and the regrowth of resistant cells was suppressed in the combined treatments with phage (MOI of 10) and both cinnamon oils (0.03 %), and phage (MOI of 1) and clove oil (0.125 %). The combined phage (MOI of 100) and cinnamon oil (0.125 %) showed high effectiveness in milk, particularly at 4 °C by reducing the viable counts under the lower detection level. Phage (MOI of 100) plus clove oil (0.5 %) decreased the surviving cells and inhibited the resistant cell growth in milk at 4 °C. These results suggested combining phage and essential oil is a potential approach for controlling *L. monocytogenes* in milk.

In Chapter 5, the biocontrol of pathogenic *L. monocytogenes* in various solid foods and their biofilm using phage vB\_LmoS-PLM9 and cinnamon or clove oils were examined. Phage and cinnamon or clove oils showed higher effectiveness than single treatments, particularly at 4 °C. Phage ( $5 \times 10^8$  PFU/mL) and cinnamon bark (1 %) on ham, phage ( $5 \times 10^8$  PFU/mL), and cinnamon bark (0.5 %) on chicken meat, cheese, mixed salad, and coleslaw reduced the viable counts compared with the single treatment, but not in smoked salmon. The combined treatment of phage ( $5 \times 10^8$  PFU/mL) and cinnamon bark (1 %) decreased the viable cells less than the detection limit in chicken

meat after 4 d storage at 4 °C. In combined use of phage ( $10^9$  PFU/mL) and clove oil (1 %) on ham, mixed salad, and coleslaw, viable counts decreased or reduced at 4 °C. Moreover, phage ( $5 \times 10^9$  PFU/mL) and cinnamon oil (0.125 %) or clove oil (0.25 %) decreased the viability of *L. monocytogenes* in the 24 h preformed biofilm at 30 °C. These results suggested that combined phage and cinnamon or clove oil might be a promising candidate for controlling pathogenic *L. monocytogenes* in the food industry.

In conclusion, this study investigated a 5-year difference surveillance on the occurrence, characterization, AMR, and pathogenicity of *L. monocytogenes* from raw chickens in Fukuoka, which will benefit the microbial risk assessment of the nation. Bacteriophages specific to *L. monocytogenes* were successfully isolated and characterized. Cinnamon bark, cinnamon cassia, and clove oils have been recognized as strong anti-listerial activities among 8 essential oils tested in this study. Moreover, combining phage and cinnamon or clove oils could be exploited as effective tools for controlling *L. monocytogenes* in various foods and their biofilms. Further studies will focus on the expression of endolysins as a promising biocontrol agent for controlling bacterial pathogens.

## **Acknowledgments**

First and foremost, I would like to extend my heartfelt gratitude to my respectable supervisor, Professor Takahisa Miyamoto, Laboratory of Food Hygienic Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, for his guidance, inspiration, patience, understanding, and support throughout my studies. His profound learning, inspiring inculcation, and constant strictness have stimulated my enthusiasm for working on this thesis and further research.

Secondly, I would like to express my sincere appreciation to my co-supervisor, Associate Professor Ken-ichi Honjoh, Laboratory of Food Hygienic Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, for his kind support and encouragement. His guidance and motivation have played a significant role in shaping my research journey.

I am also grateful to my co-reviewer, Professor Dr. Noriyuki Igura, Laboratory of Food Process Engineering, Department of Bioscience and Biotechnology, Faculty of Agriculture, Kyushu University, for his valuable insights and research suggestions. His expertise and cooperation have greatly contributed to the development and improvement of my study.

I am also deeply grateful to Assistant Professor Yoshimitsu Masuda for his valuable ideas, suggestions, and inspiration during my studies. I would like to give a special thanks to Ms. Akiko Sato, our technical staff, for her kind and full support and assistance throughout my studies.

I also express my warm appreciation and truly thank all members of the Laboratory of Food Hygienic Chemistry, for their cooperation, support, and great memories.

I would like to truly appreciate the Japanese Grant Aid for Human Resource Development Scholarship (JDS) program for financial support.

Finally, I acknowledge with a deep sense of gratitude to my parents, my husband, and my dearest friends for their unconditional and continued support and encouragement, which were a constant source of inspiration.

## References

- Abdi-Moghadam, Z., Mazaheri, Y., Rezagholizade-shirvan, A., Mahmoudzadeh, M., Sarafraz, M., Mohtashami, M., Shokri, S., Ghasemi, A., Nickfar, F., Darroudi, M., Hossieni, H., Hadian, Z., Shamloo, E., Rezaei, Z., 2023. The significance of essential oils and their antifungal properties in the food industry: A systematic review. *Heliyon*. 9, e21386. <https://doi.org/10.1016/j.heliyon.2023.e21386>
- Ackermann, H.W., 2007. 5500 Phages examined in the electron microscope. *Arch. Virol.* 152, 227–243. <https://doi.org/10.1007/s00705-006-0849-1>
- Aiyedun, J O, Olatoye, O.I., Oludairo, O.O., Adesope, A.O., Ogundijo, O., 2020. Occurrence, Antimicrobial susceptibility and biofilm production in *Listeria monocytogenes* isolated from pork and other meat processing items at Oko-Oba Abattoir, Lagos State, Nigeria. *Sahel. J. Vet. Sci* 17, 24–30.
- Akhtar, M., Viazis, S., Christensen, K., Kraemer, P., Diez-Gonzalez, F., 2017. Isolation, characterization and evaluation of virulent bacteriophages against *Listeria monocytogenes*. *Food Control*. 75, 108–115. <https://doi.org/10.1016/j.foodcont.2016.12.035>
- Al-Mashhadany, D.A., 2019. Occurrence and antibiogram of *Listeria monocytogenes* isolates from retail meat shops at Erbil city, Kurdistan region, Iraq. *Ital. J. Food. Saf.* 8, 194–198. <https://doi.org/10.4081/ijfs.2019.8451>
- Al, S., Disli, H.B., Hizlisoy, H., Ertas Onmaz, N., Yildirim, Y., Gonulalan, Z., 2022. Prevalence and molecular characterization of *Listeria monocytogenes* isolated from wastewater of cattle slaughterhouses in Turkey. *J. Appl. Microbiol.* 132, 1518–1525. <https://doi.org/10.1111/jam.15261>
- Allerberger, F., Wagner, M., 2010. Listeriosis: A resurgent foodborne infection. *Clin. Microbiol. Infect.* 16, 16-23. <https://doi.org/10.1111/j.1469-0691.2009.03109.x>

- Bai, J., Li, J., Chen, Z., Bai, X., Yang, Z., Wang, Z., Yang, Y., 2023. Antibacterial activity and mechanism of clove essential oil against foodborne pathogens. LWT. 173, 114249. <https://doi.org/10.1016/j.lwt.2022.114249>
- Bayala, B., Bassole, I.H.N., Gnoula, C., Nebie, R., Yonli, A., Morel, L., Figueredo, G., Nikiema, J.B., Lobaccaro, J.M.A., Simpore, J., 2014. Chemical composition, antioxidant, anti-inflammatory and anti-proliferative activities of essential oils of plants from Burkina Faso. PLoS One. 9, e92122. <https://doi.org/10.1371/journal.pone.0092122>
- Borucki, M.K., Peppin, J.D., White, D., Loge, F., Call, D.R., 2003. Variation in biofilm formation among strains of *Listeria monocytogenes*. Appl. Environ. Microbiol. 69, 7336–7342. doi: 10.1128/AEM.69.12.7336-7342.2003. PMID: 14660383; PMCID: PMC309931.
- Bouymajane, A., Rhazi Filali, F., Oulghazi, S., Lafkih, N., Ed-Dra, A., Aboulkacem, A., El Allaoui, A., Ouhmidou, B., Moumni, M., 2021. Occurrence, antimicrobial resistance, serotyping and virulence genes of *Listeria monocytogenes* isolated from foods. Heliyon. 7, e06169. <https://doi.org/10.1016/j.heliyon.2021.e06169>
- Briandet, R., Leriche, V., Carpentier, B., Bellon-Fontaine, M.N., 1999a. Effects of the growth procedure on the surface hydrophobicity of *Listeria monocytogenes* cells and their adhesion to stainless steel. J. Food Prot. 62, 994-998. doi: 10.4315/0362-028x-62.9.994. PMID: 10492472.
- Briandet, R., Meylheuc, T., Maher, C., Bellon-Fontaine, M.N., 1999b. *Listeria monocytogenes* Scott A: cell surface charge, hydrophobicity, and electron donor and acceptor characteristics under different environmental growth conditions. Appl. Environ. Microbiol. 65, 5328–5333. doi: 10.1128/AEM.65.12.5328-5333.1999. PMID: 10583984; PMCID: PMC91724.
- Brnawi, W.I., Hettiarachchy, N.S., Horax, R., Kumar-Phillips, G., Ricke, S., 2019. Antimicrobial activity of leaf and bark cinnamon essential oils against *Listeria*

- monocytogenes* and *Salmonella typhimurium* in broth system and on celery. J. Food Process Preserv. 43, 13888. <https://doi.org/10.1111/jfpp.13888>
- Brnawi, W.I., Hettiarachchy, N.S., Horax, R., Kumar-Phillips, G., Seo, H.S., Marcy, J., 2018. Comparison of cinnamon essential oils from leaf and bark with respect to antimicrobial activity and sensory acceptability in strawberry shake. J. Food. Sci. 83, 475–480. <https://doi.org/10.1111/1750-3841.14041>
- Buchanan, R.L., Gorris, L.G.M., Hayman, M.M., Jackson, T.C., Whiting, R.C., 2017. A review of *Listeria monocytogenes*: An update on outbreaks, virulence, dose-response, ecology, and risk assessments. Food Control. 75, 1–13. <https://doi.org/10.1016/j.foodcont.2016.12.016>
- Burt, S., 2004. Essential oils: Their antibacterial properties and potential applications in foods - A review. Int. J. Food Microbiol. 94, 223–253. <https://doi.org/10.1016/j.ijfoodmicro.2004.03.022>
- Byun, K.H., Han, S.H., Choi, M.W., Park, S.H., Ha, S. Do, 2022. Isolation, characterization, and application of bacteriophages to reduce and inhibit *Listeria monocytogenes* in celery and enoki mushroom. Food Control. 135, 108826. <https://doi.org/10.1016/j.foodcont.2022.108826>
- Callaway, T. R., Carroll, J. A., Arthington, J. D., Edrington, T. S., Anderson, R. C., Ricke, S. C., et al., 2011. Citrus products and their use against bacteria: potential health and cost benefits (chap. 17). In R. Watson, J. L. Gerald, & V. R. Preedy (Eds.), Nutrients, dietary supplements, and nutraceuticals: Cost analysis versus clinical benefits. New York, NY: Humana Press. p. 277e286.
- Caly, D., Takilt, D., Lebre, V., Tresse, O., 2009. Sodium chloride affects *Listeria monocytogenes* adhesion to polystyrene and stainless steel by regulating flagella expression. Lett. Appl. Microbiol. 49, 751–756. doi: 10.1111/j.1472-765X.2009.02735.x. PMID: 19793195.

- Cao, X., Wang, Yi, Wang, Yan, Ye, C., 2018. Isolation and characterization of *Listeria monocytogenes* from the black-headed gull feces in Kunming, China. J. Infect. Public Health. 11, 59–63. <https://doi.org/10.1016/j.jiph.2017.03.003>
- Carpentier, B., Chassaing, D., 2004. Interactions in biofilms between *Listeria monocytogenes* and resident microorganisms from food industry premises. Int. J. Food Microbiol. 97, 111–122. <https://doi.org/10.1016/j.ijfoodmicro.2004.03.031>
- Cava, R., Nowak, E., Taboada, Marin-iniesta, 2007. Antimicrobial Activity of Cloves and Cinnamon Extracts against Food. J. Food. Prot. 70, 2757–2763.
- Cavalcanti, A.A.C., Limeira, C.H., Siqueira, I.N. de, Lima, A.C. de, Medeiros, F.J.P. de, Souza, J.G. de, Medeiros, N.G. de A., Oliveira Filho, A.A. de, Melo, M.A. de, 2022. The prevalence of *Listeria monocytogenes* in meat products in Brazil: A systematic literature review and meta-analysis. Res. Vet. Sci. 145, 169–176. <https://doi.org/10.1016/j.rvsc.2022.02.015>
- Charpentier, E., Courvalin, P., 1999. Antibiotic Resistance in *Listeria* spp. Antimicrob. Agents Chemother. 43, 2103–2108.
- Chavant, P., Martinie, B., Meylheuc, T., Bellon-Fontaine, M.N., Hebraud, M., 2002. *Listeria monocytogenes* LO28: surface physicochemical properties and ability to form biofilms at different temperatures and growth phases. Appl. Environ. Microbiol. 68, 728–37. doi: 10.1128/AEM.68.2.728-737.2002. PMID: 11823213; PMCID: PMC126664.
- Chmielewski, R. A. N., Frank, J. F., 2003. Biofilm formation and control in food processing facilities. Compr. Rev. Food Sci. Food Saf. 2, 22–32.
- Chouhan, S., Sharma, K., Guleria, S., 2017. Antimicrobial Activity of Some Essential Oils—Present Status and Future Perspectives. Medicines. 4, 58. <https://doi.org/10.3390/medicines4030058>
- Clokier, M.R.J., Millard, A.D., Letarov, A. V., Heaphy, S., 2011. Phages in nature. Bacteriophage. 1, 31–45.

- CLSI, 2021. Performance Standards for Antimicrobial Susceptibility Testing, 31st edition. Clinical and Laboratory Standards Institute, Wayne, PA. Approved Guideline (M100).
- Colagiorgi, A., Bruini, I., Di Ciccio, P.A., Zanardi, E., Ghidini, S., Ianieri, A., 2017. *Listeria monocytogenes* Biofilms in the wonderland of food industry. Pathogens. 6, 41. <https://doi.org/10.3390/pathogens6030041>
- Combrouse, T., Sadovskaya, I., Faille, C., Kol, O., Guérardel, Y., Midelet-Bourdin, G., 2013. Quantification of the extracellular matrix of the *Listeria monocytogenes* biofilms of different phylogenic lineages with optimization of culture conditions. J. Appl. Microbiol. 114. 1120–1131. doi: 10.1111/jam.12127. PMID: 23317349.
- Corrêa, J.A.F., Santos, J.V.G. dos, Evangelista, A.G., Pinto, A.C.S.M., Macedo, R.E.F. de, Luciano, F.B., 2021. Combined application of phenolic acids and essential oil components against *Salmonella* Enteritidis and *Listeria monocytogenes* in vitro and in ready-to-eat cooked ham. LWT. 149, 111881. <https://doi.org/10.1016/j.lwt.2021.111881>
- Costa, M.J., Pastrana, L.M., Teixeira, J.A., Sillankorva, S.M., Cerqueira, M.A., 2023. Bacteriophage Delivery Systems for Food Applications: Opportunities and Perspectives. Viruses. 15, 1271. <https://doi.org/10.3390/v15061271>
- Cufaoglu, G., Ayaz, N.D., 2019. *Listeria monocytogenes* risk associated with chicken at slaughter and biocontrol with three new bacteriophages. J. Food Saf. e12621. <https://doi.org/10.1111/jfs.12621>
- Cui, H.Y., Zhou, H., Lin, L., Zhao, C.T., Zhang, X.J., Xiao, Z.H., Li, C.Z., 2016. Antibacterial activity and mechanism of cinnamon essential oils and its application in milk. J. Anim. Plant. Sci. 26, 532–541.
- De Almeida, C. de F.C.B.R., Ramos, M.A., de Amorim, E.L.C., de Albuquerque, U.P., 2010. A comparison of knowledge about medicinal plants for three rural

- communities in the semi-arid region of northeast of Brazil. *J. Ethnopharmacol.* 127, 674–684. <https://doi.org/10.1016/j.jep.2009.12.005>
- de Melo, A.G., Levesque, S., Moineau, S., 2018. Phages as friends and enemies in food processing. *Curr. Opin. Biotechnol.* 49, 185–190. <https://doi.org/10.1016/j.copbio.2017.09.004>
- Deniz Ayaz, N., Cufaoglu, G., 2016. *Listeria monocytogenes* as a Foodborne Pathogen: Biocontrol in Foods using Lytic Bacteriophages. *J. Clin. Microbiol. Biochem. Technol.* 2, 035–039.
- Desai, A.N., Anyoha, A., Madoff, L.C., Lassmann, B., 2019. Changing epidemiology of *Listeria monocytogenes* outbreaks, sporadic cases, and recalls globally: A review of ProMED reports from 1996 to 2018. *Int. J. Infect. Dis.* 84, 48–53. <https://doi.org/10.1016/j.ijid.2019.04.021>
- Dhifi, W., Bellili, S., Jazi, S., Bahloul, N., Mnif, W., 2016. Essential Oils' Chemical Characterization and Investigation of Some Biological Activities: A Critical Review. *Medicines* 3, 25. <https://doi.org/10.3390/medicines3040025>
- Dietert, R.R., Dietert, J.M., 2015. The microbiome and sustainable healthcare. *Healthcare.* 3, 100–129. <https://doi.org/10.3390/healthcare3010100>
- Diriba, K., Awulachew, E., Diribsa, K., 2021. The prevalence of *Listeria* species in different food items of animal and plant origin in Ethiopia: a systematic review and meta-analysis. *Eur. J. Med. Res.* 26, 60. <https://doi.org/10.1186/s40001-021-00532-8>
- Djordjevic, D., Wiedmann, M., McLandsborough, L.A., 2002. Microtiter Plate Assay for Assessment of *Listeria monocytogenes* Biofilm Formation. *Appl. Environ. Microbiol.* 68, 2950–2958. doi: 10.1128/AEM.68.6.2950-2958.2002. PMID: 12039754; PMCID: PMC123944.
- Domingo-Calap, P., Delgado-Martínez, J., 2018. Bacteriophages: Protagonists of a post-antibiotic era. *Antibiotics.* 7, 66. <https://doi.org/10.3390/antibiotics7030066>

- dos Santos, L.R., Alía, A., Martin, I., Gottardo, F.M., Rodrigues, L.B., Borges, K.A., Furian, T.Q., Córdoba, J.J., 2022. Antimicrobial activity of essential oils and natural plant extracts against *Listeria monocytogenes* in a dry-cured ham-based model. *J. Sci. Food Agric.* 102, 1729–1735. <https://doi.org/10.1002/jsfa.11475>
- Doyle, M.P., Loneragan, G.H., Scott, H.M., Singer, R.S., 2013. Antimicrobial resistance: Challenges and perspectives. *Compr. Rev. Food Sci. Food Saf.* 12, 234–248. <https://doi.org/10.1111/1541-4337.12008>
- Duc, H.M., Son, H.M., Honjoh, K. ichi, Miyamoto, T., 2018. Isolation and application of bacteriophages to reduce *Salmonella* contamination in raw chicken meat. *LWT.* 91, 353–360. <https://doi.org/10.1016/j.lwt.2018.01.072>
- Duc, H.M., Son, H.M., Ngan, P.H., Sato, J., Masuda, Y., Honjoh, K. ichi, Miyamoto, T., 2020. Isolation and application of bacteriophages alone or in combination with nisin against planktonic and biofilm cells of *Staphylococcus aureus*. *Appl. Microbiol. Biotechnol.* 104, 5145–5158. <https://doi.org/10.1007/s00253-020-10581-4>
- Duze, S.T., Marimani, M., Patel, M., 2021. Tolerance of *Listeria monocytogenes* to biocides used in food processing environments. *Food Microbiol.* 97, 103758. <https://doi.org/10.1016/j.fm.2021.103758>
- Elafify, M., Elabbasy, M.T., Mohamed, R.S., Mohamed, E.A., Saad Eldin, W.F., Darwish, W.S., Eldrehmy, E.H., Shata, R.R., 2022. Prevalence of Multidrug-Resistant *Listeria monocytogenes* in Dairy Products with Reduction Trials Using Rosmarinic Acid, Ascorbic Acid, Clove, and Thyme Essential Oils. *J. Food Qual.* 1–12. <https://doi.org/10.1155/2022/9696927>
- Elsayed, M.M., Elkenany, R.M., Zakari, A.I., Badawy, B.M., 2023. Isolation and characterization of bacteriophages for combating multidrug-resistant *Listeria monocytogenes* from dairy cattle farms in conjugation with silver nanoparticles. *BMC Microbiol.* 23, 146. <https://doi.org/10.1186/s12866-023-02893-y>

- Elsebai, M.F., Albalawi, M.A., 2022. Essential Oils and COVID-19. *Molecules*. 27, 7893. <https://doi.org/10.3390/molecules27227893>
- Endersen, L., O'Mahony, J., Hill, C., Ross, R.P., McAuliffe, O., Coffey, A., 2014. Phage therapy in the food industry. *Annu. Rev. Food Sci. Technol.* 5, 327–349. <https://doi.org/10.1146/annurev-food-030713-092415>
- Fatemi, H., Aminifard, M.H., Mohammadi, S., 2013. Efficacy of plant essential oils on post-harvest control of rot caused by *Botrytis cinerea* on kiwi fruits. *Arch. Phytopathol. Plant Prot.* 46: 536–547.
- Finn, L., Onyeaka, H., O'Neill, S., 2023. *Listeria monocytogenes* Biofilms in Food-Associated Environments: A Persistent Enigma. *Foods*. 12, 3339. <https://doi.org/10.3390/foods12183339>
- Folsom, J.P., Siragusa, G.R., Frank, J.F., 2006. Formation of biofilm at different nutrient by various genotypes of *Listeria monocytogenes*. *J. Food Prot.* 69, 826–834. <https://doi.org/10.4315/0362-028X-69.4.826>
- Friedman, M., Henika, P.R., Mandrell, R.E., 2002. Bactericidal activities of plant essential oils and some of their isolated constituents against *Campylobacter jejuni*, *Escherichia coli*, *Listeria monocytogenes*, and *Salmonella enterica*. *J. Food Prot.* 65, 1545-60. doi: 10.4315/0362-028x-65.10.1545. PMID: 12380738.
- Gamachu, S.B., Debalo, M., 2022. Review of bacteriophage and its applications. *Int. J. Vet. Sci. Res.* 8, 133–147. <https://doi.org/10.17352/ijvsr.000126>
- García, P., Martínez B., Obeso, J.M., Rodríguez, A., 2008. Bacteriophages and their application in food safety. *Lett. Appl. Microbiol.* 6, 479–485. <https://doi.org/10.1111/j.1472-765X.2008.02458.x>
- Garvey, M., 2020. Bacteriophages and the one health approach to combat multidrug resistance: is this the way? *Antibiotics*. <https://doi.org/10.3390/antibiotics9070414>

- Gómez, D., Azón, E., Marco, N., Carramiñana, J.J., Rota, C., Ariño, A., Yangüela, J., 2014. Antimicrobial resistance of *Listeria monocytogenes* and *Listeria innocua* from meat products and meat-processing environment. *Food Microbiol.* 42, 61–65. <https://doi.org/10.1016/j.fm.2014.02.017>
- Guenther, S., Loessner, M.J., 2011. Bacteriophage biocontrol of *Listeria monocytogenes* on soft ripened white mold and red-smear cheeses. *Bacteriophage*. 1, 94–100. <https://doi.org/10.4161/bact.1.2.15662>
- Gutiérrez, D., Rodríguez-Rubio, L., Fernández, L., Martínez, B., Rodríguez, A., García, P., 2017. Applicability of commercial phage-based products against *Listeria monocytogenes* for improvement of food safety in Spanish dry-cured ham and food contact surfaces. *Food Control.* 73, 1474–1482. <https://doi.org/10.1016/j.foodcont.2016.11.007>
- Guttman, B., Raya, R., Kutter, E., 2005. Basic Phage Biology. In: Kutter E, Sulakvelidze A, editors. *Bacteriophages*: CRC Press. 29-66.
- Gyles, C.L., 2008. Antimicrobial resistance in selected bacteria from poultry. *Anim. Health Res. Rev.* 9, 149–158. <https://doi.org/10.1017/S1466252308001552>
- Haddi, K., Faroni, L., Oliveira, E.E., 2017. Cinnamon oil, in *Green Pesticides Handbook: Essential Oils for Pest Control*. CRC Press. p.117-150.
- Hagens, S., Loessner, M.J., 2010. Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. *Curr. Pharm. Biotechnol.* 11. 58-68. doi: 10.2174/138920110790725429. PMID: 20214608.
- Han, X., Chen, Q., Zhang, X., Peng, J., Zhang, M., Zhong, Q., 2022. The elimination effects of lavender essential oil on *Listeria monocytogenes* biofilms developed at different temperatures and the induction of VBNC state. *Lett. Appl. Microbiol.* 74, 1016–1026. <https://doi.org/10.1111/lam.13681>
- Henriques, A.R., Fraqueza, M.J., 2017. Biofilm-forming ability and biocide susceptibility of *Listeria monocytogenes* strains isolated from the ready-to-eat

- meat-based food products food chain. LWT. 81, 180–187.  
<https://doi.org/10.1016/j.lwt.2017.03.045>
- Herman, R.A., Ayepa, E., Shittu, S., Fometu, S.S., Wang, J., 2019. Essential Oils and their applications-A mini review. Adv. Nutr. Food Sci. 4, 1–13.
- Honjoh, K., Fujihara, K., Haraguchi, T., Ono, Y., Kobayashi, H., Hiwaki, H., Kamikado, H., Jang, S.S., Ryu, S., Miyamoto, T., 2008. Subtyping of *Listeria monocytogenes* Based on Nucleotide Polymorphism in the *clpC*, *inlA*, *hlyA*, and *plcA* Genes and Rapid Identification of *L. monocytogenes* Genetically Similar to Clinical Isolates. Food Sci. Technol. Res. 14, 557–564. <https://doi.org/10.3136/fstr.14.557>
- Hossain, F., Follett, P., Dang Vu, K., Harich, M., Salmieri, S., Lacroix, M., 2016. Evidence for synergistic activity of plant-derived essential oils against fungal pathogens of food. Food Microbiol. 53, 24–30.  
<https://doi.org/10.1016/j.fm.2015.08.006>
- Hossain, M.I., Rahaman Mizan, M.F., Toushik, S.H., Roy, P.K., Jahid, I.K., Park, S.H., Ha, S. Do, 2022. Antibiofilm effect of nisin alone and combined with food-grade oil components (thymol and eugenol) against *Listeria monocytogenes* cocktail culture on food and food-contact surfaces. Food Control. 135, 108796.  
<https://doi.org/10.1016/j.foodcont.2021.108796>
- Hu, Y., Zhang, J., Kong, W., Zhao, G., Yang, M., 2017. Mechanisms of antifungal and anti-aflatoxigenic properties of essential oil derived from turmeric (*Curcuma longa* L.) on *Aspergillus flavus*. Food Chem. 220, 1–8.  
<https://doi.org/10.1016/j.foodchem.2016.09.179>
- Hyldgaard, M., Mygind, T., Meyer, R.L., 2012. Essential oils in food preservation: Mode of action, synergies, and interactions with food matrix components. Front Microbiol. 3. <https://doi.org/10.3389/fmicb.2012.00012>
- Hyman, P., 2019. Phages for phage therapy: Isolation, characterization, and host range breadth. Pharmaceuticals. <https://doi.org/10.3390/ph12010035>

- Inal, J.M., 2003. Phage therapy: a reappraisal of bacteriophages as antibiotics. *Arch Immunol Ther Exp (Warsz)*. 51, 237–244. PMID: 12956433.
- Iwu, C.D., Okoh, A.I., 2020. Characterization of antibiogram fingerprints in *Listeria monocytogenes* recovered from irrigation water and agricultural soil samples. *PLoS One*. 15. <https://doi.org/10.1371/journal.pone.0228956>
- Jamali, H., Thong, K.L., 2014. Genotypic characterization and antimicrobial resistance of *Listeria monocytogenes* from ready-to-eat foods. *Food Control*. 44, 1–6. <https://doi.org/10.1016/j.foodcont.2014.03.038>
- Joensen, K.G., Scheutz, F., Lund, O., Hasman, H., Kaas, R.S., Nielsen, E.M., Aarestrup, F.M., 2014. Real-time whole-genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic *Escherichia coli*. *J. Clin. Microbiol*. 52, 1501–1510. <https://doi.org/10.1128/JCM.03617-13>.
- Ju, J., Xu, X., Xie, Y., Guo, Y., Cheng, Y., Qian, H., Yao, W., 2018. Inhibitory effects of cinnamon and clove essential oils on mold growth on baked foods. *Food Chem*. 240, 850–855. <https://doi.org/10.1016/j.foodchem.2017.07.120>
- Kalembe, D., Kunicka, A., 2003. Antibacterial and antifungal properties of essential oils. *Curr. Med. Chem*. 10, 813–829.
- Kaptchouang Tchatchouang, C.D., Fri, J., Montso, P.K., Amagliani, G., Schiavano, G.F., Manganyi, M.C., Baldelli, G., Brandi, G., Ateba, C.N., 2022. Evidence of Virulent Multi-Drug Resistant and Biofilm-Forming *Listeria* Species Isolated from Various Sources in South Africa. *Pathogens*. 11, 843. <https://doi.org/10.3390/pathogens11080843>
- Karadal, F., Yildirim, Y., 2014. Antimicrobial susceptibility and serotype distribution of *Listeria monocytogenes* isolates obtained from raw milk cheese samples sold in Nigde. *Ankara Üniversitesi Veteriner Fakültesi Dergisi*. 61, 255–260. [https://doi.org/10.1501/Vetfak\\_00000002639](https://doi.org/10.1501/Vetfak_00000002639)

- Kawacka, I., Olejnik-Schmidt, A., Schmidt, M., Sip, A., 2020. Effectiveness of phage based inhibition of *Listeria monocytogenes* in food products and food processing environments. *Microorganisms*. <https://doi.org/10.3390/microorganisms8111764>.
- Kayode, A.J., Okoh, A.I., 2022. Assessment of multidrug-resistant *Listeria monocytogenes* in milk and milk product and One Health perspective. *PLoS One*. 17, 993. <https://doi.org/10.1371/journal.pone.0270993>
- Kemnic, T.R., Coleman, M., 2019, Trimethoprim Sulfamethoxazole. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan- Available from: <https://www.ncbi.nlm.nih.gov/books/NBK513232/>
- Khaleque, M.A., Keya, C.A., Hasan, K.N., Hoque, M.M., Inatsu, Y., Bari, M.L., 2016. Use of cloves and cinnamon essential oil to inactivate *Listeria monocytogenes* in ground beef at freezing and refrigeration temperatures. *LWT*. 74, 219–223. <https://doi.org/10.1016/j.lwt.2016.07.042>
- Khorshidian, N., Yousefi, M., Khanniri, E., Mortazavian, A.M., 2018. Potential application of essential oils as antimicrobial preservatives in cheese. *Innov. Food Sci. Emerg.* 45, 62–72. *Technol.* <https://doi.org/10.1016/j.ifset.2017.09.020>
- Kim, S.-Y., Kang, D.-H., Kim, J.-K., Ha, Y.-G., Hwang, J. Y., Kim, T., et al., 2011. Antimicrobial activity of plant extracts against *Salmonella* Typhimurium, *Escherichia coli* O157:H7, and *Listeria monocytogenes* on fresh lettuce. *J. Food Sci.* 76, M41–46. doi: 10.1111/j.1750-3841.2010.01926.x. PMID: 21535692.
- Kiran, S., Kujur, A., Prakash, B., 2016. Assessment of preservative potential of *Cinnamomum zeylanicum* Blume essential oil against food borne molds, aflatoxin B1 synthesis, its functional properties and mode of action. *Innov. Food Sci. Emerg. Technol.* 37, 184–191. <https://doi.org/10.1016/j.ifset.2016.08.018>
- Lee, B.H., Cole, S., Badel-Berchoux, S., Guillier, L., Felix, B., Krezdorn, N., Hébraud, M., Bernardi, T., Sultan, I., Piveteau, P., 2019. Biofilm Formation of *Listeria*

- monocytogenes* Strains Under Food Processing Environments and Pan-Genome-Wide Association Study. *Front Microbiol.* 10, 2698. <https://doi.org/10.3389/fmicb.2019.02698>
- Lefkowitz, E.J., Dempsey, D.M., Hendrickson, R.C., Orton, R.J., Siddell, S.G., Smith, D.B., 2018. Virus taxonomy: The database of the International Committee on Taxonomy of Viruses (ICTV). *Nucleic Acids Res.* 46, D708–D717. <https://doi.org/10.1093/nar/gkx932>
- Leverentz, B., Conway, W.S., Camp, M.J., Janisiewicz, W.J., Abuladze, T., Yang, M., Saftner, R., Sulakvelidze, A., 2003. Biocontrol of *Listeria monocytogenes* on fresh-cut produce by treatment with lytic bacteriophages and a bacteriocin. *Appl. Environ. Microbiol.* 69, 4519–4526. <https://doi.org/10.1128/AEM.69.8.4519-4526.2003>
- Lewis, R., Bolocan, A.S., Draper, L.A., Paul Ross, R., Hill, C., 2019. The effect of a commercially available bacteriophage and bacteriocin on *listeria monocytogenes* in coleslaw. *Viruses.* 11, 977. <https://doi.org/10.3390/v11110977>
- Li, Y., Gan, Z., Zhou, X., Chen, Z., 2022. Accurate classification of *Listeria* species by MALDI-TOF mass spectrometry incorporating denoising autoencoder and machine learning. *J. Microbiol. Methods.* 192, 106378. doi: 10.1016/j.mimet.2021.106378. Epub 2021 Nov 21. PMID: 34818574.
- Lima, R., Del Fiol, F.S., Balcão, V.M., 2019. Prospects for the use of new technologies to combat multidrug-resistant bacteria. *Front. Pharmacol.* 10, 692. <https://doi.org/10.3389/fphar.2019.00692>
- Liu, D., 2008. Handbook of *Listeria Monocytogenes* (1st ed.). CRC Press. <https://doi.org/10.1201/9781420051414>
- Liu, M., Guo, W., Feng, M., Bai, Y., Huang, J., Cao, Y., 2024. Antibacterial, anti-biofilm activity and underlying mechanism of garlic essential oil in water

- nanoemulsion against *Listeria monocytogenes*. LWT. 196. <https://doi.org/10.1016/j.lwt.2024.115847>
- Liu, P., Mizue, H., Fujihara, K., Kobayashi, H., Kamikado, H., Tanaka, T., Honjoh, K.-I., Miyamoto, T., 2012. A New Rapid Real-Time PCR Method for Detection of *Listeria monocytogenes* Targeting the *hlyA* Gene. Food Sci. Technol. Res. 18, 47–57.
- Liu, Y., Dong, P., Zhu, L., Zhang, Y., Luo, X., 2020a. Effect of four kinds of natural antimicrobial compounds on the biofilm formation ability of *Listeria monocytogenes* isolated from beef processing plants in China. LWT. 133, 110020. <https://doi.org/10.1016/j.lwt.2020.110020>
- Liu, Y., Sun, W., Sun, T., Gorris, L.G.M., Wang, X., Liu, B., Dong, Q., 2020b. The prevalence of *Listeria monocytogenes* in meat products in China: A systematic literature review and novel meta-analysis approach. Int. J. Food Microbiol. 312, 108358. <https://doi.org/10.1016/j.ijfoodmicro.2019.108358>
- Loc-Carrillo, C., Abedon, S.T., 2011. Pros and cons of phage therapy. Bacteriophage. 1, 111–114. <https://doi.org/10.4161/bact.1.2.14590>
- Lopes, A., Pereira, C., Almeida, A., 2018. Sequential combined effect of phages and antibiotics on the inactivation of *Escherichia coli*. Microorganisms. 6, 125. <https://doi.org/10.3390/microorganisms6040125>
- Maćkiw, E., Modzelewska, M., Maka, Ł., Ścieżyńska, H., Pawłowska, K., Postupolski, J., Korsak, D., 2016. Antimicrobial resistance profiles of *Listeria monocytogenes* isolated from ready-to-eat products in Poland in 2007-2011. Food Control. 59, 7–11. <https://doi.org/10.1016/j.foodcont.2015.05.011>
- Maggio, F., Serio, A., Rossi, C., Purgatorio, C., Buccioni, F., Chaves-López, C., Paparella, A., 2023. Effectiveness of essential oils against dual-species biofilm of *Listeria monocytogenes* and *Pseudomonas fluorescens* in a Ricotta-based model system. Ital. J. Food Saf. 12, 11048. <https://doi.org/10.4081/ijfs.2023.11048>

- Mahfuzul Hoque Md, Bari ML, Juneja K Vijay, Kawamoto S, 2008. Antimicrobial Activity of Cloves and Cinnamon Extracts against Food. Rep. Nat'l. Food Res. Inst. 72, 9–21.
- Makino, S.I., Kawamoto, K., Takeshi, K., Okada, Y., Yamasaki, M., Yamamoto, S., Igimi, S., 2005. An outbreak of food-borne listeriosis due to cheese in Japan, during 2001. Int. J. Food Microbiol. 104, 189–196. <https://doi.org/10.1016/j.ijfoodmicro.2005.02.009>
- Mamber, S.W., Mohr, T.B., Leathers, C., Mbandi, E., Bronstein, P.A., Barlow, K., Silverman, M., Aston, C., Izsak, Y., Saini, N.S., Labarre, D., Minocha, U., Smedra, J., Levine, P., Kause, J., 2020. Occurrence of *listeria monocytogenes* in ready-to-eat meat and poultry product verification testing samples from U.S. Department of agriculture-regulated producing establishments, 2005 through 2017. J. Food Prot. 83, 1598–1606 <https://doi.org/10.4315/JFP-20-010>
- Mancianti, F., Ebani, V.V., 2020. Biological activity of essential oils. Molecules. 25, 678. <https://doi.org/10.3390/molecules25030678>
- Marchese, A., Ramona, B., Erika, C., Ilkay, E.O., Maria, D., Seyed, F.N., Morteza, I., Mohammad, A., Seyed, M. N., Marjan, A., 2017. Antimicrobial Activity of Eugenol and Essential Oils Containing Eugenol: A Mechanistic Viewpoint. Crit. Rev. Microbiol. 43, 668–89. doi:10.1080/1040841X.2017.1295225.
- Martínez, B., Obeso, J.M., Rodríguez, A., García, P., 2008. Nisin-bacteriophage crossresistance in *Staphylococcus aureus*. Int. J. Food Microbiol. 122, 253–258. <https://doi.org/10.1016/j.ijfoodmicro.2008.01.011>
- Martins, N., Petropoulos, S., Ferreira, I.C.F.R., 2016. Chemical composition and bioactive compounds of garlic (*Allium sativum* L.) as affected by pre- and post-harvest conditions: A review. Food Chem. 211, 41–50. <https://doi.org/10.1016/j.foodchem.2016.05.029>

- Marzban, A., Beiranvand, M., Sedighi-Khavidak, S., 2022. Isolation and Characterization of Lytic Bacteriophages from Wastewater against *Listeria monocytogenes*. Int. J. Med. Lab. 9, 17–25. <https://doi.org/10.18502/ijml.v9i1.9082>
- Matera, R., Lucchi, E., Valgimigli, L., 2023. Plant Essential Oils as Healthy Functional Ingredients of Nutraceuticals and Diet Supplements: A Review. Molecules. 28, 901. <https://doi.org/10.3390/molecules28020901>
- Matereke, L.T., Okoh, A.I., 2020. *Listeria monocytogenes* virulence, antimicrobial resistance and environmental persistence: A review. Pathogens. 9, 528. <https://doi.org/10.3390/pathogens9070528>
- Maung, A.T., Abdelaziz, M.N.S., Noor Mohammadi, T., Lwin, S.Z.C., El-Telbany, M., Zhao, J., Wang, C., Lin, Y., Shen, C., Zayda, M., Masuda, Y., Honjoh, K.I., Miyamoto, T., 2024. Single and combined application of bacteriophage and cinnamon oils against pathogenic *Listeria monocytogenes* in milk and smoked salmon. Int. J. Food. Microbiol. 421:110797. doi: 10.1016/j.ijfoodmicro.2024.110797.
- Maung, A.T., Mohammadi, T.N., Nakashima, S., Liu, P., Masuda, Y., Honjoh, K. ichi, Miyamoto, T., 2019. Antimicrobial resistance profiles of *Listeria monocytogenes* isolated from chicken meat in Fukuoka, Japan. Int. J. Food Microbiol. 304, 49–57. <https://doi.org/10.1016/j.ijfoodmicro.2019.05.016>
- Maury, M.M., Tsai, Y.H., Charlier, C., Touchon, M., Chenal-Francisque, V., Leclercq, A., Criscuolo, A., Gaultier, C., Roussel, S., Brisabois, A., Disson, O., Rocha, E.P.C., Brisse, S., Lecuit, M., 2016. Uncovering *Listeria monocytogenes* hypervirulence by harnessing its biodiversity. Nat. Genet. 48, 308–313. <https://doi.org/10.1038/ng.3501>
- Meloni, D., 2015. Presence of *Listeria monocytogenes* in Mediterranean-Style Dry Fermented Sausages. Foods. 4, 34–50. <https://doi.org/10.3390/foods4010034>

- Milanov, D., Ašanin, R., Vidić, B., Katić, V., Plavša, N., 2009. Examination of the capabilities of attachment and biofilm formation of different *Listeria monocytogenes* strains. *Biotechnol. Anim. Husb.* 25, 1255–1265.
- Miyamoto, T., Kawagishi, J., Oishi, A., Shimotsu, S., Mishima, T., Kobayashi, H., Honjoh, K.-I., 2011. Inhibition of Adhesion of Several Bacteria onto Microtiter Plate by Selected Food Additives. *Japan J. Food Microbio.* 28, 157–166. doi:10.5803/jsfm.28.157
- Mohamed, Y., Reda, W.W., Abdel-Moein, K., Abd El-Razik, K.A., Barakat, A.M.A., el Fadaly, H.A., Hassanain, N.A., Hegazi, A.G., 2016. Prevalence and phylogenetic characterization of *Listeria monocytogenes* isolated from processed meat marketed in Egypt. *J. Genet. Eng. Biotechnol.* 14, 119–123. <https://doi.org/10.1016/j.jgeb.2016.06.001>
- Monds, R.D., O'Toole, G.A., 2009. The developmental model of microbial biofilms: ten years of a paradigm up for review. *Trends. Microbiol.* 17, 73–87. doi: 10.1016/j.tim.2008.11.001. PMID: 19162483.
- Moon, S.H., Waite-Cusic, J., Huang, E., 2020. Control of *Salmonella* in chicken meat using a combination of a commercial bacteriophage and plant-based essential oils. *Food Control.* 110, 106984. <https://doi.org/10.1016/j.foodcont.2019.106984>
- Moosavi-Nasab, M., Mirzapour-Kouhdasht, A., Oliyaei, N., 2019. Application of essential oils for shelf-life extension of seafood products. *Essential Oils-Oil of Nature.* IntechOpen.
- Mørseth, T., Langsrud, S., 2004. *Listeria monocytogenes*: biofilm formation and persistence in food-processing environments. *Biofilms.* 1, 107–121. doi:10.1017/S1479050504001322
- Mulla, M., Ahmed, J., Al-Attar, H., Castro-Aguirre, E., Arfat, Y.A., Auras, R., 2017. Antimicrobial efficacy of clove essential oil infused into chemically modified

- LLDPE film for chicken meat packaging. *Food Control*. 73, 663–671. <https://doi.org/10.1016/j.foodcont.2016.09.018>
- National Action Plan on Antimicrobial Resistance (AMR) 2016-2020, The Government of Japan, 2016. <https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000138942>. (Accessed 15 April 2016).
- Nazzaro, F., Fratianni, F., Coppola, R., De Feo, V., 2017. Essential oils and antifungal activity. *Pharmaceuticals*. 10, 86. doi: 10.3390/ph10040086. PMID: 29099084; PMCID: PMC5748643.
- Nazzaro, F., Fratianni, F., De Martino, L., Coppola, R., De Feo, V., 2013. Effect of essential oils on pathogenic bacteria. *Pharmaceuticals*. 6, 1451–74. doi: 10.3390/ph6121451. PMID: 24287491; PMCID: PMC3873673.
- Ni, P., Wang, L., Deng, B., Jiu, S., Ma, C., Zhang, C., Almeida, A., Wang, D., Xu, W., Wang, S., 2020. Combined application of bacteriophages and carvacrol in the control of *Pseudomonas syringae* pv. *actinidiae* planktonic and biofilm forms. *Microorganisms*. 8. <https://doi.org/10.3390/microorganisms8060837>
- Noor Mohammadi, T., Shen, C., Li, Y., Zayda, M.G., Sato, J., Masuda, Y., Honjoh, K. ichi, Miyamoto, T., 2022a. Characterization of *Clostridium perfringens* bacteriophages and their application in chicken meat and milk. *Int. J. Food Microbiol.* 361, 109446. <https://doi.org/10.1016/j.ijfoodmicro.2021.109446>
- Noor Mohammadi, T., Shen, C., Li, Y., Zayda, M.G., Sato, J., Masuda, Y., Honjoh, K. ichi, Miyamoto, T., 2022b. Characterization and optimization of bacteriophage cocktails to control *Clostridium perfringens* *in vitro* and in curry roux. *Int. J. Food Microbiol.* 380, 109886. <https://doi.org/10.1016/j.ijfoodmicro.2022.109886>
- Noori, S., Zeynali, F., Almasi, H., 2018. Antimicrobial and antioxidant efficiency of nanoemulsion-based edible coating containing ginger (*Zingiber officinale*) essential oil and its effect on safety and quality attributes of chicken breast fillets. *Food Control*. 84, 312–320. <https://doi.org/10.1016/j.foodcont.2017.08.015>

- Noritake, R., Hodin, M., 2022. Japan must face up to growing danger of drug-resistant germs, Available at: <https://asia.nikkei.com/Opinion/Japan-must-face-up-to-growing-danger-of-drug-resistant-germs>. (Accessed 12 February 2023).
- Ochiai, Y., Yamada, F., Batmunkh, O., Mochizuki, M., Takano, T., Hondo, R., Ueda, F., 2010. Prevalence of *Listeria monocytogenes* in retailed meat in the Tokyo metropolitan area. J. Food Prot. 73, 1688–93. <https://doi.org/10.4315/0362-028X-73.9.1688>
- Panera-Martínez, S., Rodríguez-Melcón, C., Serrano-Galán, V., Alonso-Calleja, C., Capita, R., 2022. Prevalence, quantification and antibiotic resistance of *Listeria monocytogenes* in poultry preparations. Food Control. 135, 108608. <https://doi.org/10.1016/j.foodcont.2021.108608>
- Paudel, S.K., Bhargava, K., Kotturi, H., 2019. Antimicrobial activity of cinnamon oil nanoemulsion against *Listeria monocytogenes* and *Salmonella* spp. on melons. LWT 111, 682–687. <https://doi.org/10.1016/j.lwt.2019.05.087>
- Perera, M.N., Abuladze, T., Li, M., Woolston, J., Sulakvelidze, A., 2015. Bacteriophage cocktail significantly reduces or eliminates *Listeria monocytogenes* contamination on lettuce, apples, cheese, smoked salmon and frozen foods. Food Microbiol. 52, 42–48. <https://doi.org/10.1016/j.fm.2015.06.006>
- Phillips, I., Casewell, M., Cox, T., De Groot, B., Friis, C., Jones, R., Nightingale, C., Preston, R., Waddell, J., 2004. Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data. J. Antimicrob. Chemother. 53, 28–52. <https://doi.org/10.1093/jac/dkg483>
- Pichersky, E., Noel, J.P., Dudareva, N., 2006. Biosynthesis of Plant Volatiles: Nature's Diversity and Ingenuity. Science. 311, 808-11. doi: 10.1126/science.1118510. PMID: 16469917; PMCID: PMC2861909.

- Pinheiro, L.A.M., Pereira, C., Frazão, C., Balcão, V.M., Almeida, A., 2019. Efficiency of phage  $\phi 6$  for biocontrol of *pseudomonas syringae* pv. *Syringae*: An *in vitro* preliminary study. *Microorganisms*. 7, 286. <https://doi.org/10.3390/microorganisms7090286>
- Poros-Gluchowska, J., Markiewicz, Z., 2003. Antimicrobial resistance of *Listeria monocytogenes*. *Acta. Microbiol. Pol.* 2, 113–29.
- Poyart-Salmeron, C., Carlier, C., Trieu-Cuot, P., Courtieu, a L., Courvalin, P., 1990. Transferable plasmid-mediated antibiotic resistance in *Listeria monocytogenes*. *Lancet*. 335, 1422–1426. [https://doi.org/10.1016/0140-6736\(90\)91447-I](https://doi.org/10.1016/0140-6736(90)91447-I)
- Prieto, M., Martínez, C., Aguerre, L., Rocca, M.F., Cipolla, L., Callejo, R., 2016. Antibiotic susceptibility of *Listeria monocytogenes* in Argentina. *Enferm. Infecc. Microbiol. Clin.* 34, 91–95. <https://doi.org/10.1016/j.eimc.2015.03.007>
- Pushkareva, V.I., Ermolaeva, S.A., 2010. *Listeria monocytogenes* virulence factor Listeriolysin O favors bacterial growth in co-culture with the ciliate *Tetrahymena pyriformis*, causes protozoan encystment and promotes bacterial survival inside cysts. *BMC Microbiol.* 10, 26. doi: 10.1186/1471-2180-10-26. PMID: 20109168; PMCID: PMC2827469.
- Quereda, J.J., Leclercq, A., Moura, A., Vales, G., Gómez-Martín, Á., García-Muñoz, Á., Thouvenot, P., Tessaud-Rita, N., Bracq-Dieye, H., Lecuit, M., 2020. *Listeria valentina* sp. Nov., isolated from a water trough and the faeces of healthy sheep. *Int. J. Syst. Evol. Microbiol.* 70, 5868–5879. <https://doi.org/10.1099/ijsem.0.004494>
- Quereda, J.J., Morón-García, A., Palacios-Gorba, C., Dessaux, C., García-del Portillo, F., Pucciarelli, M.G., Ortega, A.D., 2021. Pathogenicity and virulence of *Listeria monocytogenes*: A trip from environmental to medical microbiology. *Virulence*. 12, 2509–2545. <https://doi.org/10.1080/21505594.2021.1975526>
- Raeisi, M., Tabaraei, A., Hashemi, M., Behnampour, N., 2016. Effect of sodium alginate coating incorporated with nisin, *Cinnamomum zeylanicum*, and rosemary

- essential oils on microbial quality of chicken meat and fate of *Listeria monocytogenes* during refrigeration. *Int. J. Food Microbiol.* 238, 139–145. <https://doi.org/10.1016/j.ijfoodmicro.2016.08.042>
- Rodríguez-Campos, D., Rodríguez-Melcón, C., Alonso-Calleja, C., Capita, R., 2019. Persistent *listeria monocytogenes* isolates from a poultry-processing facility form more biofilm but do not have a greater resistance to disinfectants than sporadic strains. *Pathogens.* 8, 250. <https://doi.org/10.3390/pathogens8040250>
- Rodríguez-Rubio, L., García, P., Rodríguez, A., Billington, C., Hudson, J.A., Martínez, B., 2015. Listeriaphages and coagulin C23 act synergistically to kill *Listeria monocytogenes* in milk under refrigeration conditions. *Int. J. Food Microbiol.* 205, 68–72. <https://doi.org/10.1016/j.ijfoodmicro.2015.04.007>
- Rogiers, G., Kebede, B.T., Van Loey, A., Michiels, C.W., 2017. Membrane fatty acid composition as a determinant of *Listeria monocytogenes* sensitivity to trans-cinnamaldehyde. *Res. Microbiol.* 168, 536–546. <https://doi.org/10.1016/j.resmic.2017.03.001>
- Sampedro, F., Pérez-Rodríguez, F., Servadio, J.L., Gummalla, S., Hedberg, C.W., 2022. Quantitative risk assessment model to investigate the public health impact of varying *Listeria monocytogenes* allowable levels in different food commodities: A retrospective analysis. *Int. J. Food Microbiol.* 383, 109932. <https://doi.org/10.1016/j.ijfoodmicro.2022.109932>
- Santativongchai, P., Tulayakul, P., Jeon, B., 2023. Enhancement of the Antibiofilm Activity of Nisin against *Listeria monocytogenes* Using Food Plant Extracts. *Pathogens.* 12, 444. <https://doi.org/10.3390/pathogens12030444>
- Scattolini, S., D’angelantonio, D., Boni, A., Mangone, I., Marcacci, M., Battistelli, N., D’agostino, K., Pomilio, F., Camma, C., Migliorati, G., Aprea, G., 2021. Characterization and in vitro efficacy against *listeria monocytogenes* of a newly

- isolated bacteriophage,  $\phi$ izsam-1. *Microorganisms* 9, 731.  
<https://doi.org/10.3390/microorganisms9040731>
- Scharff, R.L., 2012. Economic burden from health losses due to foodborne illness in the United States. *J. Food Prot.* 75, 123-31. doi: 10.4315/0362-028X.JFP-11-058. PMID: 22221364.
- Seemann, T., 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics*. 30, 2068–2069. <https://doi.org/10.1093/bioinformatics/btu153>.
- Shahbazi, Y., Karami, N., Shavisi, N., 2018. Effect of *Ziziphora clinopodioides* essential oil on shelf life and fate of *Listeria monocytogenes* and *Staphylococcus aureus* in refrigerated chicken meatballs. *J. Food Saf.* 38, 12394. <https://doi.org/10.1111/jfs.12394>
- Sharifi-Rad, J., Salehi, B., Schnitzler, P., Ayatollahi, S.A., Kobarfard, F., Fathi, M., Eisazadeh, M., Sharifi-Rad, M., 2017. Susceptibility of herpes simplex virus type 1 to monoterpenes thymol, carvacrol, p-cymene and essential oils of *Sinapis arvensis* L., *Lallemantia royleana* Benth. and *Pulicaria vulgaris* Gaertn. *Cell. Mol. Biol.* 63, 42–47. doi: 10.14715/cmb/2017.63.8.10. PMID: 28886313.
- Sheng, L., Zhu, M.J., 2014. Inhibitory effect of Cinnamomum cassia oil on non-O157 Shiga toxin-producing *Escherichia coli*. *Food Control.* 46, 374–381. <https://doi.org/10.1016/j.foodcont.2014.05.050>
- Shimajima, Y., Ida, M., Nakama, A., Nishino, Y., Fukui, R., Kurodo, S., Hirai, A., Kai, A., Sadamasu, K., 2016. Prevalence and contamination levels of *Listeria monocytogenes* in ready-to-eat foods in Tokyo, Japan. *J. Vet. Med. Sci.* 78, 1183–1187. <https://doi.org/10.1292/jvms.15-0708>
- Simionato, I., Domingues, F.C., Nerín, C., Silva, F., 2019. Encapsulation of cinnamon oil in cyclodextrin nanosponges and their potential use for antimicrobial food packaging. *Food Chem. Toxicol.* 132. <https://doi.org/10.1016/j.fct.2019.110647>

- Singh, S., Nath, G., Maheshwari, A., 2024. Bacteriophages. *Newborn*. 2, 297–309. <https://doi.org/10.5005/jp-journals-11002-0078>
- Skowron, K., Wałęcka-Zacharska, E., Wiktorczyk-Kapischke, N., Skowron, K.J., Grudlewska-Buda, K., Bauza-Kaszewska, J., Bernaciak, Z., Borkowski, M., Gospodarek-Komkowska, E., 2020. Assessment of the prevalence and drug susceptibility of *listeria monocytogenes* strains isolated from various types of meat. *Foods*. 9, 293. <https://doi.org/10.3390/foods9091293>
- Smoot, L.M., Pierson, M.D., 1998a. Effect of environmental stress on the ability of *Listeria monocytogenes* Scott A to attach to food contact surfaces. *J. Food Prot.* 61. 1293–1298. doi: 10.4315/0362-028x-61.10.1293. PMID: 9798144.
- Smoot, L.M., Pierson, M.D., 1998b. Influence of environmental stress on the kinetics and strength of attachment of *Listeria monocytogenes* Scott A to Buna-N rubber and stainless steel. *J. Food Prot.* 61. 1286–1292. doi: 10.4315/0362-028x-61.10.1286. PMID: 9798143.
- Somrani, M., Inglés, M.C., Debbabi, H., Abidi, F., Palop, A., 2020. Garlic, onion, and cinnamon essential oil anti-biofilms' effect against *listeria monocytogenes*. *Foods*. 9, 567. <https://doi.org/10.3390/foods9050567>
- Soni, D.K., Singh, M., Singh, D.V., Dubey, S.K., 2014. Virulence and genotypic characterization of *Listeria monocytogenes* isolated from vegetable and soil samples. *BMC Microbiol.* 14, 241. <https://doi.org/10.1186/s12866-014-0241-3>
- Soni, K.A., Nannapaneni, R., 2010. Removal of *Listeria monocytogenes* Biofilms with Bacteriophage P100. *J. Food Prot.* 73, 1519–1524. doi: 10.4315/0362-028x-73.8.1519. PMID: 20819365.
- Stepanović, S., Vukovic, D., Dakic, I., Savic, B., Svabic-Vlahovic, M., 2000. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. *J. Microbiol. Methods*. 40. 175–179. [https://doi.org/10.1016/S0167-7012\(00\)00122-6](https://doi.org/10.1016/S0167-7012(00)00122-6).

- Stephenson, F.H., 2016. Working with bacteriophage. Calculations for molecular biology and biotechnology, San Diego, USA: Academic Press. p. 81–96.
- Stone, E., Lhomet, A., Neve, H., Grant, I.R., Campbell, K., McAuliffe, O., 2020. Isolation and Characterization of *Listeria monocytogenes* Phage vB\_LmoH\_P61, a Phage with Biocontrol Potential on Different Food Matrices. *Front. Sustain. Food Syst.* 4. 521645. <https://doi.org/10.3389/fsufs.2020.521645>
- Sulakvelidze, A., 2011. Safety by nature: potential bacteriophage applications. *Microbe.* 6:122–126.
- Sulakvelidze, A., Alavidze, Z., Morris, J., 2001. Bacteriophage therapy. *Antimicrob Agents Chemother.* 45, 649–659. <https://doi.org/10.1128/AAC.45.3.649-659.2001>
- Sulakvelidze, A., Barrow, P., 2005a. Phage therapy in animals and agribusiness. In *Bacteriophages: Biology and applications*. Kutter, E. and Sulakvelidze, A. (Eds). 335–380.
- Sulakvelidze, A., Kutter, E., 2005b. Bacteriophage therapy in humans. In *Bacteriophages: Biology and Application*. Kutter, E. and Sulakvelidze, A. (Eds). 381–436.
- Tahric, A., Kolic, H., Lavic, A., Latinovic, D., Pramenkovic, E., 2023. Antibacterial Activity of Oregano Essential Oil and its Effect on Biofilm Formation. *J. Pure Appl. Microbiol.* 17, 1205–1213. <https://doi.org/10.22207/JPAM.17.2.49>
- Tajkarimi, M.M., Ibrahim, S.A., Cliver, D.O., 2010. Antimicrobial herb and spice compounds in food. *Food Control.* 21, 1199–1218. <https://doi.org/10.1016/j.foodcont.2010.02.003>
- Takahashi, H., Suda, T., Tanaka, Y., Kimura, B., 2010. Cellular hydrophobicity of *Listeria monocytogenes* involves initial attachment and biofilm formation on the surface of polyvinyl chloride. *Lett. Appl. Microbiol.* 50, 618–25. doi: 10.1111/j.1472-765X.2010.02842.x. PMID: 20438621.

- Talbot, G.H., Jezek, A., Murray, B.E., Jones, R.N., Ebright, R.H., Nau, G.J., Rodvold, K.A., Newland, J.G., Boucher, H.W., 2019. Infectious Diseases Society of America. The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility? Clin. Infect. Dis. 69, 1–11. doi: 10.1093/cid/ciz089. PMID: 30715222.
- Tamura, 2016. National Veterinary Assay Laboratory Ministry of Agriculture, Forestry and Fisheries. A Report on the Japanese Veterinary Antimicrobial Resistance Monitoring System -2008 to 2011.
- Thouvenot, P., Vales, G., Bracq-Dieye, H., Tessaud-Rita, N., Maury, M.M., Moura, A., Lecuit, M., Leclercq, A., 2018. MALDI-TOF mass spectrometry-based identification of *Listeria* species in surveillance: A prospective study. J. Microbiol. Methods. 144, 29–32. doi: 10.1016/j.mimet.2017.10.009. Epub 2017 Oct 21. PMID: 29066314.
- Tomičić, R., Čabarkapa, I., Varga, A., Tomičić, Z., 2018. Antimicrobial activity of essential oils against *Listeria monocytogenes*. Food Feed Res. 45, 37–44. <https://doi.org/10.5937/ffr1801037t>
- Turner, D., Shkoporov, A.N., Lood, C., Millard, A.D., Dutilh, B.E., Alfenas-Zerbini, P., van Zyl, L.J., Aziz, R.K., Oksanen, H.M., Poranen, M.M., Kropinski, A.M., Barylski, J., Brister, J.R., Chanisvili, N., Edwards, R.A., Enault, F., Gillis, A., Knezevic, P., Krupovic, M., Kurtböke, I., Kushkina, A., Lavigne, R., Lehman, S., Lobocka, M., Moraru, C., Moreno Switt, A., Morozova, V., Nakavuma, J., Reyes Muñoz, A., Rūmnieks, J., Sarkar, B., Sullivan, M.B., Uchiyama, J., Wittmann, J., Yigang, T., Adriaenssens, E.M., 2023. Abolishment of morphology-based taxa and change to binomial species names: 2022 taxonomy update of the ICTV bacterial viruses subcommittee. Arch. Virol. 168, 74. <https://doi.org/10.1007/s00705-022-05694-2>

- Valderrama, W.B., Cutter, C.N., 2013. An ecological perspective of *Listeria monocytogenes* biofilms in food processing facilities. *Crit. Rev. Food Sci. Nutr.* 53, 801–17. doi: 10.1080/10408398.2011.561378. PMID: 23768144.
- Van Haute, S., Raes, K., Devlieghere, F., Sampers, I., 2017. Combined use of cinnamon essential oil and MAP/vacuum packaging to increase the microbial and sensorial shelf life of lean pork and salmon. *Food Packag. Shelf Life.* 12, 51–58. <https://doi.org/10.1016/j.fpsl.2017.02.004>
- Walsh, D., Duffy, G., Sheridan, J.J., Blair, I.S., McDowell, D.A., 2001. Antibiotic resistance among *Listeria*, including *Listeria monocytogenes*, in retail foods. *J. Appl. Microbiol.* 90, 517–522. <https://doi.org/10.1046/j.1365-2672.2001.01273.x>
- Wang, W., Zhou, X., Suo, Y., Deng, X., Cheng, M., Shi, C., Shi, X., 2017. Prevalence, serotype diversity, biofilm-forming ability and eradication of *Listeria monocytogenes* isolated from diverse foods in Shanghai, China. *Food Control.* 73, 1068–1073. <https://doi.org/10.1016/j.foodcont.2016.10.025>
- Wang, X.M., Lü, X.F., Yin, L., Liu, H.F., Zhang, W.J., Si, W., Yu, S.Y., Shao, M.L., Liu, S.G., 2013. Occurrence and antimicrobial susceptibility of *Listeria monocytogenes* isolates from retail raw foods. *Food Control.* 32, 153–158. <https://doi.org/10.1016/j.foodcont.2012.11.032>
- Weber-Dabrowska, B., Jończyk-Matysiak, E., Zaczek, M., Łobocka, M., Łusiak-Szelachowska, M., Górski, A., 2016. Bacteriophage procurement for therapeutic purposes. *Front. Microbiol.* 7, 1177. <https://doi.org/10.3389/fmicb.2016.01177>
- WHO, 2022. Food Safety. Available online at: <https://www.who.int/news-room/fact-sheets/detail/food-safety> (Accessed June 29, 2023).
- Wiśniewski, P., Zakrzewski, A.J., Zadernowska, A., Chajęcka-Wierzchowska, W., 2022. Antimicrobial Resistance and Virulence Characterization of *Listeria*

- monocytogenes* Strains Isolated from Food and Food Processing Environments. Pathogens. 11, 1099. <https://doi.org/10.3390/pathogens11101099>
- Wittebole, X., De Roock, S., Opal, S.M., 2014. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 5, 226–235. <https://doi.org/10.4161/viru.25991>
- Wu, S., Wu, Q., Zhang, J., Chen, M., Guo, W., 2016. Analysis of multilocus sequence typing and virulence characterization of *listeria monocytogenes* isolates from chinese retail ready-to-eat food. Front. Microbiol. 7, 168. <https://doi.org/10.3389/fmicb.2016.00168>
- Yildirim, S., Röcker, B., Pettersen, M.K., Nilsen-Nygaard, J., Ayhan, Z., Rutkaite, R., Radusin, T., Suminska, P., Marcos, B., Coma, V., 2018. Active Packaging Applications for Food. Compr Rev Food Sci Food Saf. 17. 165–199. doi: 10.1111/1541-4337.12322. Epub 2017 Nov 28. PMID: 33350066.
- Yousefi, M., Khorshidian, N., Hosseini, H., 2020. Potential Application of Essential Oils for Mitigation of *Listeria monocytogenes* in Meat and Poultry Products. Front. Nutr. 7, 577287. <https://doi.org/10.3389/fnut.2020.577287>
- Zankari, E., Hasman, H., Cosentino, S., Vestergaard, M., Rasmussen, S., Lund, O., Aarestrup, F.M., Larsen, M.V., 2012. Identification of acquired antimicrobial resistance genes. J. Antimicrob. Chemother. 67, 2640–2644. <https://doi.org/10.1093/jac/dks261>.
- Zhang, C., Li, C., Abdel-Samie, M.A., Cui, H., Lin, L., 2020. Unraveling the inhibitory mechanism of clove essential oil against *Listeria monocytogenes* biofilm and applying it to vegetable surfaces. LWT. 134, 110210. <https://doi.org/10.1016/j.lwt.2020.110210>
- Zhang, Y., Liu, X., Wang, Y., Jiang, P., Quek, S.Y., 2016. Antibacterial activity and mechanism of cinnamon essential oil against *Escherichia coli* and *Staphylococcus aureus*. Food Control. 59, 282–289. <https://doi.org/10.1016/j.foodcont.2015.05.032>

- Zhao, J., Lin, Y., Wang, C., Zayda, M., Maung, A.T., Mohammadi, T.N., Duc, H.M., Yu, P., Ma, M., Gong, D., Sato, J., Masuda, Y., Honjoh, K. ichi, Miyamoto, T., Zeng, Z., 2023. Biocontrol of *Salmonella* Typhimurium in milk, lettuce, raw pork meat and ready-to-eat steamed-chicken breast by using a novel bacteriophage with broad host range. *Int. J. Food Microbiol.* 402, 110295. <https://doi.org/10.1016/j.ijfoodmicro.2023.110295>
- Zhou, C., Zhu, M., Wang, Y., Yang, Z., Ye, M., Wu, L., Bao, H., Pang, M., Zhou, Y., Wang, R., Sun, L., Wang, H., Zheng, C., Zhang, H., 2020. Broad host range phage vB-LmoM-SH3-3 reduces the risk of *Listeria* contamination in two types of ready-to-eat food. *Food Control.* 108, 106830. <https://doi.org/10.1016/j.foodcont.2019.106830>
- Zhou, Q., Feng, X., Zhang, Q., Feng, F., Yin, X., Shan, J., Qu, H., Luo, Q., 2012. Carbon catabolite control is important for *Listeria monocytogenes* biofilm formation in response to nutrient availability. *Curr. Microbiol.* 65, 35–43. doi: 10.1007/s00284-012-0125-4. Epub 2012 Apr 18. PMID: 22526570.
- Zhu, J., Liu, J., Hong, X., Sun, Y., 2022. Synergism With  $\epsilon$ -Polylysine Hydrochloride and Cinnamon Essential Oil Against Dual-Species Biofilms of *Listeria monocytogenes* and *Pseudomonas lundensis*. *Front Microbiol.* 13, 885502. <https://doi.org/10.3389/fmicb.2022.885502>
- Żukowska, G., Durczyńska, Z., 2024. Properties and Applications of Essential Oils: A Review. *J. Ecol. Eng.* 25, 333–340. <https://doi.org/10.12911/22998993/177404>